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ABSTRACT  
In longitudinal cohort studies, potential risk factors are measured at baseline, subjects are 
followed over time, and disease endpoints are ascertained via extensive surveillance. 
Individual follow-up time is from baseline to the event, if one is observed during the 
study period.   Follow-up time is censored for subjects who are not observed to have the 
event during the study period, at the end of the study period for subjects who remain 
event-free, but during the study period for subjects who leave the study early by choice or 
by mortality, or whose last evaluation was before the end of the study. Survival analytic 
techniques are unique in that the unit of analysis is not the individual but the person-time 
contributed by the individual.   
 
Surveillance in longitudinal studies is generally quite rigorous.  Subjects are examined in 
waves and their event status is ascertained.  Surveillance continues between waves, and 
events come to the attention of the investigator.  If there is a long time between waves, 
 viii 
analyses can be conducted on all available data, with non-events censored early at the last 
examination and events followed beyond the general examination to the incident event.  
 
Motivated by analyses using the Framingham Heart Study (FHS) with cardiovascular 
endpoints, we consider four censoring methods for non-events and evaluate their impact 
on estimates of incidence, and on tests of association between risk factors and incidence. 
We further investigate the impact of early censoring of non-events (as compared to 
events) under various scenarios with respect to incidence estimation, robustness, and 
power using a simulation study of Weibull survival models over a range of sample sizes 
and distribution parameters. 
 
Our FHS and simulation investigations show early censoring of non-events causes over 
estimation of incidence, particularly when the baseline incidence is low. Early censoring 
of non-events did not affect the robustness of the Wald test [Ho: Hazard Ratio (HR) =1]. 
However, in both the FHS and over the range of simulation scenarios, under early 
censoring of non-events, estimates of HR were closer to the null (1.0), and the power to 
detect associations with risk factors was markedly reduced.  
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1. Introduction 
 
In longitudinal cohort studies, potential risk factors are measured at baseline, subjects are 
followed over time, and occurrence of disease endpoints are ascertained via extensive 
surveillance. Key components of analysis are the time origin, length of follow-up, and the 
occurrence of some specified event - with an interest in characterizing the distribution of 
time-to-event, comparing time-to-event among groups, or assessing the relationship 
between a set of risk factors and the incidence of an outcome event, such as incident 
disease or death.  
 
The time origin, or baseline, a designated point in time when follow-up (the study) 
begins, is precisely defined for each participant in the study. It is often dictated by the 
study design and could be the participant’s date of entry into the study or birth date. If the 
time origin is the date of entry, the participant’s time to event will be the time on study. If 
the time origin is the birth date, then the time to event of an individual will be the 
survival age. Irrespective of how the time origin is defined, it should be chosen in a way 
that allows one to compare individuals at the time origin for any differences in the risk 
factors of interest.  
 
The length of follow-up is the time between the individual’s time origin and the survival 
date, the last date the subject had the event or was known to be at risk for the event. The 
date that an individual is at risk depends on the endpoint of interest. For mortality 
analysis, the survival date is the date of death for the deceased, and the last known date 
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alive for the others. However, for disease incidence analyses, a variety of factors may be 
involved in identifying the date a subject was last at risk.  
 
Furthermore, an inherent characteristic of these studies is the possibility that some of the 
subjects will not be observed to have the event during the study period. Follow-up time 
for these subjects is censored at the date last known to be at risk.  This can be at the end 
of the study period for subjects who remain event free, but during the study period for 
subjects whose last evaluation was before the end of the study period due to issues such 
as lost-to-follow-up or death not related to the event of interest. Thus, within a study, the 
individual follow-up time, or time at risk, can be varied due to staggered time origins, as 
subjects enter the study at different times or have different birth dates or follow-up 
examinations at different times or censoring. Survival analytic techniques are unique in 
that the unit of analysis is not the individual but the person-time contributed by the 
individual.   
 
In these studies, both events and non-events are followed from the time origin for 
approximately the same period of time. In general, the longer the subject is in the study 
the more likely it is that the endpoint of interest will occur. Thus, it is imperative that we 
take into account different lengths of follow-up for participants in the study. Survival 
analytical approaches, which are ubiquitous in subject area literature, include the Kaplan-
Meier estimates (1958), log rank tests (Mantel’s, 1966), and Cox proportional hazard 
models (Cox, 1972) – models that assume the instantaneous risk of failure is proportional 
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for different groups of participants with similar risk factors. These methods take into 
account individual differences in the follow up time among all subjects.  
 
There may be analytical issues due to overall differences in the ascertainment of follow-
up time between those with and those without events as a result of differential censoring 
periods. The way we identify the last known date the subject is still at risk, and how or 
when the censoring time for the events and non-events are chosen can affect estimates of 
incidence, and estimates of the association between risk factors and outcomes.  
 
Surveillance in longitudinal studies is generally quite rigorous and events are identified 
rapidly, but identification of the date last known to be at risk is not always 
straightforward.  Subjects are often examined in waves and their event status is 
ascertained.  Between the waves, however, surveillance continues, and events come to the 
attention of the investigator.  If there is a long time between waves, analyses can be 
conducted on the available data, with non-events censored early at the last examination 
and events followed beyond the general examination to the incident event. 
 
Motivated by the Framingham Heart Study (FHS) with stroke, myocardial infarction (MI) 
and congestive heart failure (CHF) as primary end points of interest, this thesis describes, 
compares, and provides interpretations of four censoring methods for non-events and 
evaluates their impact on estimates of disease incidence and on tests of associations 
between risk factors and disease incidence. We further investigate the effect of early 
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censoring of non-events (as compared to events) under various scenarios with respect to 
incidence estimation, robustness, and power using a simulation study of  Weibull survival 
models over a range of sample sizes and distribution parameters. In this investigation, we 
retain the proportional hazard structure of the model and accommodate four different 
censoring methods, interpretation of which will be a key element of comparisons. 
 
We begin this dissertation with a short review of statistical and biomedical 
literature that is pertinent to our research. Chapter 2 provides background and 
motivation for issues raised in subsequent chapters. We will discuss standard 
survival analysis techniques, censoring methods and issues with staggered follow 
up in published literature, in particular, publications based on the Framingham 
Heart Study. 
 
In chapter 3, using the Framingham Heart Study design, we undertake a thorough 
overview of data generation and censoring methods.  Our primary focus is on 
analytic issues due to differences in duration of follow up between persons with 
and without the event of interest (events and non-events) as a result of differential 
censoring mechanisms. We propose and describe four censoring methods used to 
produce analysis data sets.  We also present classical methods used to estimate 
disease incidence and the association between risk factors and disease incidence, 
and methods used to evaluate model performance, all of which we apply to the 
three different data sets. This will be followed by a presentation of our simulation 
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strategy with specific parameterizations of the Weibull survival models with 
proportional hazard representation to investigate the impact of different censoring 
methods. 
 
In chapter 4, we undertake a thorough application of the four different methods of 
censoring. We extensively focus on implementation of the methods of estimation 
of disease incidence and association between several risk factors and each of the 
outcomes, stroke, MI and CHF. We compare and contrast the results, and evaluate 
model performance using discrimination, calibration and net re-classification 
improvement measures. 
 
In chapter 5, we present results obtained from analyzing survival data generated 
from Weibull survival distributions under various conditions in order to evaluate the 
impact of different methods of censoring. Finally, chapter 6 will conclude the 
thesis with a summary, recommendations and suggestions for future work.  
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2. Literature Review 
 
We begin this chapter with a brief historical background, general overview, and 
description of standard survival analysis techniques used to estimate disease 
incidence and the association between risk factors and disease incidence, along with 
a short review of newer methods used to evaluate model performance from 
statistical and biomedical literature that is pertinent to our research.  
 
2.1 Historical Background 
 
The foundation of Survival analysis, one of the oldest fields of statistics, began with the 
development of actuarial science and demography in the      century with the first 
mortality (life) tables by John Grauntin in1662 (Kreager,1988). In the beginning, the field 
was dominated by the classical approaches developed by the early actuaries (Andersen 
and Keiding, 1998). However, by the end of the Second World War, the new era of 
survival analysis evolved (Aalen et al., 2009). This evolution from strict mortality 
research to failure time research was stimulated by an interest in the reliability of military 
equipment to the consumers products as the demand of safer and more reliable products 
sky rocketed.(Smith and Smith; Kleinbaum, 2005). The beginning of this advancement in 
the field is represented by the publication where Kaplan and Meier (1958) proposed their 
famous estimator of the survival distribution. In the 1960’s and 1970’s, a literature on the 
comparison of survival distributions for two or more samples thrived. The more general 
7 
 
matter of how to adjust for covariates was introduced as a proportional hazards model by 
David Cox in1972 (Cox, 1972). This was a major advancement and is followed by 
development of theory and methods by: Mantel (1966); Breslow and Crowley (1974); 
Cox (1975); Aalen (1978); Tsiatis (1981); Anderson and Gill (1982), to name a few. 
 
After the landmark publication of Cox on statistical models for lifetime data, survival 
analytical methods, in particular, for continuous-time data have been immensely applied 
to variety of disciplines ranging from biomedical research, to industries to economics to 
social sciences, and many other fields.  Several texts that discuss Survival Analysis 
methodology are Cox & Oakes (1984), Kalbfleisch & Prentice (1980), Miller (1981), 
Lawless (1982), Allison (1982), Blossfeld, Hamerle, & Mayer (1989), Yamaguchi 
(1991), Anderson (1991), Lee (1992), Anderson et al. (1993), Collett (1994), and Hosmer 
and Lemeshow (1999). 
 
2.2 General Overview 
 
A key feature of survival data is the presence of censoring and a right skewed distribution 
of survival time. The core issue is that irrespective of the distinct time origin and the 
duration of study, for some participants, the event of interest will not be observed through 
the study period. This could be due to termination of study, loss to follow-up or even 
death. So observation of survival data is typically incomplete as the event is observed for 
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some and not for others. This mixture of complete and incomplete information is a major 
characteristic of survival data, due to this fact we have special methods to analyze these 
data.  
 
The basic quantities used to describe the time-to-event phenomena are the survival and 
the hazard functions. Let   and   be non-negative random variables representing 
participants’ time to event and the censoring time respectively, these are assumed 
independent. For the    of   independent participants    and    are the realizations of 
these random variables and we observe {  ,   } such that                 and    
    <   ). We assume that   has an underlying probability density function      and 
cumulative distribution function      such that  
 
                ∫       
 
 
    
 
the probability that the survival time is less than some value t; in other words, the 
probability that the event has occurred by time t. 
 
It is often preferred to work with the complement of the cumulative distribution function, 
known as the survival function,  
 
                        ∫       
 
 
; 
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the probability that the event of interest has not occurred at time t; such that, a 
participants survives from the time origin to sometime beyond t. 
Alternative characterization of the survival function is the hazard function, or the hazard 
rate, the instantaneous rate of occurrence of the event and is given by, 
 
               
          |    
  
  
 
Equivalently,  
 
        
    
    
   
 
  
        
 
And the cumulative hazard function, 
 
         ∫       
 
 
            
 
Methods of estimation of these functions pertaining to survival distributions in our 
research are described in the next section.  
 
2.3 Standard Survival Models 
 
We present a brief overview of methods of standard survival analysis such as the Kaplan- 
Meier (Kaplan and Meier, 1958) method for estimating cumulative incidence of events of 
interest, and Cox-proportional hazards regression for estimating the association between 
specific risk factor(s) and incident event(s). 
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2.3.1 Estimation of Cumulative Incidence 
 
As our interest is on a single end point of interest, such as stroke, MI or CHF; the Kaplan-
Meier (K-M) estimate provides a simple yet reliable basis for the estimation of 
cumulative incidence.  
The K-M estimate is derived as follows, 
 
Consider                      as the ordered failure times among M subjects such 
that    .  Let   be the number of events at time    and    be the number of subjects at 
risk at time     Then the K-M estimate of the probability of survival at time    is given by,  
 ̂              ∏(  
  
  
)
 
   
 
 
Such that the unconditional probability of failure at time    can be written as, 
 
   ̂     (
  
  
) ̂        
  
And the cumulative incidence function can be expressed as, 
   ̂      ∑  ̂    
 
    
where      ,   ̂        ̂      and   ̂      ̂     . 
 
To obtain the estimate of cumulative incidence we use a SAS macro developed by Beiser 
et.al (2000) that produces several estimates of disease incidence for use in analyses of 
prospective cohort data. Among the estimates it generates, our interest is on the    
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unadjusted cumulative incidence (UCI) based on the traditional K-M cumulative 
incidence – the complement of the K-M estimate of survival. 
 
 2.3.2 Assessment of Association  
 
To assess the association between the risk factors of interest and outcome event, we will 
use the Cox proportional hazards model (Cox, 1972), the most commonly used 
multivariable analytical approach to survival data in biomedical research. This method 
describes the relation between the incident event as expressed by the hazard function and 
a set of covariates, as follows.   
 
Mathematically, the proportional hazard regression model assumes that, 
     |                 
      
Where time is represented by  ,   represents the vector of covariates and   the vector of 
estimated covariate effects. 
 
In the model,    |          , and       is often called a baseline hazard function 
which can be interpreted as the hazard function of population of subjects with    . 
 
The survival function is given by, 
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Where        is the survival function of the subpopulation with covariate   and       is 
the baseline survival function.   
 
The above model assumes a proportional hazard such that the ratio of hazards is constant 
over time; such that, 
  
   |   
    |   
 
             
             
             
 
Equivalently, 
     (
   |   
    |   
)                                 
 
So that, for one unit increase in    keeping all other covariates fixed, 
 
     (
 ( |    )
  ( |  )
)     (  ( |    ))        ( |  )     
 
Hence,    is the estimated increase in log hazard ratio at any time relative to a unit 
increase in the    covariate. Equivalently,         is the estimated hazard ratio 
associated with one unit increase in     Thus   characterizes the effect of the covariate of 
interest on incident event; consequently, will be a focus of inference. 
 
We use the PHREG procedure in SAS 9.3 to perform the analyses based on the Cox 
proportional hazards model. The parameter     in the proportional hazard regression 
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analysis is estimated using a partial likelihood, which estimates   without specifying the 
baseline hazard. These estimates are consistent, asymptotically unbiased/normal but may 
not be efficient (Allison, 1995). We summarize results from PHREG using the estimates 
of the proportional hazard regression coefficient, and the corresponding hazard ratio with 
confidence intervals. 
 
 2.4 Performance Measures 
 
There are several ways of assessing performance of a model. We will discuss 
discrimination and calibration aspects, and then the net reclassification improvement 
(NRI) and the integrated discrimination improvement (IDI). The discrimination C-
statistic, measures the ability of a model to correctly classify subjects into one of the two 
categories, events and non-events. The calibration score, measured by a Chi-square 
statistic, is the degree of correspondence between the predicted probabilities from the 
model and the actual observed outcomes. The NRI focuses on reclassification tables 
constructed separately for participants with and without events, and quantifies the correct 
movement in categories – upwards for events and downwards for non-events for models 
with and without the risk factor. The IDI focuses on differences between average 
sensitivities and ‘one minus specificities’ for models with and without the risk factor 
(Pencina et al., 2007). 
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2.4.1 Discrimination 
 
To assess the discrimination of a survival analysis model with different censoring 
methods, we use the C-statistic, computed by means of the methodology described in 
D’Agostino and Nam (2004) and D’Agostino and Pencina (2004).  The C-statistic is 
derived as follows: 
 
Suppose we have n subjects, among whom    developed events in time t (event),    did 
not develop events in time t (non-event) and    were censored by time t (censored); so 
that,             
Let   
  = survival time for the  
   individual, i= 1, 2. . . n 
  = predicted probability for developing an event in time t for the  
   individual, i =1, 
2...n 
Such that, we have n pairs of                           
 
The C- statistic is defined as,  
  
 
 
∑ ∑      
 
   
   
   
 
Where, Q = the total number of comparisons made, 
    = 1 if        ; i, j = 1, 2… n; i <j 
      = 0, otherwise 
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    = 1 if        , and at least one member of the pair        is the predicted   
probability of an observed event; i, j = 1, 2,…, n 
      = 0, otherwise 
 
For a time to event survival model, let  
   = survival time for event, i= 1, 2…,   
   = predicted probability for event, i= 1, 2, . . .,    
   = survival time for non-event,  j = 1, 2, . . .,   
   = predicted probability for non-event,  j = 1, 2, . . .,   
   = survival time for censored,  j = 1, 2, . . .,   
   = predicted probability for censored,  j = 1, 2, . . .,   
Here, we have three sets of comparisons of interest: first, comparing those who 
developed events against those who did not, i.e. event vs. non-event; second, comparing 
those who developed events against those who also developed events, i.e. event vs. event; 
and the third, comparing those who developed events against those who were censored, 
i.e. event vs. censored. 
 
The first component of the C-statistic that concerns comparison of events vs. non-events 
is, 
   
 
  
∑∑       
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Where, 
         
    = 1 if          ; i, j = 1, 2,… ,n; 
      = 0, otherwise 
    = 1 if          , and at least one member of the pair         is the predicted 
probability of an observed event, i= 1, 2,…,   ; j=1, 2,…,    
      = 0, otherwise 
 
Because all of the survival times for those who did not develop events are greater than the 
maximum value of the event times for those who developed events,     is always 1. 
 
The second component of the C-statistic that concerns comparison of events vs. events is, 
   
 
  
∑ ∑       
 
   
    
   
 
Where, 
   
 
 
         
    = 1 if          ; i, j = 1, 2,… ,  ; i <j 
     = 0, otherwise 
    = 1 if          , i,j = 1, 2,… ,  ; i<j 
     = 0, otherwise 
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The third component of the C-statistic that concerns comparison of events vs. censored is, 
   
 
  
∑∑      
  
   
  
   
 
Where, 
   ∑∑   
  
   
  
   
 
    = 1 if          ; i = 1, 2,… ,  ; j=1,2,…,    
     = 0, otherwise 
    = 1 if         ; i = 1, 2,… ,  ; j=1,2,…,    
     = 0, otherwise 
The discrimination C-statistic is  
                     
Where,  
  
  
        
       
  
        
 
 
Thus, the C-statistic is a linear combination of three independent discrimination 
measures:             . A general interpretation is that a value of 0.5 represents a 
random discrimination; a C-statistic with a value higher than 0.5 is desired. In our 
analysis, we will compare discrimination (C-statistics) among the survival models with 
various censoring methods. The model that yields the highest C-statistic is regarded as 
the one with better discrimination ability. 
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2.4.2 Calibration 
 
Calibration measures are often statistics that partition a dataset into groups and assess 
how the average predicted probability compares with the observed outcome incidence in 
each group. For each model, based on different censoring methods, the calibration score 
is a Chi-square statistic derived from the theoretical framework of the goodness-of-fit 
statistic for generalized linear models (D’Agostino and Nam, 2004; Pencina, D’Agostino 
et al., 2004). 
    ∑
(      ̅̅ ̅)
 
  ̅̅ ̅     ̅̅ ̅ 
 
   
 
Where    are the Kaplan–Meier estimates for cumulative incidence and   ̅ are the 
average predicted probabilities for a positive outcome (event) in the    group where j = 1, 
2, . . . , M. The Chi-square measures are calculated by ranking the model’s predicted 
probabilities of survival into deciles and then comparing the KM estimates in each decile 
to the average predicted probabilities in each decile. Here each decile contains 
approximately 10 percent of the observations. Each of these statistics is summed to 
produce one overall calibration score. This overall calibration score is then compared to a 
Chi-square statistic with 9 degrees of freedom. Our hypothesis here is that the predicted 
probabilities from the model are equal to the true probabilities from the KM estimates, 
and the alternative hypothesis is that they are not equal. It is desirable that we fail to 
reject the null hypothesis; such that, the smaller the calibration Chi-square the better the 
model is calibrated. 
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2.4.3 Net Reclassification Improvement 
 
For the ‘net reclassification improvement’ (NRI), we used a method of assessing 
improvement in model performance, proposed by Pencina, D’Agostino et al. (2010).  
The NRI is derived as follows: Consider a situation in which predicted probabilities of a 
given event of interest come from two different risk prediction algorithms denoted here 
as ‘new’ and ‘old’. Let us partition the predicted probabilities based on these two 
algorithms into a set of clinically meaningful ordinal categories of absolute risk and then 
cross-tabulate these two classifications. Define upward movement (up) as a change into a 
higher category based on the new algorithm and downward movement (down) as a 
change in the opposite direction.  
 
Then, the NRI is defined as: 
 
        |             |              |               |           
 
Equivalently, using the Bayes rule, we obtain 
 
    
       |                 |             
        
      
 
           |                         |         
            
 
This can be re-written as, 
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       |                 |             
        
 
(         |     )          (         |   )       
          
 
On simplification it reduces to, 
   
 
(       |            )         (                |     )         
                     
 
 
The above expressions are extended to survival analysis with P(event), P(event|up) and 
P(event|down); all estimated using the Kaplan-Meier approach. Proportions of people 
moving up: P(up) and down: P(down) are always available. Assuming that among the 
total of n individuals,   are reclassified upwards and   downwards, then the NRI can be 
written as: 
    
       |              |        
          
 
(         |     )     (         |   )    
              
 
The quantities in the numerators represent expected numbers of events reclassified 
upwards and downwards, and expected numbers of non-events reclassified downwards 
and upwards, the first and the second numerators respectively. The denominators are the 
total expected cases of events and non-events, respectively.  
The method adopted here is applicable to survival data and is the category-free version.  
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2.4.4 Integrated Discrimination Improvement 
 
To further assess the model performance, we used, what Pencina, D’Agostino et al. call 
the integrated discrimination improvement (IDI). The IDI is defined as follows: 
 
                                      
 
Where IS is the integral of sensitivity and IP the corresponding integral of (1-specificity).   
 
As in NRI, the subscripts ‘new’ and ‘old’ refer to the two different risk prediction 
algorithms with (new) and without (old) the new risk factor. The IDI is estimated as the 
difference in discrimination slopes proposed by Yates (1982).  
 
   ̂  ( ̅̂            ̅̂          )    ̅̂                ̅̂                      
 
Where   ̅̂           is the mean of the predicted probabilities of an event from the new 
model for those who develop events,   ̅̂           is the corresponding quantity based on 
the old model,  ̅̂               is the mean of the predicted probabilities of an event from 
the new model for those who do not develop events and  ̅̂               is the 
corresponding quantity based on the old model. 
 
The above equation can be re-arranged as, 
 
   ̂  ( ̅̂            ̅̂              )    ̅̂            ̅̂                   
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and this is the difference in discrimination slopes between the new and old models, as 
proposed by Yates (1982). Thus, the discrimination slope is the difference in means of 
predicted probabilities for events and non-events, and is a measure of separation in 
predicted probabilities for event and non-events. 
 
2.5 Censoring and Truncation 
 
One key feature of time-to-event data is censoring. There are various types of censoring, 
such as right censoring, left censoring and interval censoring.  Right censoring occurs 
when after the participant enters the study, he/she is known to be alive and is censored at 
some time, say   , which is earlier than the actual, but unknown survival time. Left 
censoring is encountered when the actual survival time is earlier than the observed time. 
Interval censoring occurs when the event of interest is within a pre-specified interval of 
time but the exact time is not known. Both right censored and left censored data are 
special cases of interval censored data. 
 
We will focus exclusively on right censoring due to the fact that right censoring is the 
most frequently encountered censoring scheme in the analysis of survival data.  The 
follow-up in our motivating example from the FHS with outcomes of stroke, MI and 
CHF is right censored by the study design. 
 
Figure 2.5.1 below illustrates how right censored survival times may arise. Consider 10  
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participants in a hypothetical study where they are followed prospectively from entry. For 
participants 2, 4 and 8 the event was observed within the study period and we have 
complete survival information. Subjects 1, 5 and 9 are still at risk by the end of the study 
period and their follow-up times are censored. Participants 3 and 6 are lost to follow-up 
(LTF), and subjects 7 and 10 are censored at death. This hypothetical situation is an 
example of right censored survival data. This type of censoring is fairly common in 
lifetime data (Lawless, 1982).  
 
 
Figure 2.5.1   Follow up in a hypothetical study with 10 participants 
 
Participant      End of Study 
1 
2      Event  
3       LTF 
4                Event  
5 
6    LTF 
7           Death  
8         Event  
9 
10         Death 
  
       Entry        Time  
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Another feature of many survival studies is truncation. Truncation of survival data occurs 
when only those individuals whose event time lies within a predefined observational 
window are observed.  Any participant not in this window is not observed; consequently, 
the inference for truncated data is restricted to conditional estimation. (Klein & 
Moeschberger,  2003). Left truncation occurs when participants enter study sometime 
after the time origin, and are followed forward until the event occurs or they are 
censored. One example of left truncation in the FHS data set relates to Dementia and 
Alzheimer’s research. (Beiser et al, 2000). Right truncation occurs when only subjects 
who have experienced the event are observable. A regularly cited example of right 
truncated data corresponds to AIDS blood transfusion study from Centre for Disease 
Control (Lagakos, 1988) which corresponds to infection and induction times for 
participants infected with AIDS virus. 
 
 
2.6 Differential Follow up 
 
Lengths of follow up for participants in the longitudinal cohort studies are highly variable 
due to staggered entry and staggered survival time since censoring occurs throughout the 
study period. The survival analytical models that we have described take into account the 
staggered follow up times. However, the timing of censoring for events and non-events, 
and their impact on inference has not been discussed much in the literature. Generally 
speaking, longitudinal follow-up studies consist of ongoing waves of examinations. If the 
lag time between the waves is not very long, the effect of timing of censoring for events 
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and non-events may not make that much of a difference in terms of estimates of event 
incidence. For example, at the FHS, for the original cohort, the time lag between 
examinations is about 2 years – the events and non-events are followed through 
approximately the same time period (through the exam cycle). Consequently, there may 
not be much of an effect of timing of censoring on estimates of incidence. However, in 
generation 2 participants at the FHS, there is at least a 4 year lag between exams. Study 
periods might conclude at the ends of exams, for example, an eight year follow-up period 
could begin at examination 5 and end at examination 7.  To use a longer follow-up 
period, one would have to wait until the end of examination 8, four years later.  However, 
through extensive surveillance, events are accrued throughout the period between exams 
and there is always an urge on the part of investigators to use all available data and not to 
wait until the end of the exam. These results in unequal follow up for events and non-
events such that most non-events are censored at the last attended exam and the follow up 
for events is extended well beyond. 
 
It is often difficult to ascertain the specific details of censoring in methods sections in 
published articles.  Generally speaking, the presence of differential censoring times for 
events and non-events is not explained explicitly, or is not even mentioned. For example, 
Seshadri and Beiser (2006) in the methods section of their life time risk of stroke paper 
state that, “Participants were followed until they developed the outcome of interest (first-
ever stroke or dementia), died, or until their most recent Framingham Study evaluation 
before December 2003”. Even though the statement correctly mentions that participants 
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were followed through 2003, in fact, events were followed through 2003 but non-events 
were followed through the last exam, exam 7, which was attended in 1998-2001. We 
observed similar statements in most methods sections of other papers, with a final date of 
follow-up provided for all participants, not separated by event status.   
 
In this study, we assume that the censoring and the survival time (time-to-event) are 
independent. We investigate the effect of timing of censoring of events and non-events on 
estimates of disease incidence and on tests of associations between specific risk factors 
and outcome events.  
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3. Statistical Methods 
 
In this chapter, using the Framingham Heart Study as an example of a longitudinal 
cohort study, we undertake an overview of data generation and censoring methods.  
Our primary focus is on analytical issues due to differences in duration of follow up 
between persons with and without the event of interest (events and non -events) as a 
result of differential censoring mechanisms. We propose and describe four 
censoring methods which we then use to produce analysis data sets.  We also 
present classical methods used to estimate disease incidence and the association 
between risk factors and disease incidence, all of which we will apply to three 
different data sets. This is followed by a presentation of our simulation strategy 
with specific parameterizations of the survival model(s) to compare the impact of 
different censoring methods. 
 
 3.1 The Framingham Heart Study 
 
The Framingham Heart Study (FHS) is one of the longest longitudinal, epidemiologic 
cohort studies in the United States. Since its inception in 1948, the FHS has contributed 
enormously to the understanding of risk factors for cardiovascular and other disease 
endpoints. In the FHS original cohort, 5209 participants aged 28 to 62 years were 
recruited between 1948 and 1953, and examined biennially for cardiovascular risk factors 
and cardiovascular endpoints (Dawber, Kannel et al., 1963). Between 1971 and 1975, the 
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second generation of 5124 participants comprised of 3548 offspring of the original cohort 
and 1576 spouses of those offspring was recruited. (Kannel et al., 1979). The offspring 
and their spouses have been evaluated every 4 to 8 years for a variety of risk factors, 
including cardiovascular, socio-demographic, psychosocial and cognitive factors. 
Beginning in 2002 through 2005, 4095 adults (age: 19-72 years; 53% female) having at 
least one parent in the offspring cohort enrolled in the third generation cohort, along with 
103 parents of third generation cohort participants who were not previously enrolled in 
the offspring cohort. The objective of new recruitment was to complement phenotypic 
and genotypic information obtained from prior generations, with priority assigned to 
larger families. (Splansky et al., 2007) 
 
Since its inception in the early 1970’s, the FHS second generation participants have 
undergone 8 clinic examinations and, starting in 2012, the 9th exam is being administered. 
These participants and other cohorts from the FHS have been surveilled prospectively, 
and examined extensively for cardiovascular and other disease conditions, such as cancer 
and dementia.  
 
3.1.1 Description of Dataset 
 
At the FHS, participants are considered to have developed cardiovascular disease (CVD) 
if upon review by a panel of three investigators from the Framingham Endpoint Review 
Committee (FERC) there is agreement that there was a definite manifestation of coronary 
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heart disease, intermittent claudication, congestive heart failure, stroke or transient 
ischemic attack in absence of a previous manifestation of any of these diseases. Our 
investigation of the effect of different censoring methods was conducted on the 
Framingham second generation cohort with stroke, congestive heart failure, and 
myocardial infarction as end points (events) of interest. For each of these events, 
examination cycle 6 (1995-1998) was chosen as the entry time; attendees of the exam 
who were free of the event of interest were followed prospectively (for up to 14 years or 
through 2009). A person having more than one cardiovascular manifestation within the 
follow-up period is counted as an incident case only at the time of the first event.  
 
Cardiovascular outcomes 
Stroke: The diagnosis of stroke is based on the occurrence of a clinically evident stroke 
documented by clinical records reviewed by two neurologists. Stroke is defined as the 
sudden or rapid onset of a focal neurologic deficit persisting for greater than 24 hours. 
(Wolf et al, 1991, 1992) 
Congestive heart failure (CHF): A definite diagnosis of CHF requires that a minimum of 
two major or one major and two minor criteria be present concurrently (Kannel et al, 
1987). The presence of other conditions capable of producing the symptoms and signs are 
considered by physicians in evaluating the findings.  
Major Criteria: 
i.  Paroxysmal nocturnal dyspnea or orthopnea 
ii.  Distended neck veins (in other than the supine position) 
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iii.  Rales 
iv.  Increasing heart size by x-ray 
v.  Acute pulmonary edema on chest x-ray 
vi.  Ventricular S (3) gallop 
vii. Increased venous pressure > 16 cm H20 
viii. Hepatojugular reflux 
ix. Pulmonary edema, visceral congestion, cardiomegaly shown on autopsy  
x. Weight loss on CHF Rx: 10 lbs. /5days 
Minor criteria: 
i. Bilateral ankle edema 
ii. Night cough 
iii. Dyspnea on ordinary exertion 
iv. Hepatomegaly 
v. Pleural effusion by x-ray 
vi. Decrease in vital capacity by one-third from maximum record 
vii. Tachycardia (120 beats per minute or more) 
viii. Pulmonary vascular engorgement on chest x-ray 
 
Myocardial Infarction (MI): Recent or acute MI is designated when there were at least 
two of three findings:  
i.    Symptoms indicative of ischemia 
ii.   Changes in biomarkers of myocardial necrosis 
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iii.  Serial changes in the electrocardiograms indicating the evolution of an 
infraction including the loss of initial QRS potentials (that is, development 
of “pathologic” Q-waves of 0.04 second duration or greater) (Kannel et al, 
1987).  
 
Risk Factors 
For each of these events we considered age, sex, hypertension, current smoking status, 
diabetes mellitus, atrial fibrillation, and C - reactive protein as risk factors of interest, 
defined as follows. 
Hypertension: Stage I + hypertension is defined as a systolic blood pressure greater than 
or equal to 140 mmHg or diastolic blood pressure greater than or equal to 90 mmHg or 
under treatment for hypertension (JNC VII, 2003). 
Smoking: Current smoking status is identified with participants self-reporting at the 
specific clinic exams. 
Diabetes Mellitus (DM): DM is defined as random blood glucose greater than or equal to 
200 mg/dL or fasting blood glucose greater than or equal to 126 mg/dL or currently under 
treatment for diabetes.  
Atrial Fibrillation (AF): AF is an irregularity in the heartbeat or heart rhythm caused by 
atria, the two upper chambers of the heart, fibrillating and not beating effectively. Blood 
can pool in the atria and clots may occur.  If a clot leaves the atria and stuck in an artery 
of the brain then stroke occurs. (Benjamin, Wolf et al, 1998) 
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C - reactive protein (CRP): CRP is one of the ‘acute-phase’ proteins synthesized in the 
liver and is normally present as a trace constituent of serum or plasma. Levels of CRP 
rise during general, nonspecific response to infectious and non-infectious inflammatory 
processes. (Koenig et al, 1999)  
 
Follow-up Status 
For each participant, follow-up status can be assessed based on whether during the 
observation (follow-up) period, he/she had an event, or was censored (these censored 
participants includes those who died event free or if he/she  was alive and event free at 
the end of the observation). Follow-up time for a participant is the time from entry (date 
of examination cycle 6) to the survival date; the latter date depends on the event status of 
the participant. The survival date for a participant with an incident event is the date of 
that event.  For those who died during follow-up, before experiencing the event of 
interest, the FERC reviews all evidence including death certificate and other records 
supplied by hospitals, attending physician, pathologists, medical examiner or family to 
confirm the cause of death – and the absence of the event of interest. The survival date 
for those is the date of death. 
 
The survival date for the remaining participants is the last known date they are still at risk 
for the event of interest. This includes participants who are censored event free at the end 
of the observation period as well as those censored at some date before the end of the 
33 
 
observation period. The observation periods chosen for this study are from exam 6 
through each of exam 7 (1998-2001), 2002, 2004, 2006, exam8 (2005-2008) and 2009. 
3.2 Methods of Censoring            
Sequence of Events (SOE) and Survival Data Creation 
 
 
At the FHS, during each clinic exam cycle, participants undergo a detailed examination 
including physical examination, medical history, laboratory testing, and 
electrocardiogram. Over the years, other tests (that may not be performed at every exam 
cycle) have included pulmonary function, lifestyle, physical function, cognitive function 
questionnaires, and various noninvasive cardiovascular tests including echocardiograms. 
For all of these participants, the charts (clinic exams or, if participant had records sent to 
FHS for review after his or her most recent exam cycle) are reviewed and 
screened/flagged for any patterns related to CVD manifestation. This in turn prompts the 
review for sequence of events. 
 
Until recently, data sets for all CVD events, known also as the sequence of events (SOE) 
files, were created at each exam cycle. Corresponding CVD survival files were also 
generated based on the follow-up information on all CVD events through specific exams. 
For example, exam 7 was administered between 1998 and 2001; any participant who 
attended exam 7 and whose CVD event occurred on or before the exam 7 date was 
included in the exam 7 SOE, and the corresponding survival files. This survival file also 
includes those who attended exam 7 but did not have an event. For those who did not 
attend the exam, a cut-off date was determined using the cutoff for examination 
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attendance.  Each participant is assigned an anniversary date for all subsequent exams 
based on the date of their first ever examination.  These anniversary dates are exactly 
every four years.  However, the window for exam attendance is within two years of the 
anniversary date; the cutoff for any exam is the first of the month two years after the 
participant’s exam anniversary date.  For example, a participant whose anniversary date 
for exam 6 was May 16, 1995 could actually attend exam 6 as late as May 1, 1997.  If 
this person did not attend exam 6, and experienced an event before May 1, 1997 would be 
coded as having an exam 6 events.  Events that occurred after exam 6 (the date of 
attendance or the cutoff date if exam 6 was not attended) would not be included in the 
exam 6 SOE or in the exam 6 survival file. 
 
Specification of the time origin, the outcome of interest and censoring rules determine the 
survival time for each participant. Here, the date of the event is the survival date for those 
with the event, and for those who attended the exam but did not have an event, the exam 
date is the survival date. For the others, the last known date they are known to be event 
free is used. This date can be an earlier attended exam or the date of another SOE event 
(including death) because their entire case would have been reviewed through that time.  
This group is censored earlier than exam 7, but is relatively small as the majority of non-
event participants did attend exam 7.  By creating the SOE and corresponding survival 
files through exam cycles, participants with and without events are followed 
approximately through the same time period. This approach of censoring all participants 
at exam cycle, we call censoring Method I.  
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Creating an SOE and corresponding survival file indexed by exam cycle necessitates 
waiting for approximately four years to update incident cases. For example, let us 
consider stroke as an endpoint of interest.  There were 27 incident strokes from exam 6 to 
exam 7, which ended in 2001. Exam 8 did not begin until 2005 and was not completed 
until 2008.  By 2004 there were already an additional 48 incident strokes, and each year 
this number increased. There is an utmost desire on the part of investigators not to wait 
until the end of the exam cycle but to use all available events for study. At present, the 
SOE and corresponding survival data sets are generated annually so that the follow-up 
time for events are extended through the current date and for the non-events to the last 
known date they are still at risk. This date is the maximum of the date of their last SOE 
event (including death) or their last attended exam.  
 
In our set up, exam 6 (1995-1998) is the baseline, and subjects who are alive and free of 
events of interest at baseline are followed forward from exam 6 through exam 7(1998-
2001); follow up times for events and non-events are approximately the same. However, 
if we extend follow-up through 2006 (part-way through exam 8), the follow up for events 
will be extended through 2006 and for participants without events the follow-up will be 
through the last known date they are still at risk, but no later than 2006.  For most of the 
participants, this date will be the date of exam 7, which ended in 2001. This could result 
in different follow up periods for events and non-events. This approach we call censoring 
Method II. 
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As is generally the case in any longitudinal follow-up study, there may be many 
participants who do not attend all of the exams. The FHS is not an exception in this 
regard. Thus, it is imperative to have some effective means of maintaining up to date 
health information on all of the participants in the study who, for whatever reason, do not 
attend an exam. The FHS has fairly recently started maintaining what is known as the 
Health History Update (HHU) records such that during each exam cycle, the participant 
coordinators use Medical History Update questionnaires to obtain annual health 
information on the telephone from participants who do not attend exams. Follow-up of 
other participants who do not attend exams is performed by means of mailings which 
consist of a Medical History Update Form and a Medical Records Release Form. 
Reminder postcards are sent to those who do not respond within a reasonable time period. 
The HHU information thus obtained enables the Medical Records Department at the FHS 
to access medical records necessary to document whether or not participants have 
cardiovascular, cancer and other events of interest. 
 
The potentially uneven follow-up times for events and non-events can be addressed by 
incorporating information from the HHU. A participant who is flagged for having a 
potential event of interest from the HHU questionnaire is investigated through the FHS 
review process as described above. Those who are flagged but have not yet been 
reviewed are censored the usual way; that is, they are censored at their date of death or 
their last SOE event, or their last attended exam. For the rest, the follow-up is extended 
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through their HHU date. This allows us to extend the follow-up for non-events. This we 
call censoring Method III.  
 
Ideally, separate survival files should be created for each outcome, but the CVD survival 
file has been used to obtain censoring dates even when the outcome is one of the 
component events, or even a non-CVD event.  As noted above, the CVD survival file is 
created in such a way that a person is censored at the time of the first cardiovascular 
event. For example, a participant who developed MI during the follow-up period will 
have the date of the MI as the survival date in the CVD survival file. If the outcome of 
interest here is MI then this is fine. However, if the outcome is stroke, and we use the 
CVD survival file for the survival date, this participant will be censored and considered 
no longer at risk for stroke at the date of their incident MI; this clearly is not correct.  
Another problematic scenario involves a participant who had a non-stroke CVD event 
(given as the survival date in the CVD survival file) before entry (exam 6) and this is 
excluded as a prevalent case.  We address issues due to using an overall survival file for 
component events in what we call censoring Method IV. 
 
With exam 6 (1995-1998) as entry, we consider the following four censoring methods to 
generate survival data sets.  
 
Method I: Events and non-events are followed through approximately the same period of 
time by censoring everyone at exam 7 (1998-2001). Here, events that occurred prior to 
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exam 7 are counted; any events after exam 7 are censored as non-events at exam 7. All 
non-events are censored at exam 7 or prior based on the last date the participant was 
known to be event free (for example, based on a non-event date in the exam 7 SOE file). 
The same approach was adopted again by censoring at exam 8 (2005-2008). Here the last 
known date a participant was event-free is determined by the maximum of the exam 8 
date and the latest non-event date in the exam 8 SOE file, if available. 
 
Method II: Events are followed through each of 2002, 2004 and 2006, and non-events 
are censored at exam 7 or at the last non-event date in the exam 7 SOE file or prior based 
on the last date the participant was known to be event free. This method is repeated again 
by following events through 2009 (the most up to date with available information on 
events), and non-events are censored at exam 8 or prior based on the last known date they 
did not have an event. 
 
Method III: Events are counted through 2002; any events after 2002 are censored as 
non-events and the censoring date is 12/31/2002. For non-events, the censoring date is 
the most recent HHU or other last known event-free date prior to or during 2002 based on 
exam 7 date or non-event date in the SOE file. Similar censoring dates were determined 
for follow-up through each of 2004 and 2006, and then after exam 8, through 2009.  
 
Method IV: Events are counted through 2002, 2004, 2006 and 2009 respectively, and the 
non-events are assigned the survival date from the overall CVD (Method III) survival file 
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for 2002, 2004, 2006 and 2009 respectively, even when the event is an individual 
component of CVD.  
 
Schematic diagrams depicting these methods are presented below – 
 
 
 
Figure 3.2.1  Schematic Diagram of Censoring Methods in the FHS set up with study 
period up to Examination Cycle 8 
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40 
 
Figure 3.2.2  Schematic Diagram of Censoring Methods in the FHS set up with study 
period at and after Examination Cycle 8 
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3.3 Simulation Strategy 
 
Here we present a general theory behind our simulation strategy. Our objective is to 
simulate survival data to investigate the performance of different censoring methods in 
terms of estimates of incidence, robustness and power under different pre-specified 
conditions. 
 
3.3.1 Survival Model 
 
The survival models used in this research involve Weibull and exponential distributions. 
The exponential distribution is often used in simulating survival data because of its 
historical significance and mathematical simplicity. Historically, this distribution is 
known to have been studied as early as the nineteenth century by Clausius (1858) in 
connection with the kinetic theory of gases. Later on in studies of manufactured items 
(Davis 1952; Epstein and Sobel 1954; Epstein 1958), and to somewhat lesser extent, in 
health studies (Feigl and Zelen 1965; Sheps 1966). This distribution has long been used 
in describing time to failure. (Klein et. al., 2003) 
 
The probability density function of the exponential distribution is, 
                   λ>  0; t  ≥ 0  (1) 
 
with the survival and hazard functions given by, 
               ,          
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Where  t represents survival time and parameter λ defined as hazard or instantaneous risk 
of event. 
 
The well-known feature of the exponential distribution is the constant hazard rate such 
that the conditional probability of failure at any time t, given that the event has not 
occurred prior to t, does not depend on t. 
 
Furthermore, suppose                  are the hazard rates in the reference and the 
comparison groups respectively (for example, in groups without and with a specific risk 
factor), then the hazard ratio (HR) for the exponential distribution can be written as, 
       
     
     
      
  
  
  
 
We used the exponential distribution with various values of the parameter λ to assess how 
the different censoring methods perform under the constant hazard assumptions.  
 
Even though the exponential distribution has been historically very popular and used 
often to generate simulated survival data, its constant hazard assumption can be 
restrictive in both medical research and industrial applications. 
 
The assumption of constant baseline hazard (over time) is not necessarily a realistic 
assumption for outcome events like stroke, MI and CHF or death.  Taking this into 
consideration, we chose primarily to focus on a model which allows the hazard to change 
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over time.  The Weibull model (1939, 1951) is a probability distribution that plays a 
central role in the analysis of survival data. This distribution has been widely used in both 
biomedical and industrial applications. Lieblein and Zelen (1956), Berretoni (1964), and 
Nelson (1972) used this distribution to describe the life length of ball bearings, electron 
tubes, manufactured items and electrical insulations respectively. Pike (1966) and Peto 
and Lee (1973) gave a theoretical motivation for its consideration in representing time to 
appearance of tumor or until death in animals which were subjected to carcinogenic 
insults over time. Lee and Thompson (1974) argued that within the class of proportional 
hazard rate distributions, the Weibull distribution appears to be the most appropriate 
choice in describing lifetimes. (Klein et. al., 2003) 
 
The probability density function of the Weibull distribution is, 
 
                         α, λ  >  0; t  ≥ 0 (2) 
 
with the survival and hazard functions given by, 
 
                ,               
 
where t is survival time, λ is the scale parameter, and α is the shape parameter. 
Furthermore, based on the parameterization in (2), the hazard ratio comparing the hazards 
in two groups is given by, 
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The assumption of proportional hazards across a number of groups corresponds to the 
assumption that the shape parameter   in the baseline hazard function is the same in each 
group. (Collett, 2003)   
 
So that, for two groups, if        then the HR reduces to,  
      
  
  
 
    
The scale parameter λ controls the scale of t, with no effect on the actual shape 
parameter. This model is flexible enough to accommodate increasing (α > 1), decreasing 
(α < 1) or a constant (α = 1) hazard rates. These, along with the model’s relatively simple 
survival, hazard and probability density functions, have made this a popular lifetime 
analysis model. 
 
We used Weibull distributions with various scale parameters λ and a shape parameters 
with increasing (α > 1) and constant (α = 1) hazard rates; and assessed performance of 
different censoring mechanisms as described under censoring methods in an earlier 
section. The following diagram shows one of the survival functions generated with the 
Weibull survival model with α = 1.15 and λ=0.03. The motivations for these choices are 
based on an attempt to mimic the survival distribution at the FHS. 
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Figure 3.3.1 Survival Function for Simulated Weibull Distribution (λ=0.03, α =1.15).  
 
 
 
3.3.2  Survival Data Generation: General Considerations 
 
Recall the Cox proportional hazard regression model, 
 
     |                     (3) 
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Where   is the time,  : the vector of covariates,   : vector of estimated covariate effects, 
and       is a non-negative baseline hazard function such that it gives the hazard for an 
individual at time   whose covariates all have the value 0. 
 
The above model can be re-written as, 
 
         |                      (4) 
 
In the above equation, if             α (constant), the event time follows an exponential 
distribution; if                  the event time follows Gompertz distribution; 
whereas if            takes the form         then the event time follows Weibull 
distribution.  
 
The inverse of these functions can be used to generate survival times as detailed in 
Bender et al (2005). We adopt their approach to generate simulated survival data from the 
Weibull model. 
 
The survival function of (3) is, 
     |                          (5) 
 
 
where        ∫      
 
 
   is the cumulative baseline hazard function.  
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The distribution function can be written as, 
     |                           (6) 
   
Let Y be a random variable with distribution function F, then U = F(Y) ~ U [0, 1], 
consequently (1 – U) ~ U [0, 1] as well. (Mood et.al, 1974). 
 
Again, let T be the survival time of (3), then it follows from (6) that 
                                
If         for all  , then   can be inverted and the survival time T of (3) can be 
expressed as, 
      
                        (7) 
 
Now, the inverse of the cumulative hazard function of the Weibull distribution (2) is 
given by, 
    
            
 
 ⁄        (8) 
 
Substituting (8) in to (7), the survival time of a Cox model with the baseline hazard of a 
Weibull distribution can be expressed as, 
                        
 
 ⁄        [
      
        
]
 
 ⁄
  (9) 
 
The corresponding hazard function is given by, 
                       
 
Such that the corresponding survival times are Weibull distributed with varying scale 
parameter                and a fixed shape parameter   . 
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We then can simulate the survival data (T) using the value of U generated from a uniform 
distribution, keeping the vector of covariate effects fixed, choosing various values of  
 and assuming, first, an increasing hazard            Details of these parameters are 
summarized in table 3.6.3.  
 
The same simulation scheme is adopted separately for our simulation analyses with an 
exponential model, with constant hazard (set     in the Weibull model to obtain the 
exponential) 
 
We begin with a potential event rate of 100%, assuming that all individuals in the study 
have the potential to develop the event of interest, provided they are followed through a 
sufficiently long period of time. Even if this assumption is correct, the observed event 
rate may well be much lower. In particular, for clinical outcomes such as stroke, MI, 
CHF, etc., the observed event rate could be much lower. To mimic this situation, after 
generating the survival data, we will introduce a non-informative right censoring scheme 
as follows.  We will simulate a censoring variable (C) with the Weibull distribution and 
the same increasing hazard and scale parameter such that each individual will have a 
survival time (T) and a censoring time (C). Individuals whose censoring time precedes 
their survival time will not be observed to have the event and will be censored as non-
events at time C.  Individuals whose censoring time is later than their survival time will 
be followed to time T.  The time to event variable Y is defined as the earlier of the 
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survival and censoring times, Y=minimum (T, C). The indicator of event status, E, takes 
the value 0 if C < 0 (event of interest not observed) and 1 if C ≥ T (event observed). 
 
Sample size: For our research, we will consider sample sizes of 250, 500, 1000 per group 
resulting in total samples of 500, 1000 and 2000 simulated subjects, in various situations 
to assess the effect of sample size on the performance of different censoring methods.    
 
Censoring Methods: We chose the beginning of the study as the point of entry and 
followed participants forward in time considering four different study periods: 
                 . We assumed that there is no left censoring. The study period    is the 
initial period in which Methods 1(analogous to censoring Method III) and Method 2 
(equivalent to censoring Method II) have the same follow-up. In Method 1, both events 
and non-events are followed through each of                , while in Method 2, events 
are followed through each of the follow-up periods, but non-events are censored at   . 
We start by comparing these methods in terms of baseline cumulative incidences, 
robustness and power. 
 
3.3.3  Estimation of Cumulative Incidence, Robustness and Power 
 
In order to estimate cumulative incidences and examine robustness, two groups of 
survival data sets are generated using identical parameters from the Weibull distribution. 
The number of times these data sets are generated and compared corresponds to the 
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number of iterations used for a given set of simulations. The two groups of data are then 
compared using a Chi-square test with the PHREG procedure in SAS 9.3. Among the 
estimates it generates is a K-M estimate of survival, the complement of which gives us an 
estimate of cumulative incidence. Robustness is measured by the Type I error rate, 
calculated as the percentage of iterations in which we reject the null hypothesis of no 
difference in hazard rates between the groups, when the two groups are sampled from the 
same distribution. 
 
To evaluate the performance of the two censoring methods in terms of power, for each 
simulation scenario, we define group 1 in our simulation scheme as a reference group and 
keep the Weibull parameters as is from the robustness models (under the null hypothesis). 
Group 2, a comparison group, is created with various Weibull scale parameters. For each 
scenario, we use the PHREG procedure, and compute the percentage of times that the 
null hypothesis is rejected for each test. The power of a test is the probability of rejecting 
the null hypothesis when it is in fact false. We assess, based on these percentages, which 
of the two censoring methods is more powerful under various simulation scenarios.   
All tests are performed using SAS 9.3 at the 5% level of significance. 
 
Number of Iterations: As we set up our simulated data so that the null hypothesis of no 
difference will be true, we would expect to find a Type I error rate of approximately 5%.  
To determine if our findings are within an acceptable range, we calculated 95% 
confidence intervals around a proportion p as, 
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   )/)ˆ1(ˆˆ( 2/1 nppzp    
Assume that pˆ ~ B (n, p), where n is the number of independent iterations, pˆ =0.05,      
(1- pˆ ) =0.95 and α=0.05. With various values of n we compute 95% confidence intervals 
that correspond to the number of iterations used in a particular set of simulations. These 
are shown in table 3.5.1. 
 
Table 3.3.1  Confidence Intervals for Various Numbers of Iterations  
 
Number of Iterations   
95% Confidence Interval 
Around α = 0.05 
500 0.036 – 0.066 
1000 0.038 – 0.063 
2500 0.042 – 0.059 
5000 0.043 – 0.057 
7500 0.045 – 0.056 
10000 0.046 – 0.055 
 
We chose 5000 iterations, which ensured a margin of error of 0.007. With more iteration, 
the precision of the estimate did not increase substantially; hence, 5000 iterations are 
used throughout. 
 
3.4 Summary 
 
In brief, we will generate survival data using a Weibull regression model with 
proportional hazard representation, assuming both increasing and constant hazards, with 
various scale parameters, and total sample sizes of 500, 1000 and 2000 each, keeping the 
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number of participants in each of the exposure groups equal, and assuming a hundred 
percent event rate with 50% censoring.  Tables below summarize these scenarios. 
 
Table 3.4.1 Simulation Details  
 
Survival Distributions   Weibull, Exponential 
Survival Outcome Time on Study 
Potential Event Rate 100% 
Percent Censored 50% 
Sample Size Per Group 250, 500, 1000 
Number of Iterations 5000 
 
 
 
 
Table 3.4.2 Simulation Scenarios for Robustness and Estimate of Cumulative 
Incidence with Percent Censored ~ 50%  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Survival Distribution   Sample Size 
Weibull (1.0, 0.12) 500, 1000, 2000 
Weibull (1.0, 0.06) 500, 1000, 2000 
Weibull (1.0, 0.03) 500, 1000, 2000 
    Weibull (1.0, 0.0214) 500, 1000, 2000 
  Weibull (1.0, 0.015) 500, 1000, 2000 
Weibull (1.0, 0.01) 500, 1000, 2000 
Weibull (1.15, 0.12) 500, 1000, 2000 
Weibull (1.15, 0.06) 500, 1000, 2000 
Weibull (1.15, 0.03) 500, 1000, 2000 
    Weibull (1.15, 0.0214) 500, 1000, 2000 
  Weibull (1.15, 0.015) 500, 1000, 2000 
Weibull (1.15, 0.01) 500, 1000, 2000 
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Table 3.4.3 Simulation Scenarios for Power Analyses  
 
Survival Distribution   
Sample 
Size 
Percent 
Censored  
Baseline Group :  
Weibull (1.0, 0.03) Vs. 
500, 1000, 
2000 
~ 50% 
Weibull (1.0, 0.12) √ √ 
Weibull (1.0, 0.06) √ √ 
Weibull (1.0, 0.03) √ √ 
Weibull (1.0, 0.214) √ √ 
Weibull (1.0, 0.015) √ √ 
Weibull (1.0, 0.01) √ √ 
Baseline Group :  
Weibull (1.15, 0.03) Vs. 
  
Weibull (1.15, 0.12) √ √ 
Weibull (1.15, 0.06) √ √ 
Weibull (1.15, 0.03) √ √ 
Weibull (1.15, 0.214) √ √ 
Weibull (1.15, 0.015) √ √ 
Weibull (1.15, 0.01) √ √ 
Weibull (1.15, 0.12) √ √ 
Baseline Group :  
Weibull (1.15, 0.06) 
Vs. 
Weibull (1.15, 0.03) 
 
500, 1000 
 
√ 
Baseline Group :  
Weibull (1.15, 0.04) 
Vs. 
Weibull (1.15, 0.02) 
 
500, 1000 
 
√ 
Baseline Group :  
Weibull (1.15, 0.0214)  
Vs. 
Weibull (1.15, 0.0107) 
 
500, 1000 
 
√ 
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4. Applications 
 
This chapter discusses the adaptation of the various censoring methods described in 
Chapter 3 to the Framingham Heart Study design. Results from applying standard 
survival models and the different censoring methods to three Framingham Heart Study 
data sets are presented. For all events of interest, the effects of various methods of 
censoring techniques on the estimation of disease incidence and the association between a 
specific risk factor and disease incidence are compared and contrasted. Performance 
measures including discrimination, calibration, net reclassification improvements and 
integrated discrimination improvement are investigated for the four methods of 
censoring. 
 
4.1 Results for Stroke following Exam 6 
 
The baseline characteristics of participants at exam 6 are summarized in table 4.1.1. For 
each censoring method, the number of incident strokes, the average duration of follow up, 
and the estimate of incidence per 1000 person years are depicted in table 4.1.2. The 
impact of the four censoring methods on the estimates of association between each of 
diabetes mellitus, stage I hypertension, current smoking status, history of atrial 
fibrillation, and C - reactive protein and incident stroke are summarized in tables 4.1.3 
through 4.1.7 respectively. These tables present hazard ratios from the Cox proportional 
hazards models adjusted for age and sex, and the corresponding discrimination C-
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statistics for assessment of model performance. Additionally, evaluation of these methods 
using calibration Chi-square and Net Reclassification Improvement are displayed in 
tables 4.1.8 through 4.1.10. 
 
Table 4.1.1 Baseline Characteristics 
 
 All Male Female 
N 3475 1624 1851 
Age, (mean ± SD) 59 ± 10 59 ± 10 59 ± 10 
Male, n (%) 1624 (47%)   
Systolic Blood Pressure, (mean ± SD) 128 ± 19 130 ± 17 127 ± 20 
Diabetes Mellitus, n (%) 372 (11%) 211 (13.3%) 161 (9.0%) 
Stage I Hypertension, n (%) 1427 (41.2%) 723 (44.7%) 704 (38.1%) 
Current Smoking, n (%) 531 (15.3%) 237 (14.6%) 294 (15.9%) 
Atrial Fibrillation, n (%) 89 (2.6%) 67 (4.1%) 22 (1.2%) 
C-reactive Protein,  
[Median (min, max)] 
2.02  
(0.16, 255.80) 
1.81  
(0.16, 202.20) 
2.31  
(0.16, 255.80) 
 
 
There were 3475 offspring participants found to be alive and free of stroke when their 
FHS exam 6 assessments were made, between 1995 and 1998. The ages of these 
participants ranged from 29 to 87 years with a mean age of 59 ±10 (SD) years. Forty-
seven percent of the participants were men, 11% had diabetes mellitus, about 41% had 
stage I hypertension, and about 15% reported current smoking. In general, as compared to 
women, men had slightly higher blood pressures and a higher prevalence of diabetes 
mellitus, hypertension, and atrial fibrillation. 
 
  
 
5
6
 
Table 4.1.2  Incident Stroke, duration of follow-up and estimate of incidence 
 
 
Exam 7 
(1998-2001) 
 
Exam 8 
(2005-2008) 
 
Events 
Non-
events 
Events 
Non-
events 
Method 
I 
N 27 3448 96 3379 
FU 
 
1.86±1.44 
 
2.80±1.08 5.56±3.02 8.55±2.65 
Inc 2.40 3.81 
 2002 2004 2006 2009 
 Events 
Non-
events 
Events 
Non-
events 
Events 
Non-
events 
Events 
Non-
events 
 
Method 
II 
N 
 
49 3426 75 3400 104 3371 137 3338 
FU 3.20±2.04 2.91±1.22 4.55±2.54 3.10±1.53 5.88±3.10 3.36±1.96 7.17±3.60 8.63±2.65 
Inc 4.22 6.06 7.71 4.38 
 
Method 
III 
N 
 
49 3426 75 3400 104 3371 137 3338 
FU 3.20±2.04 4.81±1.70 4.55±2.54 6.77±1.69 5.88±3.10 7.64±1.91 7.17±3.60 10.84±2.36 
Inc 2.73 3.03 3.77 3.52 
 
Method 
IV 
N 
 
49 2954 75 2932 104 2911 137 3019 
FU 3.20±2.04 4.62±1.77 4.55±2.54 6.51±2.54 5.88±3.10 7.43±2.11 7.17±3.60 10.37±2.86 
Inc 3.30 3.61 4.47 4.05 
 
FU: Duration of Follow up, mean ± SD; Inc: Incidence per 1000 person years 
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In table 4.1.2, Method I with follow up (FU) through exam 7 (1998-2001) yields 27 
incident strokes with an average FU of 1.9 years and 3448 non-strokes with an average 
FU of 2.8 years; the estimated incidence (Inc) of stroke is 2.40 per thousand person years. 
If we wait until exam 8 (2005-2008), we have 96 incident strokes (FU 5.6 years), and 
3379 non strokes (FU 8.6 years). The stroke incidence increases from 2.40 at exam 7 to 
3.10 at exam 8. This could quite possibly be due to the aging cohort. Other possible 
options, (as described in Chapter 3) of censoring with the years 2002, 2004, 2006, and 
2009 as the end of study periods are also employed.  
 
Extension of follow-up of events through 2002 using Method II, which extends the 
follow up for events but not for non-events, yields 49 incident strokes with a mean FU of 
3.2 years; the 3426 non-strokes have an average FU of 2.9 years, and the estimated 
incidence increases to 4.22. Extending event follow-up further through 2004 results in 75 
incident strokes (4.6 years of FU), 3400 non-strokes (3.1 years of FU) and more than 
twice the original estimate of incidence (6.06 versus 2.40). Furthermore, extension 
through 2006 captures 104 incident strokes with mean FU of 5.9 years, 3371 non-strokes 
with 3.4 years of FU and an even higher estimated incidence of 7.71. Clearly, this method 
catapults the estimate of incidence of stroke as compared to that of Method I. 
 
Method III extends FU for events as does Method II, but also extends FU for non-events.  
Extension of FU through 2002 using Method III  results in 49 incident strokes with an 
average FU of 3.2 years (as in Method II); however, FU is also extended for the 3426non-
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strokes to 4.8 years, and the estimated stroke incidence, 2.73, is closer to the Method I 
estimate. Extension of follow up through 2004 results in 75 incident strokes (FU of 4.6 
years), 3400 non-strokes (FU of 6.8 years), and estimated stroke incidence of 3.03, half 
that estimated using method II. By extending the study through 2006, this method 
captures 104 incident strokes with a mean follow up of 5.9 years, as did Method II, but 
also extends follow-up of the 3371 non-strokes to a mean of 7.6 years, and the  estimated 
stroke incidence of 3.77 is much closer to that estimated using Method I at exam 8. This 
method keeps the estimate of incidence stroke more reasonable as compared to Method 
II. 
 
Method IV also yields 49 incident strokes (FU of 3.2 years) in 2002 and captures 2952 
non-events (with an average FU of 4.6 years); the estimated stroke incidence was 3.3 - 
higher than that of Methods I and III. Extending the FU through 2004 results in 75 
incidents strokes (FU 4.6 years), 2932 non-strokes (FU 6.5 years) and estimated 
incidence of 3.61. With follow up through 2006 – Method IV captures 104 incident 
strokes (FU 5.9 years) and 2911 non-strokes (7.4 years of FU), and estimates stroke 
incidence as 4.47. 
 
Again, for Method I, extending the follow up through exam 8, there were 96 incident 
strokes (FU 5.6 years) and 2121 non-strokes (FU 8.6 years) and the estimated incidence 
was 3.10.  Exam 8 was administered between 2005 and 2008, and by extending FU to 
2009 yielded 137 strokes, nearly a 50% increase. There is always a tendency for 
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investigators to not want to wait until exam 9 to use these data.  Method II again 
increases FU for events but not for non-events, and over estimates incidence as 4.38.  
Method III extends FU for non-events and the estimate of incidence drops back to 3.52.  
Method IV extends FU for non-events but the non-events are censored at any of the CVD 
events other than stroke, consequently reduced number of non-events, and over estimates 
incidence as 4.05.  
 
In summary, Methods I and III produce similar estimates of stroke incidence as expected, 
because both the events and non-events are followed through at approximately the same 
period of time with these methods. Method II increases FU for events and not for non-
events, and over estimates the incidence. Likewise, Method IV increases FU for events 
and non-events, but the FU for non-events are conditional on whether they had any of the 
CVD events other than stroke prior to or during the study period, and overestimates 
stroke incidence.  
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Table 4.1.3 Diabetes Mellitus and Incident Stroke: Hazard Ratios and the 
Discrimination C-statistic 
 
 Exam 7 
(1998-2001) 
 Exam 8 
(2005-2008) 
 
Method 
I 
HR[CI] 
p 
2.67  
[1.15, 6.24] 
0.023 
1.96  
[1.20, 3.21] 
0.001 
 2002 2004 2006 2009 
Method 
II 
HR[CI] 
p 
 1.83  
[0.94, 3.54] 
0.074 
1.72  
[1.00, 2.94] 
0.049 
1.23  
[0.77, 1.98] 
0.383 
1.85  
[1.21, 2.81] 
0.004 
Method 
III 
HR[CI] 
p 
 2.08  
[1.07, 4.04] 
0.031 
2.16  
[1.26, 3.71] 
0.005 
1.92  
[1.20, 3.08] 
0.007 
1.94  
[1.28, 2.95] 
0.002 
Method 
IV 
HR[CI] 
p 
 2.71  
[1.41, 5.23] 
0.003 
2.58  
[1.51, 4.41] 
0.001 
2.48  
[1.55, 3.96] 
<0.001 
2.48  
[1.64, 3.75] 
0.001 
 
 
Exam 7 
(1998-2001) 
 Exam 8 
 (2005-2008) 
 
Method 
I 
C-
statistic 
0.7645 0.7411 
 2002 2004 2006 2009 
Method 
II 
C-
statistic 
 
0.7521 0.7327 0.7026 0.6581 
Method 
III 
C-
statistic 
 
0.7508 0.7436 0.7381 0.7398 
Method 
IV 
C-
statistic 
 
0.7744 0.7676 0.7624 0.7669 
 
The estimates of association between DM and incident stroke adjusting for age at 
baseline and sex are summarized in table 4.1.3. It appears that the impact of different 
methods of censoring on associations between risk factors and outcomes is quite variable 
as evident by the estimated hazard ratios (HR). The Method I estimate of the effect of 
DM on stroke incidence with FU through exam 7 (1998-2001) is 2.67 with CI [1.15, 
6.24]. Extending FU through the next exam cycle 8 (2005-2008) yields an estimated HR 
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of 1.96 and CI [1.20, 3.21]. These estimates change between exams 7 and 8. This perhaps 
is dictated by an increase in the number of events by exam 8 and consequently, a more 
stable estimate of HR by then. In practice, investigators tend not to wait until the end of 
the exam cycle to exploit FU information on both events and non-events. In one such 
scenario, Method II gives a smaller and non-significant estimate of effect of DM on 
stroke incidence with FU through each of 2002, 2004 and 2006.In contrast, Method III 
yields significant and more consistent estimates of HRs with FU through 2002, 2004, and 
2006. Method IV, which incorrectly censors observations at the manifestation of any of 
the CVD events (other than stroke) as non-events resulting in a smaller number of non-
events to that of the other methods, yields estimates of HRs greater than those from other 
methods at all FU periods. 
 
Method I, we believe, gives a more stable estimate of the effect of DM on stroke 
incidence at exam 8 than at exam 7, and Method III is rather stable in terms of estimating 
HRs over time. In contrast, Method II seems to result in smaller estimates of the effect of 
DM, increasingly as FU is extended further for events and not for non-events. And 
Method IV tends to yield consistently higher estimate of the effect of DM on stroke 
incidence at all periods. 
 
The C-statistic measuring the discrimination of the models in correctly classifying 
participants into one of the two categories of strokes and non-strokes are also presented in 
table 4.1.3. In general, a model with higher C-statistic is considered to have better 
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discrimination. It turns out that for Method I, with FU through exam 7; the C-statistic is 
0.7645, with a slight decrease to 0.7411 by extending the FU through exam 8. Method III 
results in a relatively stable c-statistic throughout the extension of FU from 2002, 2004, 
2006, decreasing slightly from 0.751 to 0.744 to 0.738. Method II C-statistics decrease by 
more, from 0.752 to 0.733 to 0.703 by 2006. C-statistics from Method IV are higher than 
those of the other methods and decrease only slightly over the three study periods 
extensions.  
 
The estimates of association between Stage I hypertension and incident stroke adjusting 
for age at baseline and sex are shown in table 4.1.4. In some cases, the censoring methods 
do not appear to affect the HRs while in others there is a substantive difference.  Method 
I estimate of the effect of Stage I hypertension on stroke incidence with FU through exam 
7 is 1.74 and CI [0.76, 4.00]. There is a substantial increase in the estimate of HR to 2.23 
and CI [1.43, 3.51] with FU extending through exam 8. The latter estimate, we believe, is 
due to an increase in number of events from exam 7 to exam 8, and also due to a longer 
duration of follow up for both events and non-events, hence, is more stable. Method II 
produces a lower estimate of the effect of hypertension on stroke incidence than Method I 
over each of the FU periods. However, there is a slight increase in the estimates of HRs 
and they are significant for FU through 2006 and 2009. Method III produces significant 
and steadily increasing estimate of HRs for FU through 2002, 2004, 2006 and 2009. 
These estimates are quite similar to those of Method I. Method IV consistently yields 
higher estimates of the association between hypertension and stroke at all FU periods.  
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Table 4.1.4 Stage I Hypertension and Incident Stroke: Hazard Ratios and the 
Discrimination C-statistic      
 
 Exam 7 
(1998-2001) 
 Exam 8 
(2005-2008) 
 
Method 
I 
HR[CI] 
p 
1.74 
[0.76, 4.00] 
0.193 
2.23 
[1.43, 3.51] 
<0.001 
 2002 2004 2006 2009 
Method 
II 
HR[CI] 
p 
 1.58 
[0.85, 2.93] 
0.151 
1.39 
[0.84, 2.30] 
0.195 
1.70 
[1.10, 2.64] 
0.017 
2.44 
[1.65, 3.61] 
<0.001 
Method 
III 
HR[CI] 
p 
 1.86  
[1.00, 3.46] 
0.044 
1.92 
[1.17, 3.17] 
0.010 
2.30 
[1.44, 3.45] 
<0.001 
2.61 
[1.77, 3.84] 
<0.001 
Method 
IV 
HR[CI] 
p 
 2.02 
[1.08, 3.79] 
0.027 
2.11 
[1.28, 3.49] 
0.004 
2.55 
[1.64, 3.95] 
<0.001 
2.82  
[1.91, 4.18] 
<0.001 
 
 
Exam 7 
(1998-2001) 
 Exam 8 
 (2005-2008) 
 
Method 
I 
C-
statistic 
0.7471 0.7406 
 2002 2004 2006 2009 
Method 
II 
C-
statistic 
 
0.7388 0.7129 0.6866 0.7195 
Method 
III 
C-
statistic 
 
0.7404 0.7392 0.7373 0.7463 
Method 
IV 
C-
statistic 
 
0.7601 0.7612 0.7590 0.7709 
 
Method I thus give a more stable estimate of the association of Stage I hypertension on 
stroke incidence at exam 8, and Method III is quite stable in terms of these estimates. 
Whereas Method II seems to give smaller estimate of the effect of hypertension and 
fluctuates increasingly as FU is extended further for events and not for non-events. 
Method IV consistently tends to yield higher estimates of the effect of hypertension on 
stroke incidence. 
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Similar to results in table 4.1.3, we see again decrease in the C-statistics as we extend FU, 
with greater decreases under Method II and with Method IV always higher. 
 
 
Table 4.1.5 Smoking and Incident Stroke: Hazard Ratios and the Discrimination C-
statistic      
 
 Exam 7 
(1998-2001) 
 Exam 8 
(2005-2008) 
 
Method 
I 
HR[CI] 
p 
1.39 
[0.47, 4.11] 
0.552 
1.87 
[1.11, 3.16] 
0.019 
 2002 2004 2006 2009 
Method 
II 
HR[CI] 
p 
 2.01 
[0.97, 4.16] 
0.059 
1.68 
[0.94, 3.01] 
0.083 
1.18 
[0.70, 2.00] 
0.539 
1.36 
[0.85, 2.17] 
0.204 
Method 
III 
HR[CI] 
p 
 2.38 
[1.16, 4.86] 
0.018 
2.20 
[1.23, 3.92] 
0.008 
1.75  
[1.06, 2.91] 
0.030 
1.65 
[1.04, 2.62] 
0.035 
Method 
IV 
HR[CI] 
p 
 2.50 
[1.23, 5.10] 
0.012 
2.49 
[1.40, 4.45] 
0.002 
2.07 
[1.25, 3.44] 
0.005 
1.88 
[1.18, 3.00] 
0.008 
 
 
Exam 7 
(1998-2001) 
 Exam 8 
 (2005-2008) 
 
Method 
I 
C-
statistic 
0.7454 0.7433 
 2002 2004 2006 2009 
Method 
II 
C-
statistic 
 
0.7356 0.7133 0.6939 0.7333 
Method 
III 
C-
statistic 
 
0.7471 0.7416 0.7419 0.7406 
Method 
IV 
C-
statistic 
 
0.7668 0.7642 0.7551 0.7571 
 
Table 4.1.5 shows the estimates of association between cigarette smoking and incident 
stroke adjusting for age and sex.  The effect of different censoring methods is quite 
variable as evident from the estimated HRs.  The effect size and significance levels for 
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Method I at exam 7 vs. that at exam 8 is different perhaps due to a difference in number 
of incident strokes along with an extended FU periods for both stroke and non-stroke 
participants from those at exam 7 to exam 8 . Method II yields a smaller and non-
significant effect of smoking on stroke incidence at all time periods. The effect sizes 
seem to fluctuate increasingly as the FU for strokes are extended but non-strokes are 
restricted. Method III provides steadily decreasing but significant estimate of HRs over 
all the FU periods which is similar to that from method I exam 8 estimate. Method IV 
Estimates of HRs seem to decrease consistently over the FU periods for Method IV as 
well, and are significant. However, this method consistently gives higher estimates of the 
association between smoking and incident stroke.  
 
The discrimination C-statistics for Method I at exam 7 and exam 8 are almost identical. 
The C-statistic again decreases over the period of extended FU to 2002, 2004, and 2006 
using all three of Methods II, III and IV. The Method II C-statistics decrease more 
rapidly than the Method III C- statistics and Method IV C-statistics start out and remain 
higher than either of the others.  
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Table 4.1.6 Atrial Fibrillation and Incident Stroke: Hazard Ratios and the 
Discrimination C-statistic      
 
 Exam 7 
(1998-2001) 
 Exam 8 
(2005-2008) 
 
Method 
I 
HR[CI] 
p 
0.83  
[0.11, 6.17] 
0.852 
1.22 
[0.44, 3.34] 
0.705 
 2002 2004 2006 2009 
Method 
II 
HR[CI] 
p 
 0.94  
[0.23, 3.90] 
0.928 
0.55 
[0.17, 1.77] 
0.315 
0.69 
[0.25, 1.88] 
0.464 
1.63 
[0.76, 3.53] 
0.213 
Method 
III 
HR[CI] 
p 
 1.17 
[0.28, 4.85] 
0.834 
1.13 
[0.35, 3.61] 
0.842 
1.08 
[0.40, 2.97] 
0.876 
1.69 
[0.79, 3.65] 
0.179 
Method 
IV 
HR[CI] 
p 
 1.89 
[0.45, 7.90] 
0.386 
1.80 
[0.56, 5.79] 
0.326 
1.85  
[0.68, 5.08] 
0.232 
2.80 
[1.29, 6.08] 
0.009 
 
 
Exam 7 
(1998-2001) 
 Exam 8 
 (2005-2008) 
 
Method 
I 
C-
statistic 
0.7462 0.7263 
 2002 2004 2006 2009 
Method 
II 
C-
statistic 
 
0.7381 0.7071 0.6879 0.7288 
Method 
III 
C-
statistic 
 
0.7351 0.7281 0.7215 0.7256 
Method 
IV 
C-
statistic 
 
0.7584 0.7526 0.7467 0.7515 
 
 
Associations between the history of AF and incident stroke are shown in table 4.1.6. 
Here, the methods and time of censoring appear to affect the HR quite a bit. Method I HR 
shows a non-significant protective effect of history of AF to incident stroke at exam 7 
and a non-significant effect in the opposite direction when the FU is extended through 
exam 8. This fluctuation perhaps is due to low prevalence of AF, to the fact that the 
number of events increased from exam 7 to exam 8, and also the FU is extended quite a 
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bit for both events and non-events at exam 8. We consider the exam 8 estimate as the 
most stable. Although none are significant, Method II HRs show a protective effect of 
history of AF on through each FU period before exam 8, while Method III results are in 
the direction of the Method I exam 8 result. Method IV estimates of the association 
between prevalent AF and incident stroke are consistently higher as compared to all other 
methods. After exam 8, all three of Methods II, III and IV show HR>1, with the Method 
IV result significant. 
 
Similar to the results for other risk factors, we see again decreases in the C-statistics as 
we extend FU, with greater decreases under Method II and with Method IV always 
higher. 
 
 
The estimates of association between the biomarker CRP and incident stroke are 
summarized in table 4.1.7. The Method I estimate of the effect of CRP on incident stroke 
with FU through exam 7 is 1.02 [0.69, 1.53]. When we extend the FU through exam 
cycle 8, the estimated HR increased slightly to 1.15 [0.93, 1.43]. All three of Methods II, 
III and IV have higher estimates than Method I in FU periods through 2002 and 2004, but 
by 2006, all are similar to exam 8 Method I. 
 
 
The higher the magnitude of the C-statistic the better the discrimination of the model. It 
turns out that for Method I, with FU through exam 7 the C-statistic is 0.7465, a slight 
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Table 4.1.7 C- reactive Protein and Incident Stroke: Hazard Ratios and the 
Discrimination C-statistic      
 
 Exam 7 
(1998-2001) 
 Exam 8 
(2005-2008) 
 
Method 
I 
HR[CI] 
p 
1.02 
[0.69, 1.53] 
0.907 
1.15 
[0.93, 1.43] 
0.208 
 2002 2004 2006 2009 
Method 
II 
HR[CI] 
p 
 1.30  
[0.96, 1.76] 
0.088 
1.24 
[0.96, 1.60] 
0.096 
0.96 
[0.77, 1.19] 
0.712 
1.09 
[0.91, 1.32] 
0.336 
Method 
III 
HR[CI] 
p 
 1.37 
[1.01, 1.86] 
0.042 
1.31 
[1.02, 1.67] 
0.035 
1.11 
[0.90, 1.36] 
0.344 
1.14 
[0.95, 1.37] 
0.154 
Method 
IV 
HR[CI] 
p 
 1.36 
[1.00, 1.84] 
0.047 
1.32 
[1.04, 1.69] 
0.026 
1.13 
[0.92, 1.39] 
0.230 
1.18  
[0.98, 1.41] 
0.079 
 
 
Exam 7 
(1998-2001) 
 Exam 8 
 (2005-2008) 
 
Method 
I 
C-
statistic 
0.7465 0.7229 
 2002 2004 2006 2009 
Method 
II 
C-
statistic 
 
0.7241 0.6981 0.6980 0.6581 
Method 
III 
C-
statistic 
 
0.7283 0.7277 0.7222 0.7206 
Method 
IV 
C-
statistic 
 
0.7505 0.7505 0.7442 0.7459 
 
 
decrease to 0.7229 by extending the FU through exam 8. Method III results into a 
relatively stable C-statistic throughout the extension of FU from 2002, 2004, 2006 and 
2009. Method II gives quite an unstable C-statistic, such that it gets increasingly smaller 
as FU is extended further for events and not for non-events. Whereas C-statistics from 
Method IV are higher than those of the other methods irrespective of whether the FU is 
through 2002, 2004, 2006, and 2009,  or even exams 7 or 8 in the case of Method I.  
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Table 4.1.8 Calibration results for various risk factors on Stroke data 
 
 
Exam 7 
(1998-2001) 
 
Exam 8 
(2005-2008) 
 
Method I 
Age, Sex 216.89 116.92 
Age, Sex, DM 441.13 81.79 
Age, Sex, S1HTN 198.60 174.45 
Age, Sex, Smoking 202.36 95.20 
Age, Sex, AF 216.72 106.72 
Age, Sex, CRP 188.31 93.04 
 2002 2004 2006 2009 
 
Method II 
Age, Sex 
 
174.77 49.82 172.71 67.43 
Age, Sex, DM 204.78 45.93 143.95 70.98 
Age, Sex, S1HTN 213.04 22.83 228.04 35.79 
Age, Sex, Smoking 82.36 31.43 205.30 78.81 
Age, Sex, AF 95.66 40.55 170.63 74.88 
Age, Sex, CRP 54.35 204.31 144.73 70.33 
 
Method III 
Age, Sex 
 
59.58 23.93 31.41 21.53 
Age, Sex, DM 79.57 6.53 56.30 18.41 
Age, Sex, S1HTN 169.87 24.33 57.17 16.42 
Age, Sex, Smoking 77.69 19.46 40.82 19.30 
Age, Sex, AF 59.53 26.59 30.79 19.83 
Age, Sex, CRP 17.99 36.43 43.38 19.64 
 
Method IV 
Age, Sex 
 
150.12 18.89 33.04 55.13 
Age, Sex, DM 45.56 12.52 44.83 48.44 
Age, Sex, S1HTN 80.11 17.63 59.73 52.39 
Age, Sex, Smoking 71.13 15.43 96.88 51.31 
Age, Sex, AF 15.06 18.46 37.75 52.15 
Age, Sex, CRP 23.50 21.94 54.91 56.01 
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Calibration results along with discrimination statistics described in previous sections are 
based on the theoretical description in Chapter 3. We adopted the concepts from 
D’Agostino, Nam and Pencina (2004), and used their macro in SAS to produce these 
results. In table 4.1.8, the calibration results from different censoring methods for each 
model with corresponding risk factors are summarized. The objective here is to assess 
which of the censoring methods/models is best calibrated. To assess this, a calibration 
Chi-square score with FU through exam 7 and exam 8 for Method I, and through each of 
2002, 2004, 2006 and 2009 for the other methods is compared to the Chi-square statistic 
with 9 degrees of freedom. Here the null hypothesis being the model predicted 
probabilities are equal to the true probability from Kaplan-Meier. It is desirable not to 
reject the null, such that a smaller Chi-square corresponds to a better calibrated model. 
 
Calibration statistics for Method I show that the models with each of the RFs adjusted for 
age and sex seem better calibrated, if the FU is extended through exam 8 than through 
exam 7. Method III with the FU through each of the study periods calibration scores are 
clearly better than those from Method II. Method IV seems to calibrate as well as Method 
III but since this method tends to censor non-events incorrectly if any subjects have 
prevalent CVD other than stroke. This is hence a flawed method. 
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Table 4.1.9 Net Reclassification Improvement results for various risk factors on Stroke data [Full Follow-up] 
 Ex7 (1998-2001) 
 
Ex8(2005-2008) 
 
Method I 
Events|Non-Events 27|3448 96|3379 
Follow-up, years 7 years 14 years 
Age, Sex, DM 0.19[-0.21, 1.05] 0.34[-0.08, 0.83] 
Age, Sex, S1HTN 0.64[-0.18, 1.07] 0.54[0.04, 0.97] 
Age, Sex, Smoking -0.23[-0.45, 0.31] 0.14[-0.22, 0.54] 
Age, Sex, AF 0.50[-0.37, 0.94] -0.11[-0.56, 0.41] 
Age, Sex, CRP -0.55[-1.18, 0.55] -0.02[-0.51, 0.33] 
 2002 2004 2006 2009 
 
Method II 
Events|Non-Events 
 
49|3426 75|3400 104|3371 137|3338 
Follow-up, years 8 years 10 years 12 years 15 years 
Age, Sex, DM -0.23[-0.66, 0.19] 0.16[-0.13, 0.49] -0.42[-1.01, 0.18] -0.17[-0.56, 0.19] 
Age, Sex, S1HTN -0.46[-1.60, 0.81] 0.17[-0.26, 0.60] -0.74[-1.35, 2.15] 1.08[-0.004, 2.75] 
Age, Sex, Smoking 0.30[-0.44, 1.17] 0.25[-0.16, 0.67] -0.46[-1.43, 0.15] -0.60[-1.36, -0.25] 
Age, Sex, AF -0.40[-1.44, 0.63] 0.26[0.09, 0.41] -1.09[-1.62, 1.29] 0.03[-1.43, 1.44] 
Age, Sex, CRP 0.98[0.41, 1.52] 0.31[-0.11, 0.75] -1.29[-2.38, 0.55] -1.59[-2.22, 0.38] 
 
Method III 
Events|Non-Events 
 
49|3426 75|3400 104|3371 137|3338 
Follow-up, years 8 years 10 years 12 years 15 years 
Age, Sex, DM 0.17[-0.08, 0.37] 0.33[0.04, 0.63] 0.63[-0.05, 0.83] 0.10[-0.07,0.18] 
Age, Sex, S1HTN -0.33[-0.75, 0.91] 0.63[0.37, 0.88] 0.32[-0.18, 1.03] 0.87[0.58,1.12] 
Age, Sex, Smoking 0.70[-0.22, 1.41] 0.25[-0.05, 0.55] 0.22[-0.09, 0.22] 0.10[-0.12,0.19] 
Age, Sex, AF -0.80[-1.63, 0.31] -0.43[-0.54, -0.30] 0.46[-0.96, 2.08] -0.58[-0.80,-0.34] 
Age, Sex, CRP 0.98[0.15, 1.47] 0.30[-0.01, 0.59] -0.40[-1.45, 0.84] -0.41[-0.92,0.18] 
 
Method IV 
Events|Non-Events 
 
49|2952 75|2932 104|2911 137|3019 
Follow-up, years 8 years 10 years 12 years 15 years 
Age, Sex, DM 0.03[-0.11, 0.40] 0.42[0.09, 0.75] 0.71[-0.50, 1.21] 0.03[-0.21, 0.25] 
Age, Sex, S1HTN -0.20[-0.67, 0.96] 0.73[0.44, 0.99] 0.20[-1.09, 1.39] 1.01[0.70, 1.42] 
Age, Sex, Smoking 0.64[-0.21, 1.36] 0.29[-0.02, 0.62] 0.16[-0.39, 0.48] 0.09[-0.03, 0.11] 
Age, Sex, AF 0.09[-1.05, 0.58] -0.51[-0.68, -0.30] 0.62[-1.09, 2.24] -0.69[-1.04, -0.30] 
Age, Sex, CRP 0.95[0.26, 1.33] 0.31[0.01, 0.61] -0.74[-2.24, 0.86] -0.36[-0.84, 0.25] 
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Table 4.1.10 Net Reclassification Improvement results for various risk factors on Stroke data [10 years Follow-up] 
 Ex7 (1998-2001) 
 
Ex8 (2005-2008) 
 
Method I 
Events|Non-Events 27|3448 96|3379 
Follow-up, years 7 years 10 years 
Age, Sex, DM 0.19[-0.21, 1.05] 0.20[0.01,0.38] 
Age, Sex, S1HTN 0.64[-0.18, 1.07] 0.66[0.46,0.86] 
Age, Sex, Smoking -0.23[-0.46, 0.31] 0.11[-0.11,0.23] 
Age, Sex, AF 0.50[-0.37, 0.94] -0.26[-0.37,-0.11] 
Age, Sex, CRP -0.55[-1.18, 0.55] -0.04[-0.24,0.20] 
 2002 2004 2006 2009 
 
Method II 
Events|Non-Events 
 
49|3426 75|3400 104|3371 137|3338 
Follow-up, years 8 years 10 years 10 years 10 years 
Age, Sex, DM -0.23[-0.66, 0.19] 0.16[-0.13, 0.49] -0.01[-0.19,0.20] 0.21[0.05,0.39] 
Age, Sex, S1HTN -0.46[-1.60, 0.81] 0.17[-0.26, 0.60] 0.44[0.16,0.72] 0.75[0.58,0.92] 
Age, Sex, Smoking 0.30[-0.44, 1.17] 0.25[-0.16, 0.67] -0.09[-0.27,0.11] 0.06[-0.10,0.23] 
Age, Sex, AF -0.40[-1.44, 0.63] 0.26[0.09, 0.41] 0.20[-0.05,0.40] -0.28[-0.39,-0.15] 
Age, Sex, CRP 0.98[0.41, 1.52] 0.31[-0.11, 0.75] 0.14[-0.28,0.54] -0.06[-0.28,0.18] 
 
Method III 
Events|Non-Events 
 
49|3426 75|3400 104|3371 137|3338 
Follow-up, years 8 years 10 years 10 years 10 years 
Age, Sex, DM 0.17[-0.08, 0.37] 0.33[0.04, 0.63] 0.27[-0.01,0.40] 0.27[0.09,0.46] 
Age, Sex, S1HTN -0.33[-0.75, 0.91] 0.63[0.37, 0.88] 0.80[0.61,0.95] 0.67[0.49,0.86] 
Age, Sex, Smoking 0.70[-0.22, 1.41] 0.25[-0.05, 0.55] 0.09[-0.12,0.33] 0.07[-0.09,0.25] 
Age, Sex, AF -0.80[-1.63, 0.31] -0.43[-0.54, -0.30] -0.36[-0.48,-0.20] -0.08[-0.18,0.05] 
Age, Sex, CRP 0.98[0.15, 1.47] 0.30[-0.01, 0.59] -0.04[-0.32,0.26] -0.10[-0.31,0.11] 
 
Method IV 
Events|Non-Events 
 
49|2952 75|2932 104|2911 137|3019 
Follow-up, years 8 years 10 years 10 years 10 years 
Age, Sex, DM 0.03[-0.11, 0.40] 0.42[0.09, 0.75] 0.28[0.07,0.53] 0.33[0.15,0.52] 
Age, Sex, S1HTN -0.20[-0.67, 0.96] 0.73[0.44, 0.99] 0.90[0.70,1.08] 0.76[0.57,0.94] 
Age, Sex, Smoking 0.64[-0.21, 1.36] 0.29[-0.02, 0.62] 0.11[-0.10,0.36] 0.09[-0.06,0.25] 
Age, Sex, AF 0.09[-1.05, 0.58] -0.51[-0.68, -0.30] -0.53[-0.66,-0.37] -0.24[-0.34,-0.13] 
Age, Sex, CRP 0.95[0.26, 1.33] 0.31[0.01, 0.61] -0.02[-0.30,0.30] -0.04[-0.26,0.18] 
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For net reclassification improvement, we used a method developed by Pencina, 
D’Agostino et al. (2011), which gives a general form of NRI as a prospective measure 
that quantifies the correctness of upward and downward reclassification of predicted 
probabilities as a result of adding a new marker. Pencina and Kennedy’s SAS macro was 
adopted to calculate these scores with our four censoring methods for each of the risk 
factors, and comparisons were made between models at each of the study periods. 
 
As the NRI is designed to quantify improvements in performance, and its magnitude is 
considered to be more important than statistical significance, we present, as 
recommended by Pencina et al. (2011), NRIs with confidence intervals. Here we are 
looking at the improvement in model performance based on including a RF of interest in 
the basic model with just age and sex. Table 4.3.9 summarizes these results with full FU 
for each method at each of the study periods, while table 4.3.10 shows similar results if 
we restrict to 10 years of FU. 
 
Diabetes Mellitus: 
Estimates for DM, show that Method I with FU through exam 7 has an estimated NRI of 
0.19 [-0.21, 1.05].  If we extend the FU through exam 8, the estimate increases to 0.34 [-
0.08, 0.83] which is a substantial improvement in an estimate of calibration. 
Extending the study period through each of 2002, 2004 and 2006, Method III 
outperforms Methods II and IV except in 2006, where Method IV seems to have better 
improvement in discrimination. However, recall that Method IV incorrectly censors 
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participants at the manifestation of any of the CVD events other than stroke, resulting in a 
reduced number of non-events as compared to other methods.   Hence, Method IV should 
not be used. Also, Method II results are extremely variable. 
 
If we consider 10 years of FU (table 4.3.10) instead of the full FU, Method I with FU 
through exam 7 yields an estimate of NRI of 0.19 [-0.21, 1.05]. By extending the FU 
through exam 8, Method I yields an estimate of NRI 0.20 with a much narrower CI of 
[0.01, 0.38]. Again, this reduction in variability is perhaps due to an increased length of 
FU for both strokes and non-strokes from exam 7 to exam 8 and also due to an increased 
number of incident events,   even though, this may partly be due to an aging cohort from 
exam 7 to exam 8. Yet again, Method II which extends the FU for events but not for non-
events shows quite an unstable estimate of NRI.  This is not the case with Method III. In 
fact, Method III gives a relatively stable estimate of NRIs at each of 2002, 2004, 2006 
and 2009 periods, and close to those from Method I. Although Method IV results seem to 
be closer to that of Method III, this is a flawed method in terms of censoring non-events, 
and therefore should not be considered. 
 
Stage I Hypertension: 
For stage I hypertension, Method I with a study period through exam 7, produces an 
estimate NRI of 0.64 [-0.18, 1.07]. There is a slight decrease in magnitude of NRI when 
we extend the FU through exam 8: 0.54 [0.04, 0.97]. With Method II, as we extend the 
FU for events but not for non-events, the NRI estimates fluctuate widely. Method III with 
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FU through 2004 shows similar improvement in NRI as Method I. Even though Method 
IV seems to do as good as Method III the study period extended through 2004 and 2009, 
as discussed earlier, it is still a flawed method.  
 
When we limit the follow-up to 10 years for all methods, the NRI estimates for Method I 
(study period through exam 8) and Method III extending the study periods through each 
of 2004, 2006 and 2009 are similar. Method II estimates of NRI increase as the FU is 
extended for events but not for non-events.  Again, for all study periods except through 
2002, Method IV seems to yield higher NRIs.  
 
Smoking: 
The estimates of improvement in discrimination with smoking as a marker shows (table 
4.1.9) that with each method, as we extend the FU further, NRI decreases. As with other 
RFs, Method I shows a better improvement in NRI as the FU is extended through exam 8 
than exam 7.  
 
Method II, which extends the FU for strokes but not for non-stroke cohort, estimates of 
NRIs varies widely.  The NRI decreases rapidly as FU is extended further. Method III, 
where the FU is extended for subjects with strokes and non-strokes, shows NRIs similar 
to those observed for Method I, and larger estimates than Method II at FU through 2002, 
2006 and 2009 respectively.   
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With 10 years of FU (table 4.1.10), we see similar trends with Method I showing better 
discrimination with FU periods through exam 8 as compared to FU through exam 7. 
Method II yields a decreased estimate of NRIs as we extend the FU for events but not for 
non-events. Likewise, both Methods III and IV estimates decline over the FU periods. 
 
Furthermore, with a FU period through 2002, Method III yields higher estimate of NRIs 
than Methods II and IV. At 2004based on the estimates of NRIs, Method IV seems to do 
better than Methods II and III.  Although estimates for the latter are equal in magnitude, 
Method III shows less variability. We obtained similar findings by extending the FU 
through 2006 and 2009. 
 
Atrial Fibrillation: 
The estimates of improvement in discrimination with AF as a marker are quite variable in 
terms of NRIs for every method at each of the FU periods. With full follow-up (table 
4.1.9), Method I with study period through exam 7 outperforms other methods at all 
study periods, except perhaps at 2006 where Method III does equally well, and Method 
IV seem to do better. 
 
At the FU period of 2002, Method IV is better, followed by Methods II and III 
respectively based on the estimates of NRIs. Likewise, with FU through 2006, NRI 
estimate from Method IV seem to be better than Method III followed by Method II. With 
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the FU through 2004 and 2009 however, Method II seems to outperform the other two 
methods.  
 
With 10 years of follow-up, we see similar findings. Except for FU through 2006, 
Method II performs better followed by Method III and then Method IV.   At 2009, the 
Method III estimate of NRI is better than that of Method IV followed by Method II. 
 
Overall, with AF as a biomarker, estimates of improvement in discrimination are quite 
unstable. This perhaps is due to the fact that prevalence of AF is low. 
 
C –reactive Protein: 
For the CRP data, the values of NRI varied widely depending on which method of 
censoring we used and how far the FU was extended. Method I with the FU period 
through exam 7 and exam 8 both yield similar magnitudes yet in opposite direction. With 
the FU through 2002, the NRIs for each of Methods II, III and IV are almost identical, in 
positive directions. When we extend FU through 2004, the magnitudes of the estimates 
reduced to one third of those at 2002, but are in positive direction. However, extending 
FU through 2006 and 2009, estimates of NRI varies widely.  The estimates of NRIs are in 
opposite directions. This trend persists even when we use a 10 year follow up for the 
development of stroke
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4.2 Results for Myocardial Infarction following Exam 6 
 
The baseline characteristics of participants at exam 6 are summarized in table 4.2.1. For 
each censoring method, the number of incident MIs, the average duration of follow up 
and the estimate of incidence per 1000 person years are depicted in table 4.2.2. The 
impact of the four censoring methods on the estimates of association between each of 
diabetes mellitus, stage I hypertension, current smoking status, history of atrial 
fibrillation, and C - reactive protein and incident MI are summarized in tables 4.2.3 
through 4.2.7 respectively. These tables present hazard ratios from the Cox proportional 
hazards models adjusted for age and sex, and the corresponding discrimination C-
statistics for assessment of model performance. Additionally, evaluation of these methods 
using calibration Chi-square and Net Reclassification Improvement are displayed in 
tables 4.2.8 through 4.2.10. 
 
Table 4.2.1  Baseline Characteristic 
 
 All Male Female 
N 3374 1531 1843 
Age, (mean± SD) 59 ± 10 59 ± 10 59 ± 10 
Male, n (%) 1531 (45%)   
Systolic Blood Pressure, (mean± SD) 128 ± 19 130 ± 17 127 ± 20 
Diabetes Mellitus, n (%) 340 (10.4%) 181 (12.1%) 159 (8.9%) 
Stage I Hypertension, n (%) 1361 (40.5%) 670 (43.9%) 691 (37.6%) 
Current Smoking, n (%) 513 (15.2%) 223 (14.6%) 290 (15.7%) 
Atrial Fibrillation, n (%) 71 (2.1%) 51 (3.3%) 20 (1.1%) 
C-reactive Protein,  
Median (min, max)] 
2.03  
(0.16, 255.80) 
1.81  
(0.16, 202.20) 
2.34  
(0.16, 255.80) 
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There were 3374 offspring participants found to be alive and free of MI when their FHS 
examination 6 assessments were made, between 1995 and 1998.  The ages of these 
participants ranged from 29 to 87 years with a mean age of 59 ±10 years. Forty-five 
percent of the participants were men, 10% had diabetes mellitus, about 41% had stage I 
hypertension and about 15% reported current smoking. In general, as compared to 
women, more men had slightly higher blood pressures and a higher prevalence of 
diabetes mellitus, hypertension, and atrial fibrillation. On average, C-reactive protein was 
higher in women than in men. 
 
In Table 4.2.2,  Method I with FU through exam 7(1998- 2001) yields 38 incident MIs 
with an average FU of 1.7 years and 3336 non-MIs have an average FU of 2.8 years.  The 
estimated incidence of MI is 3.50 per thousand person years. If we wait until exam 8 
(2005-2008) we have 114 incident MIs (FU 4.7 years) and 3260 non MIs (FU 8.6 years). 
The MI incidence increases from 3.50 at exam 7 to 3.81 at exam 8.  This could possibly 
be due to the aging cohort. Other possible options, as described in Chapter 3, of censoring 
with the years 2002, 2004, 2006, and 2009 as the end of study periods are also employed.  
 
 
 
 
 
 
 
 
  
 
8
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Table 4.2.2 Incident MI, duration of follow up and estimates of incidence  
 
 
Exam 7 
(1998-2001) 
 
Exam 8 
(2005-2008) 
 
Events 
Non-
events 
Events 
Non-
events 
Method 
I 
N 38 3336 114 3260 
FU 
 
1.69±1.12 
 
2.80±1.08 4.72±2.70 
8.56±2.6
3 
Inc 3.50 3.81 
 2002 2004 2006 2009 
 Events 
Non-
events 
Events 
Non-
events 
Events 
Non-
events 
Events 
Non-
events 
 
Method 
II 
N 
 
74 3300 101 3273 125 3249 153 3221 
FU 3.19±1.89 2.91±1.22 4.22±2.44 3.08±1.51 5.15±2.96 3.34±1.96 6.18±3.46 8.64±2.64 
Inc 6.55 6.06 9.62 5.06 
 
Method 
III 
N 
 
74 3300 101 3273 125 3249 153 3221 
FU 3.19±1.89 4.73±1.72 4.22±2.44 6.71±1.67 5.15±2.96 7.63±1.88 6.18±3.46 10.79±2.36 
Inc 4.32 3.03 4.65 4.09 
 
Method 
IV 
N 
 
74 3061 101 2932 125 3016 153 2995 
FU 3.19±1.89 4.62±1.78 4.22±2.44 6.58±1.83 5.15±2.96 7.45±2.10 6.18±3.46 10.41±2.82 
Inc 4.77 3.61 5.11 4.54 
 
FU: Duration of Follow up, mean ± SD; Inc: Incidence per 1000 person years 
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Method II which extends the follow up for events but not for non-events, by extending 
the duration of follow up for events through 2002, yields 74 incident MIs with a mean FU 
of 3.2 years. The 3300 non-MIs have an average follow up of 2.9 years, and a much 
higher estimated incidence of 6.55. Extending event FU further through 2004 results in 
101 incident MIs (4.2 years of FU), 3273 non-MIs (3.1 years of FU) and more than two 
times the original estimate of incidence (8.43 versus 3.50). In addition, extension through 
2006 captures 125 incident MIs with average FU of 5.2 years, 3249 non-MIs with 3.3 
years of mean FU and even higher estimated incidence of 9.62. Evidently, this method 
shoots the estimate of incidence of MI as compared to that of Method I. 
 
Method III extends FU for MIs as does Method II, but also extends FU for non MIs. 
Extension of FU through 2002 using Method III results in 74 incident MIs with an 
average FU of 3.2 years (similar to that in Method II). However, FU is also extended for 
the 3300 non-MIs to an average of 4.7 years, and the estimated MI incidence drops back 
to 4.32, which is closer to the Method I estimate. Extension of FU through 2004 results in 
101 incident MIs (FU 4.2 years), 3273 non-MIs (FU 6.7 years), and estimated MI 
incidence of 4.25, almost half of that estimated by using Method II. By extending the 
study through 2006, this method also captures 125 incident MIs with the mean FU of 5.2 
years, as did Method II, but also extends FU of the 3249 non-MIs to a mean of 7.6 years, 
and the estimated MI incidence of 4.65is much closer to that estimated using Method I at 
exam 8. This method maintains the estimate of incidence MI more realistic as compared 
to Method II. 
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Method IV also yields 74 incident MIs (FU 3.2 years) in 2002   and captures 3061 non-
MIs with an average FU of 4.6 years. The estimated MI incidence was 4.77 - higher than 
that of Methods I and III. Extending the FU through 2004 results in 101 incidents MIs 
(FU of 4.2 years), 2932 non-MIs (FU of 6.6 years), and estimated incidence of 4.66. With 
follow up through 2006 – Method IV captures 125 incident MIs (FU 5.2 years), 3016 
non-MIs (7.5 years FU), and estimates MI incidence as 5.11. 
 
Again, for Method I, extending the follow up through exam 8, there were 114 incident 
MIs (FU 4.7 years) and 3260 non-MIs (FU 8.6 years) and the estimated incidence was 
3.81.  The exam 8 was administered between 2005 and 2008, and by extending FU to 
2009 yielded 153 incident MIs, nearly a 50% increase. There is always a tendency for 
investigators to not want to wait until exam 9 to use these data.  Method II again 
increases FU for events but not for non-events, and over estimates incidence as 5.06.  
Method III extends FU for non-events and the estimate of incidence drops back to 4.09.  
Method IV extends FU for non-events but the non-events are censored at any of the CVD 
events other than MI, consequently reduced number of non-events, and over estimates 
incidence as 4.54.  
 
In summary, Methods I and III produce similar estimates of MI incidence, as was 
expected, because both the events and non-events followed through approximately the 
same period of time with these methods. In contrast, Method II increases FU for events 
and not for non-events, and over estimates the incidence. Likewise, Method IV increases 
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FU for events and non-events, but the FU for non-events are conditional on whether they 
had any of the CVD events other than MI prior to or during the study period, and gives 
consistently higher MI incidence. 
 
Table 4.2.3 Diabetes Mellitus and Incident MI: Hazard Ratios and the 
Discrimination C-statistic      
 
 Exam 7 
(1998-2001) 
 Exam 8 
(2005-2008) 
 
Method 
I 
HR[CI] 
p 
3.40 
[1.69, 6.85] 
0.001 
2.86 
[1.86, 4.40] 
<0.001 
 2002 2004 2006 2009 
Method 
II 
HR[CI] 
p 
 2.72 
[1.62, 4.56] 
<0.001 
1.94  
[1.21, 3.12] 
0.006 
1.91 
[1.25, 2.92] 
0.003 
2.53 
[1.72, 3.71] 
<0.001 
Method 
III 
HR[CI] 
p 
 3.20 
[1.91, 5.38] 
<0.001 
2.63 
[1.64, 4.20] 
<0.001 
2.52 
[1.65, 3.85] 
<0.001 
2.55 
[1.74, 3.75] 
<0.001 
Method 
IV 
HR[CI] 
p 
 3.57 
[2.14, 5.97] 
<0.001 
2.97  
[1.86, 4.74] 
<0.001 
2.92  
[1.91, 4.46] 
<0.001 
2.88 
[1.96, 4.23] 
<0.001 
 
 
Exam 7 
(1998-2001) 
 Exam 8 
 (2005-2008) 
 
Method 
I 
C-
statistic 
0.7499 0.7253 
 2002 2004 2006 2009 
Method 
II 
C-
statistic 
 
0.7442 0.7225 0.6978 0.7177 
Method 
III 
C-
statistic 
 
0.7361 0.7189 0.7132 0.7119 
Method 
IV 
C-
statistic 
 
0.7492 0.7339 0.7301 0.7323 
 
 
The estimates of association between DM and incident MI adjusting for age at baseline 
and sex are summarized in table 4.2.3. It appears that the impact of different methods of 
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censoring on associations between risk factors and outcomes is quite variable as 
evidenced by the estimated Hrs. The Method I estimate of the effect of DM on MI 
incidence with FU through exam 7 (1998-2001) is 3.40 with CI of [1.69, 6.85]. Extending 
the FU through exam cycle 8 (2005-2008) results an estimated HR of 2.86, CI [1.86, 
4.40]. Apparently these estimates change between exams 7 and 8, which perhaps is 
dictated by an increase in the number of MIs by exam 8,and longer duration of FU for 
both events and non-events,  hence, a more stable estimate of HR by then. In practice, 
investigators do tend not to wait until the end of the exam cycle to make use of FU 
information on both events and non-events. In one such scenario, Method II gives a 
smaller but significant estimate of the effect of DM on MI incidence with FU through 
each of 2002, 2004, 2006 and 2009. Method III yields significant and more consistent 
estimates of HRs with FU through 2002, 2004, 2006 and 2009. Method IV, which 
incorrectly censors observations at the manifestation of any of the CVD events (other 
than MI) as non-events resulting in a smaller number of non-MIs to that from the other 
methods, gives estimates of HRs greater than those from other methods at all FU periods 
even though the effect size drops from the first period to the last. 
 
Method I, we believe, gives a more stable estimate of the effects of DM on MI incidence 
at exam 8 than at exam 7, and Method III is rather stable in terms of estimate of the HRs 
over time. Whereas estimates from Method II seem to be smaller, the effect size dips as 
the FU is extended further for events and not for non-events. Method IV tends to yield 
consistently higher estimate of the effect of DM on MI incidence at all periods. 
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The discrimination ability of a survival model under various censoring method are also 
presented in table 4.2.3. In general, a model with higher C-statistic is considered to have 
better discrimination. It turns out that for Method I, with FU through exam 7, the C-
statistic of 0.7499, slightly decreases to 0.7253 by extending the FU through exam 8. 
Method III results into rather stable C-statistic throughout the extension of FU from 2002, 
2004, 2006, decreasing slightly from 0.736 to 0.719to 0.713. The C-statistics from 
Method II decrease by more, from 0.744 to 0.723 to 0.698 by 2006. The C-statistics from 
Method IV are higher than those of the other methods and decrease only slightly from 
0.749 to 0.734 to 0.730 by 2006.  
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Table 4.2.4 Stage I Hypertension and Incident MI: Hazard Ratios and the 
Discrimination C-statistic      
 
 Exam 7 
(1998-2001) 
 Exam 8 
(2005-2008) 
 
Method 
I 
HR[CI] 
p 
1.60 
[0.80, 3.18] 
0.183 
2.37 
[1.56, 3.58] 
<0.001 
 2002 2004 2006 2009 
Method 
II 
HR[CI] 
p 
 2.00  
[1.20, 3.32] 
0.008 
1.76 
[1.15, 2.70] 
0.009 
1.58 
[1.08, 3.32] 
0.020 
2.10  
[1.47, 2.99] 
<0.001 
Method 
III 
HR[CI] 
p 
 2.48  
[1.48, 4.15] 
0.001 
2.24  
[1.45, 3.45] 
<0.001 
2.04 
[1.39, 3.00] 
<0.001 
2.13  
[1.50, 3.03] 
<0.001 
Method 
IV 
HR[CI] 
p 
 2.55 
[1.53, 4.27] 
<0.001 
2.29 
[1.48, 3.53] 
<0.001 
2.18  
[1.48, 3.21] 
<0.001 
2.28 
[1.61, 3.25] 
<0.001 
 
 
Exam 7 
(1998-2001) 
 Exam 8 
 (2005-2008) 
 
Method 
I 
C-
statistic 
0.7528 0.7232 
 2002 2004 2006 2009 
Method 
II 
C-
statistic 
 
0.7381 0.7141 0.6911 0.7166 
Method 
III 
C-
statistic 
 
0.7299 0.7153 0.7066 0.7134 
Method 
IV 
C-
statistic 
 
0.7457 0.7319 0.7255 0.7351 
 
The estimates of association between Stage I hypertension and incident MI adjusting for 
age at baseline and sex are shown in table 4.2.4.  It turns out that the censoring methods 
do not appear to affect the HRs in some cases, while in others, there is a difference.  
Method I estimate of the effect of Stage I hypertension on MI incidence with FU through 
exam 7 is 1.60 and CI [0.80, 3.18]. There is a substantial increase in the estimate of HR 
to 2.37 and CI [1.56, 3.58] with FU extending through exam 8. The latter estimate, we 
believe, is due to an increase in number of events from exam 7 to exam 8, and also due to 
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a longer duration of follow up for both MIs and non-MIs, consequently, is more stable. 
Method II produces lower estimates of the effect of hypertension on MI incidence over 
each of the FU periods 2002, 2004 and 2006.  However, there is a slight increase in the 
estimate of HR for FU through 2009. Method III produces a significant and steadier 
estimate of HRs for FU through each of 2002, 2004, 2006 and 2009. These estimates are 
fairly similar to those from Method I exam 8. Method IV consistently yields higher 
estimates of the association between hypertension and MI as compared to other methods 
at each of the FU periods.  
 
To sum up, Method I gives a more stable estimate of the association of Stage I 
hypertension on MI incidence at exam 8, and Method III is relatively stable in terms of 
these estimates. Whereas Method II seems to give consistently lower estimates of the 
effect of hypertension and fluctuates increasingly as FU is extended further for MIs and 
not for non-MIs. Method IV tends to produce higher estimates of the effect of 
hypertension on MI incidence. 
 
Similar to the results in table 4.2.3, we see again decreases in the C-statistics as we 
extend FU, with greater decreases under Method II and with Method IV always higher. 
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Table 4.2.5 Smoking and Incident MI: Hazard Ratios and the Discrimination C-
statistic      
 
 Exam 7 
(1998-2001) 
 Exam 8 
(2005-2008) 
 
Method 
I 
HR[CI] 
p 
3.03 
[1.48, 6.22] 
0.003 
4.21 
[1.20, 3.21] 
0.001 
 2002 2004 2006 2009 
Method 
II 
HR[CI] 
p 
 2.17 
[1.28, 3.69] 
0.004 
2.81 
[1.82, 4.33] 
<0.001 
2.38  
[1.61, 3.51] 
<0.001 
3.16 
[2.21, 4.52] 
<0.001 
Method 
III 
HR[CI] 
p 
 3.19  
[1.90, 5.37] 
<0.001 
4.20 
[2.75, 6.42] 
<0.001 
3.54 
[2.40, 5.20] 
<0.001 
3.38  
[2.36, 4.83] 
<0.001 
Method 
IV 
HR[CI] 
p 
 3.34 
[1.99, 5.61] 
<0.001 
4.53 
[2.97, 6.92] 
<0.001 
3.83 
[2.60, 5.63] 
<0.001 
3.59 
[2.51, 5.14] 
<0.001 
 
 
Exam 7 
(1998-2001) 
 Exam 8 
 (2005-2008) 
 
Method 
I 
C-
statistic 
0.7730 0.7615 
 2002 2004 2006 2009 
Method 
II 
C-
statistic 
 
0.7554 0.7421 0.7172 0.7492 
Method 
III 
C-
statistic 
 
0.7546 0.7647 0.7572 0.7394 
Method 
IV 
C-
statistic 
 
0.7663 0.7782 0.7714 0.7571 
 
 
Table 4.2.5 shows the estimates of association between cigarette smoking and incident 
MI adjusted for age and sex. As evident by the estimated HRs, the effect of different 
censoring methods is quite variable. The effect size and significance levels for Method I 
at exam 7 versus that at exam 8 is different, perhaps due to a difference in the number of 
incident MIs along with an extended FU periods for both MI and non-MI participants 
from those at exam 7 to exam 8 . Method II yields a smaller but significant effect of 
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smoking on MI incidence at all time periods. The effect sizes fluctuate increasingly as the 
FU for MIs are extended but non-MIs are restricted. Method III provides fairly stable and 
significant estimate of HRs over all the FU periods which is in line with that from 
Method I exam 8. Method IV estimates of HRs displays similar pattern as of Method III 
and are significant. However, this method consistently produces higher estimates of the 
association between smoking and incident MI at each time periods.  
 
The discrimination C-statistics for Method I at exam 7 and exam 8 are almost identical. 
The C-statistics again decreases over the period of extended FU to 2002, 2004, and 2006 
using Method II. This decrease is more rapid as compared to the other Methods. Method 
III results into relatively stable C-statistic throughout the extended FU periods and 
Method IV C-statistic start out and remain higher than either of the others. 
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Table 4.2.6 Atrial Fibrillation and Incident MI: Hazard Ratios and the Discrimination 
C-statistic      
 
 Exam 7 
(1998-2001) 
 Exam 8 
(2005-2008) 
 
Method 
I 
HR[CI] 
p 
2.36 
[0.71, 7.85] 
0.161 
1.44 
[0.58, 3.56] 
0.432 
 2002 2004 2006 2009 
Method 
II 
HR[CI] 
p 
 1.85 
[0.67, 5.12] 
0.237 
0.73 
[0.26, 2.01] 
0.536 
0.90  
[0.36, 2.24] 
0.826 
1.14 
[0.46, 2.81] 
0.773 
Method 
III 
HR[CI] 
p 
 2.43 
[0.87, 6.76] 
0.090 
1.43 
[0.52, 3.93] 
0.487 
1.38 
[0.56, 3.42] 
0.482 
1.27 
[1.52, 3.12] 
0.603 
Method 
IV 
HR[CI] 
p 
 2.59  
[0.93, 7.23] 
0.070 
1.75 
[0.64, 4.84] 
0.278 
1.90 
[0.77, 4.71] 
0.164 
1.76  
[0.72, 4.33] 
0.219 
 
 
Exam 7 
(1998-2001) 
 Exam 8 
 (2005-2008) 
 
Method 
I 
C-
statistic 
0.7490 0.6968 
 2002 2004 2006 2009 
Method 
II 
C-
statistic 
 
0.7362 0.7090 0.6879 0.6907 
Method 
III 
C-
statistic 
 
0.7214 0.7013 0.6906 0.6971 
Method 
IV 
C-
statistic 
 
0.7342 0.7159 0.7165 0.7164 
 
 
Associations between the history of AF and incident MI adjusting for age and sex are 
shown in table 4.2.6. Here, the methods and time of censoring appear to affect the HRs 
considerably. The Method I estimate of the effect of AF on incident MI with FU through 
exam 7 is 2.36.    When we extend the FU through exam 8, the estimated HR declines to 
1.44. The estimate at exam 8, we believe , is more stable as the number of MIs increased 
by exam 8 and is based on the extended FU for both MIs and non- MIs. Yet again, 
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Method II yields smaller estimates of the effect size through the FU periods before exam 
8, and show protective effects of AF on MI incidence, but the FU through 2002 and 2009 
yields estimated effect as detrimental. The Method III results are in the direction of the 
Method I exam 8 result. The Method IV estimates of HRs are consistently greater than 
those of the other methods irrespective of whether the FU is through 2002, 2004, 2006 or 
2009.  
Similar to the results for other risk factors, we see again decreases in the C-statistics as 
we extend FU, with greater decreases under Method II and with Method IV always 
higher. 
 
The estimates of association between the biomarker CRP and incident MI are 
summarized in table 4.2.7. The Method I estimate of the effect of CRP on incident MI 
with FU through exam 7 is 1.26 [0.90, 1.77]. When we extend the FU through exam 
cycle 8, the estimated HR increased slightly to 1.45[1.19, 1.76] and is significant. The 
change in these estimates is conceivably due to an increase in the number of MIs and the 
extended FU by exam 8.The Method II estimates are closer to Method I estimate as exm7 
in FU periods through 2002, 2004 and 2006. Method III and IV have higher estimates 
than Methods I and II in FU periods through 2002, 2004 and 2006, but all are similar to 
exam 8 Method I.  
 
The discrimination C-statistics for Method I, with FU through exam 7 is 0.7443,   a slight 
decrease to 0.7269 by extending the FU through exam 8. Method III results into relatively 
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Table 4.2.7 C - reactive Protein and Incident MI: Hazard Ratios and the 
Discrimination C-statistic      
 
 Exam 7 
(1998-2001) 
 Exam 8 
(2005-2008) 
 
Method 
I 
HR[CI] 
p 
1.26  
[0.90, 1.77] 
0.173 
1.45 
[1.19, 1.76] 
<0.001 
 2002 2004 2006 2009 
Method 
II 
HR[CI] 
p 
 1.25 
[0.98, 1.59] 
0.078 
1.25 
[1.03, 1.53] 
0.028 
1.30 
[1.08, 1.56] 
0.006 
1.39 
[1.17, 1.65] 
<0.001 
Method 
III 
HR[CI] 
p 
 1.41 
[1.11, 1.80] 
0.005 
1.44 
[1.17, 1.76] 
0.001 
1.44 
[1.20, 1.73] 
<0.001 
1.42 
[1.20, 1.69] 
<0.001 
Method 
IV 
HR[CI] 
p 
 1.43 
[1.12, 1.82] 
0.004 
1.47 
[1.20, 1.81] 
<0.001 
1.47 
[1.22, 1.77] 
<0.001 
1.46  
[1.23, 1.73] 
<0.001 
 
 
Exam 7 
(1998-2001) 
 Exam 8 
 (2005-2008) 
 
Method 
I 
C-
statistic 
0.7443 0.7269 
 2002 2004 2006 2009 
Method 
II 
C-
statistic 
 
0.7345 0.7149 0.6721 0.7054 
Method 
III 
C-
statistic 
 
0.7313 0.7213 0.7124 0.7209 
Method 
IV 
C-
statistic 
 
0.7438 0.7352 0.7276 0.7310 
 
similar C-statistic throughout the extension of FU from 2002, 2004 and 2006. Method II 
gives quite an unstable C-statistic, such that it gets increasingly smaller as FU is extended 
further for events and not for non-events, and dips quite a bit with the FU at 2006. 
Whereas C-statistics from Method IV are higher than those of the other methods 
irrespective of whether we extend the FU through 2002, 2004, 2006, or 2009. 
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Table 4.2.8 Calibration results for various risk factors on MI data 
 
 
Exam 7 
(1998-2001) 
 
Exam 8 
(2005-2008) 
 
Method I 
Age, Sex 21.637 7.530 
Age, Sex, DM 14.193 16.919 
Age, Sex, S1HTN 22.651 9.963 
Age, Sex, Smoking 18.187 13.228 
Age, Sex, AF 21.928 7.574 
Age, Sex, CRP 11.500 13.083 
 2002 2004 2006 2009 
 
Method II 
Age, Sex 
 
235.07 297.53 66.61 406.86 
Age, Sex, DM 122.93 284.65 112.10 87.20 
Age, Sex, S1HTN 77.59 162.78 88.26 136.57 
Age, Sex, Smoking 59.86 129.30 44.78 572.61 
Age, Sex, AF 221.57 257.09 66.34 407.58 
Age, Sex, CRP 49.65 167.85 69.96 226.42 
 
Method III 
Age, Sex 
 
40.410 42.84 44.16 13.904 
Age, Sex, DM 33.304 297.51 125.99 22.213 
Age, Sex, S1HTN 11.568 267.05 180.99 14.561 
Age, Sex, Smoking 17.391 112.93 45.56 10.367 
Age, Sex, AF 41.193 235.75 124.43 11.180 
Age, Sex, CRP 19.032 156.0 15.05 9.450 
 
Method IV 
Age, Sex 
 
25.442 56.70 42.16 8.047 
Age, Sex, DM 43.476 221.20 60.85 16.922 
Age, Sex, S1HTN 21.136 166.61 181.24 17.235 
Age, Sex, Smoking 16.258 83.23 39.01 15.488 
Age, Sex, AF 23.917 58.14 43.22 13.599 
Age, Sex, CRP 37.846 79.72 8.13 7.164 
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Calibration results for MI data set based on different censoring methods for each model 
with corresponding risk factors are summarized in table 4.2.8. The objective here is to 
assess which of the censoring methods/model is best calibrated. To evaluate this, a 
calibration Chi-square score for each model from different censoring methods is 
compared to the Chi-square statistic with 9 degrees of freedom. We hypothesize that the 
model predicted probabilities are equal to the true probability from Kaplan-Meier. It is 
sought-after not to reject the null hypothesis. Therefore, a smaller Chi-square corresponds 
to a better calibrated model. 
 
Calibration scores for Method I with the FU through exam 7 show that the models with 
each of the RFs seem better calibrated. If the FU is extended through exam 8, the 
calibration gets even better for each of the models. This perhaps is due to an extended FU 
for both MIs and non-MIs, and an increased number of incident MIs by exam 8. Method 
II, which extends the FU for events but not for non-events, shows a poor calibration at 
some periods for some RFs and relatively better at the other time periods. The Method 
III, which extends the FU for both events and non-events, seem to calibrate as well as 
Method I, with the FU through 2002 and 2009. Again, Method IV appear to calibrate as 
well as Method III, but since this method tends to censor non-events incorrectly if there is 
a manifestation of any prevalent CVD other than MI, it is not a good  method. 
Based on these results, Method I with the FU through exam 8 would be considered to 
have better calibration followed by Method III with FU extended through 2009, and then 
Method I with study period through exam 7 and Method III through 2002. 
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For net reclassification improvement, we used a method developed by Pencina, 
D’Agostino et al. (2011), which gives a general form of NRI as a prospective measure 
that quantifies the correctness of upward and downward reclassification of predicted 
probabilities as a result of adding a new marker. Pencina and Kennedy’s SAS macro was 
adopted to calculate these scores with our four censoring methods for each of the risk 
factors, and comparisons were made between models at each of the study periods. 
 
As the NRI is designed to quantify improvements in performance, and its magnitude is 
considered to be more important than statistical significance, we present, as 
recommended by Pencina et al. (2011), NRIs with confidence intervals. Here we are 
looking at the improvement in model performance based on including a RF of interest in 
the basic model with just age and sex. Table 4.3.9 summarizes these results with full FU 
for each method at each of the study periods, while table 4.3.10 shows similar results if 
we restrict to 10 years of FU. These findings are similar to those obtained for stroke as an 
outcome, and for brevity’s shake, we have only shown the results. 
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Table 4.2.9 Net Reclassification Improvement results for various risk factors on MI data [Full Follow-up] 
 Ex7 (1998-2001) 
 
Ex8(2005-2008) 
 
Method I 
Events| Non-Events   
Follow-up, years 7 years 13 years 
Age, Sex, DM 0.42[0.04,0.85] 0.33[0.16,0.50] 
Age, Sex, S1HTN 0.28[-0.14,0.74] 0.65[0.47,0.82] 
Age, Sex, Smoking 0.56[0.12,0.92] 0.42[0.24,0.60] 
Age, Sex, AF -0.14[-0.61,0.29] -0.34[-0.46,-0.20] 
Age, Sex, CRP 0.54[0.16,0.79] 0.32[0.10,0.51] 
 2002 2004 2006 2009 
 
Method II 
Events| Non-Events 
 
    
Follow-up, years 8 years 10 years 12 years 15 years 
Age, Sex, DM 0.34[-0.07,0.77] -0.74[-1.70,0.46] -0.07[-0.33,0.13] 0.30[-0.16,0.77] 
Age, Sex, S1HTN 0.63[0.17,0.98] 1.26[-1.22,2.59] -0.11[-1.31,0.92] -0.02[-0.80,0.68] 
Age, Sex, Smoking 0.37[-0.10,0.83] 1.16[-1.24,2.90] 0.88[-0.01,2.48] -0.10[-0.37,0.24] 
Age, Sex, AF 0.01[-0.62,0.60] 0.84[-0.19,1.74] 0.15[-0.90,1.36] 0.84[-0.49,2.27] 
Age, Sex, CRP 0.14[-0.42,0.67] -1.32[-1.74,0.50] 1.12[-0.26,2.08] -0.03[-0.90,0.68] 
 
Method III 
Events| Non-Events 
 
    
Follow-up, years 8 years 10 years 12 years 15 years 
Age, Sex, DM 0.39[0.08,0.70] -1.00[-2.39,-0.21] -0.54[-1.12,0.16] 0.32[0.15,0.50] 
Age, Sex, S1HTN 0.76[0.49,1.01] 1.75[-0.58,2.64] -0.20[-0.97,0.86] 0.52[0.34,0.70] 
Age, Sex, Smoking 0.50[0.19,0.81] 0.83[-0.58,2.58] 1.00[0.04,1.55] 0.28[0.14,0.43] 
Age, Sex, AF -0.21[-0.46,0.08] -0.08[-2.16,1.66] -0.60[-1.18,0.13] -0.32[-0.45,-0.17] 
Age, Sex, CRP 0.47[0.16,0.72] -0.52[-1.89,0.35] 0.82[-0.10,1.89] 0.34[0.14,0.52] 
 
Method IV 
Events| Non-Events 
 
    
Follow-up, years 8 years 10 years 12 years 15 years 
Age, Sex, DM 0.47[0.17,0.82] -0.70[-1.22,-0.12] -0.35[-0.76,0.28] 0.34[0.17,0.52] 
Age, Sex, S1HTN 0.78[0.53,1.01] 0.65[-0.69,2.04] -0.13[-0.88,0.90] 0.59[0.40,0.79] 
Age, Sex, Smoking 0.49[0.16,0.81] 0.82[-0.23,1.69] 1.38[0.06,1.65] 0.29[0.14,0.45] 
Age, Sex, AF -0.36[-0.62,-0.06] 0.16[-1.10,1.53] -0.69[-1.39,0.07] -0.37[-0.52,-0.22] 
Age, Sex, CRP 0.48[0.19,0.73] -0.33[-0.91,0.65] 0.80[-0.06,1.69] 0.35[0.16,0.53] 
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Table 4.2.10 Net Reclassification Improvement results for various risk factors on MI data [10 years Follow-up] 
 Ex7 (1998-2001) 
 
Ex8 (2005-2008) 
 
Method I 
Events| Non-Events  114|3260 
Follow-up, years 10 years 10 years 
Age, Sex, DM 0.42[0.04,0.85] 0.33[0.16,0.50] 
Age, Sex, S1HTN 0.28[-0.14,0.74] 0.65[0.47,0.82] 
Age, Sex, Smoking 0.56[0.12,0.92] 0.42[0.24,0.60] 
Age, Sex, AF -0.14[-0.61,0.29] -0.34[-0.46,-0.20] 
Age, Sex, CRP 0.54[0.16,0.79] 0.32[0.10,0.51] 
 2002 2004 2006 2009 
 
Method II 
Events| Non-Events 
 
    
Follow-up, years 10 years 10 years 10 years 10 years 
Age, Sex, DM 0.34[-0.07,0.77] -0.74[-1.70,0.46] 0.11[-0.08,0.30] 0.30[0.14,0.45] 
Age, Sex, S1HTN 0.63[0.17,0.98] 1.26[-1.22,2.59] 0.22[-0.14,0.55] 0.58[0.39,0.76] 
Age, Sex, Smoking 0.37[-0.10,0.83] 1.16[-1.24,2.90] 0.41[0.18,0.67] 0.37[0.19,0.55] 
Age, Sex, AF 0.01[-0.62,0.60] 0.84[-0.19,1.74] 0.11[-0.17,0.37] -0.33[-0.45,-0.19] 
Age, Sex, CRP 0.14[-0.42,0.67] -1.32[-1.74,0.50] 0.27[-0.05,0.59] 0.30[0.10,0.50] 
 
Method III 
Events| Non-Events 
 
    
Follow-up, years 10 years 10 years 10 years 10 years 
Age, Sex, DM 0.39[0.08,0.70] -1.00[-2.39,-0.21] 0.26[0.08,0.45] 0.30[0.15,0.45] 
Age, Sex, S1HTN 0.76[0.49,1.01] 1.75[-0.58,2.64] 0.58[0.32,0.80] 0.57[0.38,0.74] 
Age, Sex, Smoking 0.50[0.19,0.81] 0.83[-0.58,2.58] 0.40[0.18,0.65] 0.37[0.20,0.54] 
Age, Sex, AF -0.21[-0.46,0.08] -0.08[-2.16,1.66] -0.34[-0.48,-0.17] -0.25[-0.35,-0.14] 
Age, Sex, CRP 0.47[0.16,0.72] -0.52[-1.89,0.35] 0.27[-0.003,0.55] 0.34[0.13,0.53] 
 
Method IV 
Events| Non-Events 
 
    
Follow-up, years 10 years 10 years 10 years 10 years 
Age, Sex, DM 0.47[0.17,0.82] -0.70[-1.22,-0.12] 0.31[0.12,0.53] 0.33[0.17,0.49] 
Age, Sex, S1HTN 0.78[0.53,1.01] 0.65[-0.69,2.04] 0.65[0.38,0.89] 0.63[0.45,0.82] 
Age, Sex, Smoking 0.49[0.16,0.81] 0.82[-0.23,1.69] 0.42[0.20,0.66] 0.37[0.20,0.54] 
Age, Sex, AF -0.36[-0.62,-0.06] 0.16[-1.10,1.53] -0.33[-0.51,-0.12] -0.29[-0.40,-0.18] 
Age, Sex, CRP 0.48[0.19,0.73] -0.33[-0.91,0.65] 0.28[0.01,0.56] 0.36[0.17,0.54] 
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4.3 Results for Congestive Heart Failure following Exam 6 
 
The baseline characteristics of participants at exam 6 are summarized in table 4.3.1. For 
each censoring method, the number of incident CHFs, the average duration of follow up 
and the estimate of incidence per 1000 person years are depicted in table 4.3.2. The effect 
of these four censoring methods on estimates of association between each of diabetes 
mellitus, stage I hypertension, current smoking status, history of atrial fibrillation, and C - 
reactive protein and incident CHF are summarized in tables 4.3.3 through 4.3.7 
respectively. These tables present hazard ratios from the Cox proportional hazards 
models adjusted for age and sex, and the corresponding discrimination C-statistics for 
assessment of model performance. Additionally, evaluation of these methods using 
calibration Chi-square and Net Reclassification Improvement are displayed in tables 4.3.8 
through 4.3.10. 
 
Table 4.3.1  Baseline Characteristic 
 
 All Male Female 
N 3492 1630 1862 
Age, (mean ± SD) 59 ± 10 59 ± 10 59 ± 10 
Male, n (%) 1630 (47%)   
Systolic Blood Pressure, (mean ± SD) 128 ± 19 130 ± 17 127 ± 20 
Diabetes Mellitus, n (%) 374 (11%) 211 (13.2%) 163 (9.1%) 
Stage I Hypertension, n (%) 1440 (41.4%) 730 (45%) 710 (38.2%) 
Current Smoking, n (%) 536 (15.4%) 240 (14.7%) 296 (15.9%) 
Atrial Fibrillation, n (%) 80 (2.3%) 63 (3.9%) 17 (0.9%) 
C-reactive Protein,  
[Median (min, max)] 
2.03  
(0.16, 255.80) 
1.82  
(0.16, 202.20) 
2.30  
(0.16, 255.80) 
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There were 3492 offspring participants found to be alive and free of CHF when their FHS 
examination 6 assessments were made, between 1995 and 1998. The ages of these 
participants ranged from 29 to 87 years with the mean age of 59 ±10 (SD) years. Forty-
seven percent of the participants were men, 11% had diabetes mellitus, about 41% had 
stage I hypertension, and about 15% reported current smoking. In general, as compared to 
women, men had slightly higher blood pressure, and higher prevalence of diabetes 
mellitus, hypertension, and atrial fibrillation but lower level of C- reactive protein. 
 
As shown in table 4.3.2, Method I with FU through exam 7 (1998-2001) yields 27 
incident CHFs with an average FU of 1.8 years and 3465 non-CHFs have an average FU 
of 2.8 years.   The estimated incidence of CHF is 2.39 per thousand person years. If we 
wait until exam 8 (2005-2008), we have 129 incident CHFs (FU 5.5 years) and 3363 non 
CHFs (FU 8.6 years). The CHF incidence increases from 2.39 at exam 7 to 4.16 at exam 
8. This is possibly due to the aging cohort. Other possible alternatives, as described in 
Chapter 3, of censoring with the years 2002, 2004, 2006, and 2009 as the end of study 
periods are also employed.  
 
 
 
 
 
  
 
1
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Table 4.3.2 Incident CHF, duration of follow up and estimates of incidence  
 
 
Exam 7 
(1998-2001) 
 
Exam 8 
(2005-2008) 
 
Events 
Non-
events 
Events 
Non-
events 
Method 
I 
N 27 3465 129 3363 
FU 
 
1.83±1.26 
 
2.81±1.07 5.48±2.61 8.56±2.64 
Inc 2.39 3.81 
 2002 2004 2006 2009 
 Events 
Non-
events 
Events 
Non-
events 
Events 
Non-
events 
Events 
Non-
events 
 
Method 
II 
N 
 
66 3426 109 3383 139 3353 176 3316 
FU 3.39±1.75 2.95±1.25 4.85±2.36 3.11±1.53 5.72±7.42 3.37±1.99 6.84±3.29 8.63±2.65 
Inc 5.59 8.68 10.17 5.61 
 
Method 
III 
N 
 
66 3426 109 3383 139 3353 176 3316 
FU 3.39±1.75 4.74±1.71 4.85±2.36 6.71±1.67 5.72±7.42 7.63±1.90 6.84±3.29 10.80±2.35 
Inc 3.71 4.42 4.99 4.54 
 
Method 
IV 
N 
 
66 3080 109 2932 139 3035 176 3012 
FU 3.39±2.04 4.61±1.79 4.85±2.36 6.55±1.86 5.72±7.42 7.42±2.13 6.84±3.29 10.38±2.86 
Inc 4.24 4.99 5.63 5.17 
 
FU: Duration of Follow up, mean ± SD; Inc: Incidence per 1000 person years 
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Method II extends the follow up for events but not for non-events. Extending FU of 
events through 2002 using this method results 49 incident CHFs with a mean FU of 3.4 
years.    The 3426 non-CHFs have an average FU of 3.0 years, and the estimated 
incidence increases to 5.59. Extending event follow-up further through 2004 results in 
109 incident CHFs (4.9 years of FU), 3383 non-CHFs (3.1 years of FU) and more than 
three times the original estimate of incidence. Furthermore, extension through 2006 
captures 139 incident CHFs with mean FU of 5.7 years, 3353 non-CHFs with 3.4 years of 
FU and a much higher estimated incidence of 10.17. Clearly, this method catapults the 
estimate of incidence of CHF as compared to that of Method I. 
 
The Method III extends FU for both participants with CHF and non-CHF. Extension of 
FU through 2002, using this method, results in 66 incident CHFs with an average FU of 
3.4 years.  In addition, the extension of FU for the 3426 non-CHFs to a mean FU of 4.7 
years, and the estimated CHF incidence, 3.71, is closer to that from Method I at exam 
8.Extension of FU through 2004 results in 109 incident CHFs (FU 4.9 years), 3383 non-
CHFs (FU 6.7 years), and estimated CHF incidence of 4.42, almost one half of that 
estimated from Method II. By extending the study through 2006, this method also 
captures 139 incident CHFs with a mean FU of 5.7 years, as did Method II, but also 
extends the FU of the 3353 non-CHFs to a mean of 7.6 years, and the estimated CHF 
incidence of 4.99 is closer to that estimated using Method I at exam 8.Evidently, this 
method keeps the estimate of incidence CHF more reasonable when compared to Method 
II. 
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Method IV also yields 66 incident CHFs (FU of 3.4 years) in 2002 and captures 3080 
non-CHFs (average FU of 4.6 years) with the estimated CHF incidence of 4.24 - higher 
than that of Methods I and III. Extending the FU through 2004 results in 109 incident 
CHFs (mean FU of 4.9 years), 2932 non-CHFs (mean FU of 6.6 years), and estimated 
incidence of 4.99. With the follow up through 2006, Method IV captures 139 incident 
CHFs (mean FU 5.7 years), 3035 non-CHFs (7.4 years of average FU), and an estimated 
CHF incidence of 5.63. 
 
Again, for Method I, extending the follow up through Exam 8, there were 129 incident 
CHFs (FU 5.5 years) and 3363 non-CHFs (FU of 8.6 years), and the estimated incidence 
was 4.16 per 1000 person-years. The exam 8 was administered between 2005 and 2008, 
and by extending the FU to 2009 yielded 153 incident CHFs, almost a 19% increase. The 
next examination cycle will be about 4 years later. There is always a tendency for 
investigators to not want to wait until exam 9 to use these data.  Method II which extends 
the follow-up for events to 2009 but not for non-events yields a higher estimated 
incidence of 5.61. The Method III extends the FU for CHFs as well as non-CHFs results 
in a drop of an estimated CHF incidence to 4.54. The Method IV also extends the FU for 
CHFs and non-CHFs, but the non-CHFs are censored at the manifestation of any of the 
CVD events other than CHF yields a reduced number of non-CHFs, over estimates the 
CHF incidence as 5.17. 
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Summing up, both Methods I and III results into relatively similar estimates of CHF 
incidence, as was expected, as both the events and non-events are followed through 
approximately the same period of time with these methods. Method II increases FU for 
events and not for non-events, and over estimates the CHF incidence. Again, Method IV 
increases FU for events and non-events, but the FU for non-events are conditional on 
whether they had any CVD events other than CHF, prior to or during the study period, 
and yields higher estimates of CHF incidence. 
Table 4.3.3 Diabetes Mellitus and Incident CHF: Hazard Ratios and the 
Discrimination C-statistic      
 Exam 7 
(1998-2001) 
 Exam 8 
(2005-2008) 
 
Method 
I 
HR[CI] 
p 
7.23 
[3.29, 15.90] 
<0.001 
3.83 
[2.64, 5.54] 
<0.001 
 2002 2004 2006 2009 
Method 
II 
HR[CI] 
p 
 3.66 
[2.20, 6.06] 
<0.001 
2.76 
[1.84, 4.14] 
<0.001 
2.38 
[1.66, 3.42] 
<0.001 
3.07 
[2.21, 4.26] 
<0.001 
Method 
III 
HR[CI] 
p 
 4.37 
[2.63, 7.28] 
<0.001 
3.60 
[2.40, 5.39] 
<0.001 
3.29  
[2.29, 4.72] 
<0.001 
3.10 
[2.23, 4.31] 
<0.001 
Method 
IV 
HR[CI] 
p 
 5.20 
[3.14, 8.62] 
<0.001 
4.35 
[2.90, 6.51] 
<0.001 
3.97  
[2.77, 5.69] 
<0.001 
3.62 
[2.61, 5.02] 
<0.001 
 
 
Exam 7 
(1998-2001) 
 Exam 8 
 (2005-2008) 
 
Method 
I 
C-
statistic 
0.7999 0.8115 
 2002 2004 2006 2009 
Method 
II 
C-
statistic 
 
0.7699 0.7525 0.7363 0.8089 
Method 
III 
C-
statistic 
 
0.7871 0.8018 0.8025 0.8063 
Method 
IV 
C-
statistic 
 
0.8066 0.8205 0.8214 0.8239 
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The estimates of association between DM and incident CHF adjusted for age and sex are 
shown in table 4.3.3. It appears that impacts of different methods of censoring on the 
estimated HRs are all significant but effect size is quite variable as evident by the 
estimated HRs. The Method I estimate of the effect of DM on CHF incidence with FU 
through exam 7 (1998-2001) is 7.23. Extending FU through the next exam cycle 8 (2005-
2008) results in an estimated HR of 3.83. The change in these estimates between exams, 
is perhaps, dictated by an increase in the number of events by exam 8 and, also, an 
extended FU for both events and non-events, and consequently, a more stable estimate of 
HR by then. Investigators, in practice, tend not to wait until the end of the exam cycle to 
exploit FU information on both events and non-events. In one such scenario, Method II 
gives a relatively smaller estimate of effect of DM on CHF incidence with FU through 
each of 2002, 2004 and 2006. In addition, these estimates decrease as the FU is extended 
further. In contrast, Method III yields significant and more consistent estimates of HRs 
with FU through 2002, 2004, 2006 and 2009   and are similar to that from Method I. 
Method IV, which incorrectly censors observations at the manifestation of any of the 
CVD events (other than CHF) as non-events resulting in a smaller number of non-CHFs 
to that from the other methods, yields estimates of HRs greater than those from other 
methods at all FU periods. 
 
Method I, we believe, gives a more stable estimate of the effects of DM on CHF 
incidence at exam 8 than at exam 7, and Method III remains rather stable in terms of 
estimate of the HRs over time, and consistent with the estimates from Method I exam 8. 
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By contrast, Method II seems to give lower estimates of the effect of DM, increasingly as 
FU is extended further for events and not for non-events.   Method IV tends to yield 
higher estimates of the effect of DM on CHF incidence at all periods. 
 
The discrimination C-statistic for the model with Method I with FU through 2007 is  
0.7999 slightly increases to 0.8115 if the FU is extended through exam 8. Method III 
results into relatively stable C-statistic throughout the extension of the FU from 2002, 
2004, 2006, increasing slightly from 0.787 to 0.802 to 0.803. Method II C-statistics 
decrease by more, from 0.770 to 0.753 to 0.736 by 2006. C-statistics from Method IV are 
higher than those of the other methods, and increase slightly over the three FU periods. 
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Table 4.3.4 Stage I Hypertension and Incident CHF: Hazard Ratios and the 
Discrimination C-statistic      
 
 Exam 7 
(1998-2001) 
 Exam 8 
(2005-2008) 
 
Method 
I 
HR[CI] 
p 
2.34  
[0.97, 5.64] 
0.060 
2.07 
[1.40, 3.06] 
0.003 
 2002 2004 2006 2009 
Method 
II 
HR[CI] 
p 
 1.28 
[0.76, 2.15] 
0.361 
1.67 
[1.09, 2.56] 
0.020 
1.56 
[1.08, 2.27] 
0.019 
1.94 
[1.39, 2.72] 
0.001 
Method 
III 
HR[CI] 
p 
 1.55 
[0.92, 2.60] 
0.103 
2.20 
[1.43, 3.39] 
<0.001 
2.00 
[1.37, 2.91] 
<0.001 
2.06 
[1.48, 2.88] 
<0.001 
Method 
IV 
HR[CI] 
p 
 1.63 
[0.96, 2.76] 
0.070 
2.31 
[1.49, 3.57] 
<0.001 
2.15  
[1.47, 3.15] 
<0.001 
2.19 
[1.56, 3.07] 
<0.001 
 
 
Exam 7 
(1998-2001) 
 Exam 8 
 (2005-2008) 
 
Method 
I 
C-
statistic 
0.7768 0.7957 
 2002 2004 2006 2009 
Method 
II 
C-
statistic 
 
0.7468 0.7266 0.7098 0.7962 
Method 
III 
C-
statistic 
 
0.7558 0.7851 0.7861 0.7990 
Method 
IV 
C-
statistic 
 
0.7775 0.8029 0.8039 0.8165 
 
 
The estimates of association between Stage I hypertension and incident CHF adjusting 
for age and sex are shown in table 4.3.4. Method I estimate of the effect of hypertension 
on CHF incidence with FU through exam 7 is 2.34. There is a slight decrease in the 
estimate of HR to 2.07 with FU extending through exam 8, and is significant. The latter 
estimate, we believe, is due to an increase in the number of events and a longer duration 
of follow up for both events and non-events by exam 8. Method II produces smaller 
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estimates of the effect of hypertension on CHF incidence than Method I over each of the 
FU periods; for FU through 2002, the result is non-significant. But there is a slight 
increase in the estimates of HRs and are significant for FU through the rest of the periods.  
Method III produces steady and estimates of HRs for FU through 2004, 2006 and 2009, 
except for 2002 the estimate is non-significant. Method IV with relatively smaller 
number of non-events due to censoring of subjects for CVD events other than CHF, also 
shows a similar pattern but it constantly yields higher estimates of the measure of 
association between hypertension and CHF at all FU periods.  
 
Thus, Method I give more stable estimates of the association of Stage I hypertension on 
CHF incidence at exam 8, and Method III results are quite similar, except in 2002. 
Method II results show smaller estimates of the effect of hypertension and fluctuate quite. 
Method IV tends to give higher estimates of the effect of hypertension on CHF incidence 
in comparison to Methods I and III. 
 
Similar to the results in 4.3.3, we see again decreases in the C-statistics as we extend FU, 
with greater decreases under Method II and with Method IV always higher. 
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Table 4.3.5 Smoking and Incident CHF: Hazard Ratios and the Discrimination C-
statistic      
 
 Exam 7 
(1998-2001) 
 Exam 8 
(2005-2008) 
 
Method 
I 
HR[CI] 
p 
2.15 
[0.79, 5.86] 
0.134 
2.05 
[1.28, 3.27] 
0.003 
 2002 2004 2006 2009 
Method 
II 
HR[CI] 
p 
 1.52 
[0.76, 3.05] 
0.234 
1.85 
[1.12, 3.06] 
0.049 
1.25 
[0.78, 2.02] 
0.357 
1.52 
[0.99, 2.35] 
0.057 
Method 
III 
HR[CI] 
p 
 1.80 
[0.91, 3.59] 
0.093 
2.34 
[1.42, 3.84] 
0.005 
1.92  
[1.04, 2.70] 
0.033 
1.65 
[1.07, 2.55] 
0.023 
Method 
IV 
HR[CI] 
p 
 1.95 
[0.98, 3.87] 
0.057 
2.52 
[1.54, 4.13] 
<0.001 
2.48  
[1.18, 3.03] 
0.009 
1.84 
[1.20, 2.83] 
0.006 
 
 
Exam 7 
(1998-2001) 
 Exam 8 
 (2005-2008) 
 
Method 
I 
C-
statistic 
0.7915 0.7895 
 2002 2004 2006 2009 
Method 
II 
C-
statistic 
 
0.7412 0.7125 0.6997 0.7862 
Method 
III 
C-
statistic 
 
0.7528 0.7772 0.7797 0.7880 
Method 
IV 
C-
statistic 
 
0.7742 0.7963 0.7977 0.8053 
 
Table 4.3.4 shows the estimates of association between cigarette smoking and incident 
CHF adjusting for age and sex and the discrimination measures.  The effect of different 
censoring methods is inconsistent as is apparent by the estimated HRs. 
 
The estimate of effect size with the FU through exam 7 is 2.15.   When the FU is 
extended through 2008 it dropped slightly to 2.05. The estimated HR is non-significant at 
exam 7 but is not the case at exam 8, perhaps due to a difference in number of incident 
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CHF along with an extended FU periods for subjects with both CHF and non-CHF from 
exam 7 to exam 8.  With Method II, the effect sizes seem to fluctuate increasingly as the 
FU for strokes are extended but non-strokes are restricted. This method yields a smaller 
and non-significant effect of smoking on CHF incidence at all time periods, except at 
2004 where the estimate is a borderline significant. Method III provides steadily 
decreasing but significant estimate of HRs over the FU periods from 2004 through 2009. 
The estimated HRs with FUs through 2004 and 2006 are similar to that from Method I 
exam 8.  Method IV estimates of HRs seem to increase as we extend the FU periods from 
2002 to 2006 but declines by 2009. Nonetheless, this method yields higher estimates of 
association between smoking and incident CHF as compared to others at each of the FU 
periods.  
 
The discrimination C-statistics for methods I at exam 7 and exam 8 are almost identical. 
Method II C-statistics decrease over the period of extended FU to 2002, 2004 and 2006. 
In contrast, the C-statistics increases over the FU periods. Method III results into 
relatively similar and stable estimate of C-statistic throughout the extension of FU to 
2002, 2004, 2006 and 2009. These are quite similar to those obtained by Method I, except 
in 2002 where it is slightly smaller. Whereas discrimination measures from Method IV 
are higher than those form the other methods from extended FU through 2004, for 2002 
the estimate is close to Method I estimate.  
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Table 4.3.6 Atrial Fibrillation and Incident CHF: Hazard Ratios and the 
Discrimination C-statistic      
 
 Exam 7 
(1998-2001) 
 Exam 8 
(2005-2008) 
 
Method 
I 
HR[CI] 
p 
8.74 
[3.57, 21.44] 
<0.001 
6.75 
[4.26, 10.70] 
<0.001 
 2002 2004 2006 2009 
Method 
II 
HR[CI] 
p 
 4.63 
[2.49, 8.62] 
<0.001 
3.43 
[2.06, 5.71] 
<0.001 
3.88 
[2.46, 6.14] 
<0.001 
5.66 
[3.67, 8.71] 
<0.001 
Method 
III 
HR[CI] 
p 
 7.77 
[4.16, 14.53] 
<0.001 
7.16 
[4.33, 11.82] 
<0.001 
6.22 
[3.95, 9.80] 
<0.001 
6.12 
[3.98, 9.41] 
<0.001 
Method 
IV 
HR[CI] 
p 
 9.77 
[5.15, 18.53] 
<0.001 
7.97 
[4.87, 13.28] 
<0.001 
7.07 
[4.49, 11.12] 
<0.001 
6.62  
[4.30, 10.19] 
<0.001 
 
 
Exam 7 
(1998-2001) 
 Exam 8 
 (2005-2008) 
 
Method 
I 
C-
statistic 
0.7735 0.7999 
 2002 2004 2006 2009 
Method 
II 
C-
statistic 
 
0.7395 0.7152 0.7071 0.7987 
Method 
III 
C-
statistic 
 
0.7574 0.7837 0.7875 0.7998 
Method 
IV 
C-
statistic 
 
0.7778 0.8007 0.8032 0.8148 
 
 
Associations between the history of AF and incident CHF are shown in table 4.3.6.  The 
Method I estimate of the effect of AF on incident CHF with FU through exam 7 is 8.74. 
When we extend the FU through exam cycle 8 the estimated HR decreases slightly to 
6.75. The change in these estimates is conceivably due to the low prevalence of AF, an 
increase in number of CHFs and extended FU for both CHFs and non-CHFs by exam 8. 
We consider the exam 8 estimate as the stable. Method II results into reasonably smaller 
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effect size and it decreases as the FU is extended further for events but not for non-
events. Whereas, Method III estimates of HRs are more consistent and are relatively 
similar to that from Method I at exam 8. The Method IV, which incorrectly censors 
observations at the manifestation of any of the CVD events other than CHF as non-events 
results in a smaller number of non-CHFs to that of the other methods, yields an estimated 
HRs greater than those from other methods at each of the four study periods.  
 
Similar to the results for the other RFs, we again see decrease in the C-statistics for 
Method II as we extend the FU. For the other Methods, as we extend the FU, the C-
statistics increases slightly, with Method IV estimates always higher. 
 
 
The estimates of association between the CRP biomarker and incident CHF are 
summarized in table 4.3.7. The Method I estimate of the HR with FU through exam7 is 
1.41 and is non-significant. When we extend the FU through exam 8, the estimated HR 
increased to 1.48 and is significant. HRs estimated using Method II are reasonably 
smaller and non-significant than those estimated using other methods for three of the four 
study periods. For 2009however, the HR is significant and similar to the other methods. 
Method III gives a more consistent and significant estimates of HRs throughout the FU 
periods. These are similar to that from Method I at exam 8. The estimates from Method 
IV are slightly larger than those from other methods at each of the study periods.  
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Table 4.3.7 C –reactive Protein and Incident CHF: Hazard Ratios and the 
Discrimination C-statistic 
 
 Exam 7 
(1998-2001) 
 Exam 8 
(2005-2008) 
 
Method 
I 
HR[CI] 
p 
1.41 
[0.92 , 2.19] 
0.119 
1.48 
[1.22 , 1.80] 
<0.001 
 2002 2004 2006 2009 
Method 
II 
HR[CI] 
p 
 1.29 
[0.97, 1.72] 
0.080 
1.15  
[0.92, 1.43] 
0.223 
1.18 
[0.97, 1.43] 
0.091 
1.45 
[1.23, 1.71] 
<0.001 
Method 
III 
HR[CI] 
p 
 1.42 
[1.08, 1.87] 
0.012 
137 
[1.11, 1.69] 
0.004 
1.37 
[1.13, 1.65] 
0.001 
1.48 
[1.25, 1.74] 
<0.001 
Method 
IV 
HR[CI] 
p 
 1.44 
[1.10, 1.90] 
0.009 
1.41 
[1.14, 1.74] 
0.002 
1.42 
[1.17, 1.71] 
<0.001 
1.50 
[1.27, 1.76] 
<0.001 
 
 
Exam 7 
(1998-2001) 
 Exam 8 
 (2005-2008) 
 
Method 
I 
C-
statistic 
0.7773 0.79 
 2002 2004 2006 2009 
Method 
II 
C-
statistic 
 
0.7395 0.7118 0.7005 0.78 
Method 
III 
C-
statistic 
 
0.7513 0.7747 0.7780 0.79 
Method 
IV 
C-
statistic 
 
0.7732 0.7931 0.7972 0.81 
 
 
Similar to the results for the other RFs, we again see decrease in the C-statistics for 
Method II as we extend the FU. For the other Methods, as we extend the FU, the C-
statistics increases slightly, with Method IV estimates always higher. 
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Table 4.3.8 Calibration results for various risk factors on CHF data 
 
Exam 7 
(1998-2001) 
 
Exam 8 
(2005-2008) 
 
Method I 
Age, Sex 33.44 13.71 
Age, Sex, DM 27.83 22.77 
Age, Sex, S1HTN 86.75 16.41 
Age, Sex, Smoking 27.72 11.91 
Age, Sex, AF 32.01 11.26 
Age, Sex, CRP 34.63 6.02 
 2002 2004 2006 2009 
 
Method II 
Age, Sex 
 
88.19 39.36 50.41 70.03 
Age, Sex, DM 67.59 159.32 59.93 77.27 
Age, Sex, S1HTN 39.59 83.87 52.99 26.30 
Age, Sex, Smoking 136.18 86.68 88.01 62.46 
Age, Sex, AF 81.27 152.41 53.54 59.63 
Age, Sex, CRP 21.89 73.28 69.74 28.17 
 
Method III 
Age, Sex 
 
24.45 22.18 67.67 63.03 
Age, Sex, DM 13.14 129.84 39.75 65.76 
Age, Sex, S1HTN 24.21 60.53 37.32 38.44 
Age, Sex, Smoking 22.24 18.25 70.71 24.35 
Age, Sex, AF 23.97 92.57 60.08 56.95 
Age, Sex, CRP 9.18 60.68 31.21 17.73 
 
Method IV 
Age, Sex 
 
29.328 16.46 41.28 51.46 
Age, Sex, DM 13.016 66.65 115.93 23.93 
Age, Sex, S1HTN 29.612 27.98 38.30 10.27 
Age, Sex, Smoking 25.510 14.76 69.96 36.70 
Age, Sex, AF 24.141 81.78 67.11 53.41 
Age, Sex, CRP 18.685 40.47 30.41 51.18 
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Calibration results for CHF data set based on different censoring methods for each model 
with corresponding risk factors are summarized in table 4.3.8. Calibration scores for 
Method I with the FU through exam 7 show that the models with each of the RFs seem to 
calibrate well.   If we extend the FU through exam 8, the calibration gets even better for 
each model. Method II shows a relatively poor calibration at most time periods. The 
Method III calibrates better than Method II and almost as good as Method I. Yet again, 
Method IV appear to calibrate as  well as Method III, but since this method tend to censor 
non-events incorrectly if there is a manifestation of any prevalent CVD other than CHF, 
it cannot be considered a good method.  
Thus, based on these results, Method I with the FU through exam 8 would be considered 
to have better calibration followed by those with FU through exam 7, and Method III for 
each of the FU periods. 
 
For net reclassification improvement, we used similar methods as in the case of stroke 
and MI. The results for full FU are summarized in table 4.3.9, and with restriction to 10 
years of FU are in table 4.3.10. These findings are similar to those obtained for stroke as 
an outcome, and for brevity’s shake, we have only shown the results. 
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Table 4.3.9 Net Reclassification Improvement results for various risk factors on CHF data [Full Follow-up] 
 Ex7 (1998-2001) 
 
Ex8(2005-2008) 
 
Method I 
Events| Non-Events   
Follow-up, years 7 years 14 years 
Age, Sex, DM 1.46[0.63,2.24] 0.67[0.43,0.95] 
Age, Sex, S1HTN 0.72[-0.30,1.11] 0.74[0.54,0.92] 
Age, Sex, Smoking -0.09[-0.44,0.94] 0.04[-0.10,0.19] 
Age, Sex, AF -0.94[-1.27,-0.04] -0.19[-0.34,-0.01] 
Age, Sex, CRP 0.57[-0.47,0.93] 0.36[0.13,0.60] 
 2002 2004 2006 2009 
 
Method II 
Events| Non-Events 
 
    
Follow-up, years 8 years 10 years 12 years 15 years 
Age, Sex, DM 0.19[-0.11,0.58] 0.29[0.03,0.60] 0.10[-0.07,0.30] 0.12[-0.18,0.59] 
Age, Sex, S1HTN -0.02[-0.71,0.58] 0.30[-0.34,0.87] 0.24[-0.36,0.81] 0.91[0.39,1.84] 
Age, Sex, Smoking 0.07[-0.26,0.53] 0.53[0.07,0.93] -0.19[-0.49,0.08] -0.31[-0.79,0.07] 
Age, Sex, AF 0.07[-0.07,0.24] 0.01[-0.21,0.24] -0.10[-0.53,0.35] -0.54[-1.34,0.07] 
Age, Sex, CRP 0.05[-0.50,0.56] -0.07[-0.55,0.46] -0.36[-0.98,0.16] 0.91[0.21,1.85] 
 
Method III 
Events| Non-Events 
 
    
Follow-up, years 8 years 10 years 12 years 15 years 
Age, Sex, DM 0.51[0.23,0.83] 0.40[0.14,0.75] 0.20[0.03,0.44] 0.32[0.15,0.53] 
Age, Sex, S1HTN 0.56[0.22,0.88] 0.82[0.46,1.09] 0.60[0.20,0.95] 0.78[0.57,0.94] 
Age, Sex, Smoking 0.06[-0.16,0.34] 0.40[-0.02,0.82] -0.08[-0.20,0.09] -0.05[-0.18,0.11] 
Age, Sex, AF -0.14[-0.38,0.14] -0.38[-0.52,-0.19] -0.32[-0.52,-0.05] -0.34[-0.51,-0.16] 
Age, Sex, CRP 0.30[-0.04,0.61] 0.36[0.02,0.69] -0.04[-0.33,0.34] 0.54[0.30,0.76] 
 
Method IV 
Events| Non-Events 
 
    
Follow-up, years 8 years 10 years 12 years 15 years 
Age, Sex, DM 0.57[0.28,0.88] 0.53[0.25,0.92] 0.31[0.13,0.57] 0.40[0.22,0.60] 
Age, Sex, S1HTN 0.62[0.29,0.92] 0.87[0.55,1.17] 0.68[0.28,1.05] 0.87[0.68,1.05] 
Age, Sex, Smoking 0.05[-0.17,0.31] 0.39[0.01,0.81] -0.05[-0.17,0.12] -0.03[-0.17,0.12] 
Age, Sex, AF -0.43[-0.68,-0.16] -0.44[-0.64,-0.17] -0.42[-0.62,-0.15] -0.44[-0.61,-0.25] 
Age, Sex, CRP 0.29[-0.05,0.60] 0.37[-0.001,0.69] -0.02[-0.32,0.35] 0.54[0.29,0.78] 
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Table 4.3.10 Net Reclassification Improvement results for various risk factors on CHF data [10 years Follow-up] 
 Ex7 (1998-2001) 
 
Ex8 (2005-2008) 
 
Method I 
Events| Non-Events   
Follow-up, years 10 years 10 years 
Age, Sex, DM 1.46[0.63,2.24] 0.53[0.37,0.74] 
Age, Sex, S1HTN 0.72[-0.30,1.11] 0.67[050,0.85] 
Age, Sex, Smoking -0.09[-0.44,0.94] 0.08[-0.07,0.23] 
Age, Sex, AF -0.94[-1.27,-0.04] -0.11[-0.27,0.07] 
Age, Sex, CRP 0.57[-0.47,0.93] 0.35[0.15,0.57] 
 2002 2004 2006 2009 
 
Method II 
Events| Non-Events 
 
    
Follow-up, years 10 years 10 years 10 years 10 years 
Age, Sex, DM 0.19[-0.11,0.58] 0.29[0.03,0.60] 0.24[0.05,0.45] 0.54[0.37,0.72] 
Age, Sex, S1HTN -0.02[-0.71,0.58] 0.30[-0.34,0.87] 0.31[0.01,0.60] 0.69[0.52,0.86] 
Age, Sex, Smoking 0.07[-0.26,0.53] 0.53[0.07,0.93] 0.02[-0.19,0.22] 0.06[-0.07,0.20] 
Age, Sex, AF 0.07[-0.07,0.24] 0.01[-0.21,0.24] 0.32[-0.07,0.76] -0.15[-0.30,0.03] 
Age, Sex, CRP 0.05[-0.50,0.56] -0.07[-0.55,0.46] 0.09[-0.21,0.38] 0.30[0.11,0.50] 
 
Method III 
Events| Non-Events 
 
    
Follow-up, years 10 years 10 years 10 years 10 years 
Age, Sex, DM 0.51[0.23,0.83] 0.40[0.14,0.75] 0.48[0.28,0.70] 0.54[0.38,0.73] 
Age, Sex, S1HTN 0.56[0.22,0.88] 0.82[0.46,1.09] 0.70[0.48,0.88] 0.68[0.51,0.84] 
Age, Sex, Smoking 0.06[-0.16,0.34] 0.40[-0.02,0.82] 0.01[-0.14,0.18] 0.05[-0.07,0.20] 
Age, Sex, AF -0.14[-0.38,0.14] -0.38[-0.52,-0.19] -0.08[-0.34,0.22] 0.05[-0.07,0.20] 
Age, Sex, CRP 0.30[-0.04,0.61] 0.36[0.02,0.69] 0.35[0.11,0.59] 0.29[0.10,0.48] 
 
Method IV 
Events| Non-Events 
 
    
Follow-up, years 10 years 10 years 10 years 10 years 
Age, Sex, DM 0.57[0.28,0.88] 0.53[0.25,0.92] 0.57[0.35,0.79] 0.59[0.42,0.77] 
Age, Sex, S1HTN 0.62[0.29,0.92] 0.87[0.55,1.17] 0.79[0.57,0.98] 0.75[0.59,0.90] 
Age, Sex, Smoking 0.05[-0.17,0.31] 0.39[0.01,0.81] 0.03[-0.13,0.20] 0.04[-0.08,0.19] 
Age, Sex, AF -0.43[-0.68,-0.16] -0.44[-0.64,-0.17] -0.13[-0.38,0.18] -0.03[-0.17,0.11] 
Age, Sex, CRP 0.29[-0.05,0.60] 0.37[-0.001,0.69] 0.35[0.12,0.60] 0.29[0.10,0.49] 
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5. Results from Simulations 
 
This chapter presents results obtained from analyzing survival data generated from 
Weibull survival distributions under various conditions as described in sections 3.5 and 
3.6. We also conducted similar analyses with the Exponential distribution as a limiting 
case of the Weibull distribution. Those results are summarized in Appendix B.  
 
We start by comparing Method A (analogous to censoring Method III) and Method B 
(equivalent to censoring Method II), in terms of baseline cumulative incidences, 
robustness and power.  The study period    is the initial period in which Methods A and 
B have the same follow-up (an average of 5 time units, e.g. years, from entry).  We 
present results for three study periods indexed by                  corresponding to 
follow-up periods of increasing length (with a maximum of 8, 10 and 15 time units). 
 
5.1 Estimate of Cumulative Incidence  
 
To assess the performance of Method A and Method B in terms of estimates of baseline 
cumulative incidence, we use PROC PHREG in SAS 9.3 which gives a K-M estimate of 
survival – the complement of which is the estimate of cumulative incidence. In the first 
set of simulations, we chose Weibull distributions with increasing hazard functions by 
setting α = 1.15 and we selected distributions with different λ’s to represent range of 
incidences. We used sample sizes of 500, 1000, and 2000 to examine whether 
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any differences between the methods are affected by sample size. In addition, we used 
different study periods (      ), to evaluate the effect of extending the FU period on the 
performance of Methods A and B.  In Method A, both events and non-events are 
followed through each of                , while in Method B, events are followed through 
the follow-up period, but non-events are censored at   . Each of these scenarios is run 
with 5,000 iterations. Estimates of cumulative incidence at the end of each study period 
are depicted in table 5.1.1 for different sample sizes and indexed by the various Weibull 
distribution parameters.  The results shown are the means and standard deviations of the 
sampling distributions of cumulative incidence based on the 5,000 iterations.  
 
We expect the final cumulative incidence to vary with the Weibull parameter λ, and to 
increase with the length of the follow-up period, but not to be affected by sample size.  
Method A results follows this expectation.   
 
As evident from these results, Method B always over estimates the cumulative incidence 
irrespective of whether the FU is extended for non-events through                . The 
estimate is less affected when the incidence is higher, but when the incidence is low, the 
difference is quite large. This substantial increase in an estimate of incidence from 
Method B as compared to Method A is perhaps due to the fact that there is no non-event 
data in the study period after    as we extend the FU for events through each of 
               respectively but in each of these study periods, non-events are censored at 
   resulting in the mean FU for events well exceeding that of non-events. 
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We see a similar pattern with the exponential distribution as a limiting case of the 
Weibull distribution (with a shape parameter of 1) and various scale parameters to 
produce several levels of incidence. These results are summarized in Table B.1 in 
Appendix B.
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Table 5.1.1 Estimates of Cumulative Incidence Indexed by Weibull Distribution Parameters  
 
Distribution 
Study 
Period 
N=500  N=1000 N=2000 
Method A Method B Method A Method B Method A Method B 
 
Weibull (1.15, 0.12) 
T1 72.70±4.27 98.53±0.34 72.89±3.05 99.27±0.11 72.98±2.17 99.64±0.04 
T2 81.13±4.39 98.85±0.21 81.39±3.08 99.43±0.07   82.55±2.20
 81.55±2z 
99.71±0.03 
T3 91.58±4.14 99.00±0.17 92.47±3.05 99.51±0.06 92.92±2.21 99.75±0.02 
 
Weibull (1.15, 0.06) 
T1 44.92±3.84 98.41±0.31 48.00±2.69 99.21±0.11 48.04±1.91 99.61±0.04 
T2 56.96±4.00 98.90±0.17 57.06±2.85 99.45±0.06 57.10±2.02 99.73±0.02 
T3 73.74±4.29 99.23±0.09 73.93±3.04 99.61±0.03 74.04±2.17 99.81±0.01 
 
Weibull (1.15, 0.03) 
T1 27.90±3.10 97.69±0.53 27.93±2.20 98.86±0.18 27.93±1.55 99.43±0.06 
T2 34.46±3.83 98.52±0.25 34.49±2.39 99.27±0.09 34.51±1.69 99.63±0.03 
T3 48.93±3.83 99.12±0.11 49.02±2.71 99.56±0.04 49.06±1.92 99.78±0.01 
 
Weibull (1.15, 0.0214) 
T1 20.80±2.73 97.03±0.76 20.83±1.92 98.53±0.26 20.83±1.37 99.27±0.09 
T2 26.03±3.01 98.16±0.35 26.06±2.13 99.08±0.12 26.6±1.51 99.54±0.04 
T3 38.14±3.50 98.96±0.14 38.18±2.47 99.48±0.05 38.20±1.74 99.74±0.02 
 
Weibull (1.15, 0.015) 
T1 15.06±2.36 95.98±1.24 15.10±1.67 98.03±0.40 15.11±1.20 99.03±0.14 
T2 19.05±2.63 97.57±0.53 19.08±1.86 98.75±0.18 19.08±1.32 99.40±0.06 
T3 28.61±3.14 98.71±0.20 28.64±2.23 99.35±0.07 28.64±1.53 99.68±0.02 
 
Weibull (1.15, 0.01) 
T1 10.31±1.99 94.18±2.40 10.35±1.40 97.18±0.69 10.35±1.01 98.61±0.23 
T2 13.11±2.20 96.57±0.93 13.15±1.57 98.31±0.31 13.17±1.11 99.16±0.11 
T3 20.11±2.69 98.19±0.32 20.15±1.90 99.13±0.11 20.15±1.35 99.56±0.04 
 Results are mean± standard deviation 
 
121 
 
 
5.2 Robustness Results 
  
To assess the robustness of Method A and Method B, we generated two independent 
samples from each of six Weibull survival distributions using a monotone increasing 
hazard with α=1.15 and λ’s of 0.12, 0.06, 0.03, 0.0214, 0.015 and 0.01. These selections 
are consistent with what we used for the estimation of cumulative incidences. For each 
simulation scenario, we employed 5,000 iterations. In each iteration, we used SAS PROC 
PHREG to estimate the hazard ratio comparing groups 1 and 2 (for example, participants 
with and without a risk factors of interest) and to test the null hypothesis of no difference 
in hazard rates between the groups (H0: HR=1). The robustness of the test under each 
censoring method is measured by the Type I error rate, calculated as a percentage of 
iterations in which we reject the null hypothesis. We focus here on tests using α=5%, and 
expect to reject the (true) null hypothesis in 4.3% - 5.7% of the iterations. Table 5.2.1 
shows, for samples of 2,000 (1,000 per group), at study periods indexed by 
                , under Methods A and B, the median and interquartile ranges of the 
estimated HRs along with the percent rejected. The HRs are all very close to 1, under 
both methods. This is consistent with previous results for Method A but it is interesting 
for Method B given the incidences are overestimated. Similarly, the robustness results for 
both Methods A and B at each of the study periods are very close. The observed type I 
error rates ranged from 4.2% to 6.0% for Method A and from 4.3% to 6.6% for Method 
B. Except for a couple of instances with Weibull (1.15, 0.0214) and Weibull (1.15, 0.01), 
all other results are within the expected range of 4.3% to 5.7%. 
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The results summarized in Table 5.2.2 are based on sample sizes of 1,000. As anticipated, 
Method A estimates HRs that are very close to 1, and, as with the larger sample size, the 
Method B estimates are also nearly always 1.  Here, the type I error rates between the two 
methods are very close and are mostly within the expected range. These ranged from 
4.1% to 5.9% for Method A and from 4.1% to 6.0% for Method B.  
 
The next set of results, shown in table 5.2.3, is based on sample sizes of 500 participants 
per group. As we saw with larger sample sizes, the HRs as estimated by both methods are 
equal to, or very close to one over the range of length of study period and Weibull 
parameters. The robustness results are all quite good with rejection percentages close to 
5% and all within the confidence interval of (4.3%-5.7%). 
 
We see a similar pattern with the exponential distribution as a limiting case of Weibull 
where we set a shape parameter at 1 and vary the scale parameter as previously described. 
These results are very similar to those observed with each of the sample sizes of 2000, 
1000 and 500, except perhaps with slightly less variability in the Type I error rates for a 
sample of 500 as compared to the primary Weibull model. These results are summarized 
in tables B.2, B.3 and B.4 in Appendix B.
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Table 5.2.1    Robustness Results for Weibull Distribution, N=2000.  
 
Distribution 
Study 
Period 
Method A Method B 
HR [Q1, Q2] % Rejected HR [Q1, Q2] % Rejected 
 
Weibull (1.15, 0.12) 
T1 1.00 [0.95, 1.05] 5.1 1.00 [0.96, 1.05] 5.0 
T2 1.00 [0.96, 1.05] 4.8 1.00 [0.96, 1.04] 4.9 
T3 1.00 [0.96, 1.05] 5.1 1.00 [0.96, 1.04] 4.9 
 
Weibull (1.15, 0.06) 
T1 1.00 [0.95, 1.05] 4.8 1.00 [0.95, 1.05] 5.1 
T2 1.00 [0.95, 1.05] 5.1 1.00 [0.95, 1.05] 4.8 
T3 1.00 [0.95, 1.05] 5.0 1.00 [0.96, 1.04] 4.9 
 
Weibull (1.15, 0.03) 
T1 1.00 [0.94, 1.06] 5.1 1.00 [0.94, 1.06] 5.5 
T2 1.00 [0.94, 1.06] 5.1 1.00 [0.95, 1.06] 5.3 
T3 1.00 [0.95, 1.05] 5.0 1.00 [0.95, 1.05] 5.2 
 
Weibull (1.15, 0.0214) 
T1 1.00 [0.93, 1.07] 5.4 1.00 [0.93, 1.08] 5.1 
T2 1.00 [0.94, 1.06] 5.0 1.00 [0.94, 1.07] 4.9 
T3 1.00 [0.95, 1.04] 4.9 1.00 [0.95, 1.05] 5.2 
 
Weibull (1.15, 0.015) 
T1 1.00 [0.92, 1.09] 4.8 1.00 [0.92, 1.08] 4.6 
T2 1.00 [0.93, 1.08] 5.2 1.00 [0.93, 1.08] 5.1 
T3 1.00 [0.94, 1.06] 5.0 1.00 [0.94, 1.06] 5.3 
 
Weibull (1.15, 0.01) 
T1 1.00 [0.91, 1.10] 5.3 1.00 [0.91, 1.11] 4.9 
T2 1.00 [0.92, 1.09] 5.0 1.00 [0.92, 1.09] 5.7 
T3 1.00 [0.93, 1.07] 5.4 1.00 [0.93, 1.08] 5.6 
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Table 5.2.2    Robustness Results for Weibull Distribution, N=1000.  
 
Distribution 
Study 
Period 
Method A Method B 
HR [Q1, Q2] % Rejected HR [Q1, Q2] % Rejected 
 
Weibull (1.15, 0.12) 
T1 1.00 [0.94, 1.06] 4.8 1.00 [0.94, 1.06] 4.6 
T2 1.00 [0.94, 1.06] 5.0 1.00 [0.94, 1.06] 4.6 
T3 1.00 [0.94, 1.06] 4.7 1.00 [0.94, 1.06] 5.1 
 
Weibull (1.15, 0.06) 
T1 1.00 [0.93, 1.07] 4.9 1.00 [0.93, 1.07] 4.7 
T2 1.00 [0.93, 1.07] 4.7 1.00 [0.94, 1.07] 5.0 
T3 1.00 [0.94, 1.06] 4.9 1.00 [0.94, 1.07] 4.5 
 
Weibull (1.15, 0.03) 
T1 1.00 [0.92, 1.09] 5.3 1.00 [0.92, 1.10] 5.2 
T2 1.00 [0.92, 1.08] 4.8 1.00 [0.92, 1.09] 5.3 
T3 1.00 [0.93, 1.07] 5.0 1.00 [0.93, 1.07] 4.8 
 
Weibull (1.15, 0.0214) 
T1 1.00 [0.91, 1.11] 4.8 1.00 [0.91, 1.11] 4.7 
T2 1.00 [0.91, 1.09] 5.1 1.00 [0.91, 1.10] 4.9 
T3 1.00 [0.92, 1.08] 4.9 1.00 [0.93, 1.08] 5.3 
 
Weibull (1.15, 0.015) 
T1 1.01 [0.89, 1.13] 4.7 1.00 [0.89, 1.13] 5.1 
T2 1.00 [0.90, 1.11] 4.6 1.00 [0.91, 1.12] 5.2 
T3 1.00 [0.92, 1.09] 5.3 1.00 [0.92, 1.10] 5.2 
 
Weibull (1.15, 0.01) 
T1 1.00 [0.87, 1.15] 5.1 1.01 [0.87, 1.16] 5.1 
T2 1.00 [0.89, 1.14] 5.1 1.00 [0.88, 1.13] 5.3 
T3 1.00 [0.91, 1.11] 5.1 1.00 [0.90, 1.11] 5.4 
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Table 5.2.3    Robustness Results for Weibull Distribution, N=500.  
 
Distribution 
Study 
Period 
Method A Method B 
HR [Q1, Q2] % Rejected HR [Q1, Q2] % Rejected 
 
Weibull (1.15, 0.12) 
T1 1.00 [0.91, 1.10] 4.8 1.00 [0.91, 1.10] 5.0 
T2 1.00 [0.91, 1.10] 4.7 1.00 [0.92, 1.09] 4.9 
T3 1.00 [0.91, 1.10] 4.5 1.00 [0.91, 1.09] 4.9 
 
Weibull (1.15, 0.06) 
T1 1.00 [0.90, 1.10] 4.9 0.99 [0.90, 1.10] 4.9 
T2 1.00 [0.91, 1.10] 5.0 1.00 [0.91, 1.10] 4.8 
T3 1.00 [0.91, 1.09] 4.5 1.00 [0.91, 1.10] 5.2 
 
Weibull (1.15, 0.03) 
T1 1.00 [0.88, 1.14] 4.8 1.00 [0.88, 1.14] 5.5 
T2 0.99 [0.89, 1.12] 4.6 1.00 [0.89, 1.12] 5.6 
T3 1.00 [0.90, 1.10] 4.9 0.99 [0.90, 1.10] 5.2 
 
Weibull (1.15, 0.0214) 
T1 0.99 [0.87, 1.15] 5.0 1.00 [0.87, 1.16] 5.7 
T2 0.99 [0.88, 1.13] 5.0 1.00 [0.88, 1.14] 5.4 
T3 1.00 [0.90, 1.11] 4.7 1.00 [0.89, 1.11] 5.4 
 
Weibull (1.15, 0.015) 
T1 1.00 [0.85, 1.18] 5.2 1.00 [0.84, 1.18] 4.9 
T2 1.00 [0.86, 1.16] 5.2 1.00 [0.86, 1.17] 5.6 
T3 1.00 [0.88, 1.13] 5.0 1.00 [0.88, 1.14] 5.4  
 
Weibull (1.15, 0.01) 
T1 1.00 [0.82, 1.22] 4.8 1.00 [0.82, 1.24] 5.1 
T2 1.00 [0.84, 1.20] 4.9 1.00 [0.83, 1.20] 5.8 
T3 1.00 [0.86, 1.15] 5.1 1.00 [0.87, 1.16] 5.9 
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5.3 Power Analyses Results 
  
To assess the performance of Method A and Method B in terms of estimates of HRs and 
power when there is a difference in survival between groups, we considered a range of 
Weibull distributions.  We generated the reference group from a Weibull (1.15, 0.03) 
distribution and the comparison groups from Weibull distributions with α = 1.15, and 
various λ’s.  For each comparison we used sample sizes of 2000, 1000 and 500 with the 
study period extended through        and    respectively. For each scenario, and using 
each method, we present the median and interquartile range of HRs over the 5,000 
iterations, along with the percent of iterations in which the null hypothesis (H0: HR=1) 
was rejected.   
 
Table 5.3.1 shows the power analysis results for a sample of size 2000. Method A, which 
extends the FU for both events and non-events, yields estimates of HR equivalent to the 
“true” HR. These estimates are consistent irrespective of whether we extend the FU 
through     or    .  Method B, which extends the FU for events but not for non-events, 
always, produces estimates closer to the null, overestimating the HRs when the true HR is 
less than 1, and underestimating when the true HR is greater than 1. This is true when FU 
is extended through     and   . 
 
When the hazard ratio is extreme (the comparison groups from Weibull distributions with 
scale parameters of 0.12, 0.06, 0.01 yield HRs of 0.25, 0.5 and 3.0), Methods A and B are 
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equally powerful, with the null rejected in all (100%) of the iterations. When the true HR 
is 2, results are nearly the same (close to 100% power using either method).   
 
As the HR approaches the null, although the Method A estimates of the HR remain very 
good (the median estimated HR is always equal to the true HR) the power naturally 
decreases.  For example, for HRs of 0.8 and 1.4, the Method A power at T1 is 79%, and 
for HR=1.2, the power is 49%.   
 
Furthermore, with increasing follow up time, the power of Method A increases, which is 
expected due to the fact that the number of events increases and the FU is extended for 
both events and non-events.  
 
Method B power is much lower than the Method A power.  For example, for HR= 0.8, 
the Method B power at T1 is 42%, and for HR=1.2, the power is only 26%.  As the 
follow-up period increases, the Method B power does not always increase as did the 
Method A power.  For example, when HR=1.4, the power is 79% at T1 and 61% at T3.  
Although the number of events increases from T1 to T3, the FU in non-events does not 
increase.  
 
Next, we assess performance of Methods A and B using the same set of scenarios but 
reducing the sample size by half to 500 subjects per group. Table 5.3.2 displays these 
results. Halving the sample size doesn’t seem to affect the estimates of HRs with Method 
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A, as this method yields identical estimates of HRs with less precision or wider CIs, 
which was expected given the smaller sample. Method B estimates are closer to the null 
than Method A estimates and are similar to those seen with the larger sample size. 
 
The power, as expected, is lower with the smaller sample size, both for Method A and 
Method B, and Method B is always less powerful by comparison. 
 
To ascertain if this trend continues, we reduced the sample size further, to 250 subjects 
per group and reran all analyses repeating the same scenarios. The findings are 
summarized in table 5.3.3.  Again we see that, compared to Method A, the Method B 
estimates are closer to the null, the Method B power is lower, and these differences are 
more pronounced with longer FU. 
 
In summary, under all the simulation scenarios, Method A yields accurate estimates of 
HRs, and power increases with increasing follow-up. However, Method B either 
underestimates (for HR>1) or overestimates (if HR<1) the HRs but always moves 
towards the null. Method B power is less than Method A power, except when the true HR 
is quite extreme (in which case both methods have 100% power).  This difference 
increases with the length of FU. 
We obtained similar results when we used the exponential distribution (as a limiting case 
of Weibull distribution) where we set the shape parameter at 1. These results are 
displayed in Appendix B.
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Table 5.3.1    Power Analysis Results for Baseline Weibull Distribution (1.15, 0.03), N=2000.  
Group 2 
Distribution 
HR 
Study 
Period 
Method A Method B 
HR [Q1, Q2] Power (%) HR [Q1, Q2] Power (%) 
Weibull (1.15, 0.12) 
HR=0.25 
T1 0.25[0.24,0.26] 100 0.33[0.31,0.35] 100 
T2 0.25[0.24,0.26] 100 0.34[0.32,0.36] 100 
T3 0.25[0.24,0.26] 100 0.32[0.30,0.34] 100 
 
Weibull (1.15, 0.06) 
HR=0.50 
T1 0.50[0.47, 0.53] 100 0.60[0.57,0.63] 100 
T2 0.50[0.47, 0.53] 100 0.62[0.59,0.66] 100 
T3 0.50[0.48,0.53] 100 0.62[0.59,0.65] 100 
 
Weibull (1.15, 0.0375) 
HR=0.80 
T1 0.80[0.76, 0.85] 70.84 0.85[0.81,0.91] 42.36 
T2 0.80[0.76, 0.85] 78.38 0.87[0.82,0.92] 40.38 
T3 0.80[0.76, 0.84] 87.46 0.88[0.83,0.92] 45.72 
 
Weibull (1.15, 0.03) 
HR=1.0 
T1 1.00[0.94,1.07] 5.03 1.00[0.94,1.07] 5.46 
T2 1.00[0.95,1.06] 5.02 1.00[0.94,1.06] 5.28 
T3 1.00[0.95,1.05] 4.98 1.00[0.95,1.05] 5.16 
 
Weibull (1.15, 0.025) 
HR=1.2 
T1 1.20[1.13,1.28] 49.34 1.13[1.06,1.21] 26.02 
T2 1.20[1.13,1.28] 56.96 1.12[1.05,1.18] 24.14 
T3 1.20[1.14,1.26] 68.02 1.11[1.05,1.16] 26.64 
 
Weibull (1.15, 0.0214) 
HR=1.4 
T1 1.40[1.29,1.52] 79.12 1.40[1.29,1.52] 79.12 
T2 1.40[1.31,1.50] 93.78 1.26[1.18,1.35] 64.24 
T3 1.40[1.32,1.49] 96.84 1.22[1.15,1.30] 60.62 
 
Weibull (1.15, 0.015) 
HR=2.0 
T1 1.99[1.82,2.19] 99.90 1.99[1.82,2.19] 99.90 
T2 2.00[1.86,2.15] 100 1.60[1.49,1.73] 99.54 
T3 2.00[1.87,2.14] 100 1.50[1.41,1.60] 98.96 
 
Weibull (1.15, 0.01) 
HR=3.0 
T1 2.99[2.70,3.32] 100 2.99[2.70,3.32] 100 
T2 3.00[2.76,3.25] 100 2.15[1.98,2.33] 100 
T3 3.00[2.79,3.23] 100 1.92[1.79,2.06] 100 
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Table 5.3.2    Power Analysis Results for Baseline Weibull Distribution (1.15, 0.03), N=1000.  
Group 2 
Distribution 
HR 
Study 
Period 
Method A Method B 
HR [Q1, Q2] Power (%) HR [Q1, Q2] Power (%) 
Weibull (1.15, 0.12) 
HR=0.25 
T1 0.25[0.23,0.27] 100 0.33[0.28,0.38] 100 
T2 0.25[0.23,0.27] 100 0.34[0.29,0.39] 100 
T3 0.25[0.23,0.27] 100 0.32[0.27,0.37] 100 
 
Weibull (1.15, 0.06) 
HR=0.50 
T1 0.50[0.46, 0.54] 100 0.60[0.55,0.65] 99.06 
T2 0.50[0.46, 0.54] 100 0.62[0.58,0.67] 99.12 
T3 0.50[0.47,0.54] 100 0.62[0.58,0.67] 99.82 
 
Weibull (1.15, 0.0375) 
HR=0.80 
T1 0.80[0.74, 0.87] 42.88 0.85[0.78,0.93] 25.32 
T2 0.80[0.74, 0.87] 48.58 0.87[0.80,0.94] 23.26 
T3 0.80[0.75, 0.86] 59.48 0.88[0.81,0.93] 26.26 
 
Weibull (1.15, 0.03) 
HR=1.0 
T1 1.00[0.92,1.09] 5.03 1.00[0.91,1.09] 5.20 
T2 1.00[0.93,1.08] 4.80 1.00[0.92,1.08] 5.32 
T3 1.00[0.93,1.07] 4.96 1.00[0.93,1.07] 4.82 
 
Weibull (1.15, 0.025) 
HR=1.2 
T1 1.20[1.10,1.31] 27.48 1.13[1.03,1.24] 15.42 
T2 1.20[1.11,1.30] 31.98 1.11[1.02,1.21] 14.00 
T3 1.20[1.12,1.29] 40.40 1.11[1.03,1.19] 16.22 
 
Weibull (1.15, 0.0214) 
HR=1.4 
T1 1.40[1.28,1.54] 69.22 1.26[1.14,1.39] 38.34 
T2 1.40[1.29,1.53] 77.04 1.22[1.12,1.33] 34.66 
T3 1.40[1.31,1.51] 87.48 1.20[1.12,1.29] 38.28 
 
Weibull (1.15, 0.015) 
HR=2.0 
T1 2.00[1.81,2.22] 99.72 1.61[1.45,1.79] 88.12 
T2 2.00[1.83,2.19] 99.92 1.50[1.37,1.65] 85.09 
T3 2.00[1.85,2.16] 100 1.42[1.32,1.54] 85.96 
 
Weibull (1.15, 0.01) 
HR=3.0 
T1 3.01[2.68,3.37] 100 2.16[1.93,2.42] 99.56 
T2 3.00[2.72,3.33] 100 1.93[1.75,2.13] 99.20 
T3 3.00[2.76,3.27] 100 1.73[1.58,1.87] 99.10 
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Table 5.3.3    Power Analysis Results for Baseline Weibull Distribution (1.15, 0.03), N=500.  
Group 2 
Distribution 
HR 
Study 
Period 
Method A Method B 
HR [Q1, Q2] Power (%) HR [Q1, Q2] Power (%) 
Weibull (1.15, 0.12) 
HR=0.25 
T1 0.25[0.22,0.28] 100 0.32[0.16,0.58] 100 
T2 0.25[0.13,0.44] 100 0.34[0.16,0.59] 100 
T3 0.25[0.13,0.45] 100 0.32[0.15,0.54] 100 
 
Weibull (1.15, 0.06) 
HR=0.50 
T1 0.50[0.45,0.56] 98.68 0.60[0.53,0.67] 87.44 
T2 0.50[0.45,0.56] 99.36 0.62[0.56,0.69] 86.60 
T3 0.50[0.45,0.55] 99.82 0.62[0.56,0.68] 92.24 
 
Weibull (1.15, 0.0375) 
HR=0.80 
T1 0.80[0.71, 0.90] 23.10 0.85[0.75, 0.96] 15.32 
T2 0.80[0.72, 0.89] 27.70 0.87[0.78, 0.97] 13.50 
T3 0.80[0.73, 0.88] 33.60 0.88[0.79,0.96] 14.92 
 
Weibull (1.15, 0.03) 
HR=1.0 
T1 1.00[0.89,1.13] 4.82 1.00[0.88,1.14] 5.52 
T2 1.01[0.90,1.12] 4.62 1.00[0.89,1.12] 5.78 
T3 1.00[0.91,1.09] 4.86 1.00[0.91,1.11] 5.18 
 
Weibull (1.15, 0.025) 
HR=1.2 
T1 1.21[1.06,1.37] 16.04 1.14[0.99,1.29] 10.72 
T2 1.21[1.07,1.35] 19.00 1.12[0.99,1.27] 9.48 
T3 1.20[1.09,1.33] 23.32 1.11[1.00,1.23] 9.94 
 
Weibull (1.15, 0.0214) 
HR=1.4 
T1 1.41[1.23,1.61] 41.58 1.26[1.10,1.45] 21.52 
T2 1.41[1.25,1.59] 48.74 1.23[1.09,1.39] 20.26 
T3 1.41[1.27,1.56] 59.88 1.20[1.08,1.34] 21.98 
 
Weibull (1.15, 0.015) 
HR=2.0 
T1 2.01[1.74,2.32] 91.22 1.62[1.40,1.89] 60.76 
T2 2.01[1.76,2.29] 95.24 1.52[1.32,1.73] 56.60 
T3 2.01[1.79,2.24] 99.08 1.44[1.29,1.60] 57.60 
 
Weibull (1.15, 0.01) 
HR=3.0 
T1 3.02[2.58,3.56] 99.84 2.19[1.85,2.60] 89.66 
T2 3.02[2.62,3.49] 99.98 1.96[1.68,2.27] 86.38 
T3 3.02[2.66,3.41] 100 1.73[1.54,1.96] 85.68 
132 
 
 
Tables 5.3.1-5.3.3 display results for various simulation scenarios when the reference 
group is from the Weibull Distribution (1.15, 0.03) and the comparison groups represent 
differences in survival operationalized by a range of HRs.  Table 5.3.4 and 5.3.5 display 
results for fixed HR of 2.0 with a range of baseline distributions. Method A, with the FU 
through each of        and    , generates a precise estimate of HRs for all the baseline 
Weibull distributions. Method B, which extends the FU for events but not for non-events, 
in all cases underestimates the HR of 2. Furthermore, as the FU for events is extended, 
the estimates decrease. This effect is stronger when the baseline incidence is low (for 
example, with Weibull (1.15, 0.0214) vs. Weibull (1.15, 0.017)). 
 
Method A exhibits 100% power under almost all of the scenarios with a small dip when 
the baseline incidence is low. The power of the test based on Method B is similar to that 
observed with Method A, when the baseline incidence is higher [Weibull (1.15, 0.06) vs. 
Weibull (1.15, 0.03)] but decreases sharply when the baseline incidence is low [Weibull 
(1.15, 0.0214) vs. Weibull (1.15, 0.0107)]. This trend is evident when we have a smaller 
sample size of 500 (table 5.3.5). 
 
For HR=2.0, Methods A and B yield similar power when the baseline incidence is 
relatively large, but Method B has lower power when the baseline incidence is smaller. 
Furthermore, Method B which increases the FU for events but not for non-events, always 
underestimates the HR.
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Table 5.3.4   Power Analysis Results for Various Baseline Weibull Distributions, N=1000.  
 
Distributions 
Study 
Period 
Method A Method B 
HR [Q1, Q2] Power (%) HR [Q1, Q2] Power (%) 
Weibull (1.15, 0.06) 
Vs. 
Weibull (1.15, 0.03) 
T1 2.00 [1.85, 2.17] 100 1.67 [1.55, 1.81] 99.42 
T2 2.01 [1.87, 2.16] 100 1.60 [1.49, 1.73] 99.14 
T3 2.00 [1.87, 2.14] 100 1.61 [1.51, 1.72] 99.80 
Weibull (1.15, 0.04) 
Vs. 
Weibull (1.15, 0.02) 
T1 2.00 [1.83, 2.19] 99.96 1.63 [1.49, 1.78] 95.16 
T2 2.00 [1.84, 2.17] 100 1.55 [1.42, 1.67] 94.24 
T3 2.00 [1.87, 2.15] 100 1.49 [1.38, 1.60] 95.82 
Weibull (1.15, 0.03) 
Vs. 
Weibull (1.15, 0.015) 
T1 2.00 [1.81, 2.22] 99.72 1.61 [1.45, 1.79] 88.12 
T2 2.00 [1.83, 2.19] 99.92 1.50 [1.37, 1.65] 85.09 
T3 2.00 [1.85, 2.16] 100 1.42 [1.32, 1.54] 85.96 
Weibull (1.15, 0.0214) 
Vs. 
Weibull (1.15, 0.0107) 
T1 2.00 [1.78, 2.25] 98.72 1.58 [1.41, 1.79] 75.34 
T2 2.00 [1.80, 2.23] 99.48 1.48 [1.33, 1.65] 70.06 
T3 2.00 [1.83, 2.19] 99.96 1.37 [1.26, 1.50] 66.98 
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Table 5.3.5   Power Analysis Results for Various Baseline Weibull Distributions, N=500.  
 
Distributions 
Study 
Period 
Method A Method B 
HR [Q1, Q2] Power (%) HR [Q1, Q2] Power (%) 
Weibull (1.15, 0.06) 
Vs. 
Weibull (1.15, 0.03) 
T1 2.01 [1.79, 2.24] 99.00 1.69 [1.51, 1.89] 87.74 
T2 2.01 [1.81, 2.23] 99.68 1.62 [1.45, 1.79] 86.56 
T3 2.01 [1.82, 2.21] 99.90 1.62 [1.47, 1.78] 92.54 
Weibull (1.15, 0.04) 
Vs. 
Weibull (1.15, 0.02) 
T1 2.00 [1.83, 2.19] 99.96 1.63 [1.49, 1.78] 95.16 
T2 2.00 [1.84, 2.17] 100 1.55 [1.42, 1.67] 94.24 
T3 2.00 [1.87, 2.15] 100 1.49 [1.38, 1.60] 95.82 
Weibull (1.15, 0.03) 
Vs. 
Weibull (1.15, 0.015) 
T1 2.01 [1.74, 2.32] 91.22 
98.42 
99.76 
 
1.62 [1.40, 1.89] 60.76 
T2 2.01 [1.76, 2.29] 5 24
 
1.52 [1.32, 1.73] 56.60 
T3 2.01 [1.79, 2.24] 99.08 1.44 [1.29, 1.60] 57.60 
Weibull (1.15, 0.0214) 
Vs. 
Weibull (1.15, 0.0107) 
T1 2.02 [1.71, 2.38] 82.38 1.60 [1.35, 1.90] 46.14 
T2 2.02 [1.74, 2.34] 89.60 1.49 [1.28, 1.74] 41.70 
T3 2.01 [1.77, 2.27] 96.92 1.38 [1.21,1.57] 39.96 
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We generated eighteen sets of power curves based on the proportional hazard Weibull 
models. Nine of these are using our primary reference group (from the Weibull 
distribution (1.15, 0.03)) and include one curve for each of the three  follow-up periods, 
for each of the three sample sizes, 2000, 1000 and 500.  In these figures, we plot power as 
a function of the HR. The other nine are using the exponential as a limiting case of the 
Weibull distribution (1.0, 0.03) as a reference group, and for each of the three follow-up 
periods and each of the three sample sizes, 2000, 1000 and 500. We use 8 to 12 data 
points to plot these curves. A complete set of data is included in Appendix C. 
 
In addition, we show 6 plots which include one plot for each of the three follow-up 
periods, for each of the two sample sizes, 1000 and 500. Here we plot power as a function 
of baseline incidences by varying the Weibull scale parameters to retain the HR at 2.  
 
Figure 5.3.1 displays power curves for a total sample of 2000 subjects (1000 per group) 
with study period through time T1. The minimum power on the curves corresponds to the 
percentage rejected under the null hypothesis, when HR=1, and represents the robustness 
of the test.  We used a 5% level of significance for all the tests. For Method A, the 
maximum power is attained at HR ≤ 0.70 and at HR ≥ 1.6. For Method B, the maximum 
power is attained at the HR ≤ 0.5 and ≥ 2.0. For HR less than 1, both methods (are) 
similar but Method B has consistently lower power than Method A. The departure is 
greater when the HR is between 1 and 2. Furthermore, to detect an HR of 1.4, Method A 
exhibits about 95% power to that of about 65% for Method B. 
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Figure 5.3.1 
 
 
 
 
Figure 5.3.2 shows power curves when the FU is extended through T2 for both events and 
non-events with Method A, and for events but not for non-events with Method B. The 
maximum power for Method A is attained at 0.7 and 1.5 and for Method B at 0.5 and 2.0 
respectively.  Method A again exhibits a more narrow power curve as that of Method B.  
Moreover, to detect an HR of 1.4, Method A exhibits about 95% power to that of about 
65% for Method B. 
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Figure 5.3.2  
 
 
 
 
 
Figure 5.3.3 shows power curves when the FU is extended through T3 for both events and 
non-events with Method A, and for events but not for non-events with Method B. The 
maximum power for Method A is attained at 0.7 and 1.8 and for Method B at 0.5 and 2.0 
respectively. Method A consistently exhibits higher power than Method B, and the power 
curves are slightly wider for Method B on either side noticeably so for the HR between 1 
and 2.  Additionally, Method A exhibits about 95% power to detect an HR of 1.4 as 
compared to about 60% for Method B. 
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Figure 5.3.3 
 
 
 
 
 
The next three power curves are based on a total of 1000 subjects, or 500 subjects per 
group. Figure 5.3.4 corresponds to power curves with the study period through T1. The 
test is robust using either method as is evident from the 5% level at HR=1. For Method 
A, the maximum power is attained at HR ≤ 0.05 and at HR > 2.0. For Method B, the 
maximum power is attained at HR < 0.025 and ≥ 3.0. For HR less than 1, both methods 
display similar patterns but power for Method B is generally lower than that of Method 
A. The departure is greater when the HR is between 1 and 3.  
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Figure 5.3.4 
 
 
 
 
Figure 5.3.5 shows power curves when the FU is extended through T2 for both events and 
non-events with Method A, and for events but not for non-events with Method B. The 
test is robust using either method as is evident from the 5% level at HR=1. The power for 
Method B is lower when compared to that of Method A and reaches maximum power at 
HR of ≤ 0.025 and ≥ 3.0, compared to HRs ≤ 0.5 and ≥ 1.8 for Method A. Method A, as 
before, is relatively more powerful than Method B at all HRs, especially for HR greater 
than 1.  We saw an identical pattern when the FU was further extended through T3, for 
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both events and non-events with Method A, and for events but not non-events with 
Method B (Figure 5.3.6). 
 
Figure 5.3.5 
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Figure 5.3.6 
 
 
 
 
 
We next assess the power of the two methods for a sample of 250 subjects per group with 
the study periods extended through T1, T2 and T3.  Figure 5.3.7 shows plots with the study 
period through T1. Again, Method A shows the higher power, especially for HR greater 
than 1. For example, the power to detect an HR of 2.0, Method A yields about 100% 
power but about 85% in Method B. Likewise, Method A has more than 90% power to 
detect HR of 1.5 but Method B has less than 50%.  
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Figure 5.3.7 
 
 
 
 
 
Figure 5.3.8 show power curves when the FU is extended through T2 for both events and 
non-events with Method A, and for events but not for non-events with Method B. The 
power curve bottoms out at the intersection of HR of 1 and about 5% power for Method 
A, and at a slightly greater than 5% power for Method B. The maximum power for 
Method A is attained at HR ≤ 0.5 and ≥ 3.0 and for Method B at HR ≤ 0.25 and ≥ 3.0. 
These power curves, as expected with smaller sample size, are wider as compared to the 
larger samples. Yet again, Method A exhibits more power than Method B throughout, but 
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noticeably more so with HR greater than 1.  For instance, to detect an HR of 2.0, Method 
A yields 90% power but Method B has only 60% power.  
 
Figure 5.3.8 
 
 
 
 
Figure 5.3.9 shows power curves when the FU is extended through T3 for both events and 
non-events with Method A, and for events but not for non-events with Method B. Here 
again, the power curve bottoms out at the intersection of HR of 1 and about 5% power. 
The maximum power for Method A is attained at 0.5 and about 2.0 and for Method B at 
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0.25 and somewhere at >3 respectively. As before, these power curves are relatively 
wider than those with larger samples. Again, Method A shows larger values of power, in 
particular, for HR greater than 1. Method A has about 98% power to detect an HR of 2 as 
opposed to less than 60% for Method B. 
 
Figure 5.3.9 
 
 
 
 
 
Next, we wanted to assess the performance of these methods by imposing a constant HR 
with different Weibull parameters for reference and comparison groups and varying 
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levels of baseline incidences. Several of these scenarios are summarized above in Tables 
5.3.5 and 5.3.6. The following six graphs depict power plots for baseline Weibull 
distributions assuming increasing hazard, ~50% censoring and HR of 2. For each method, 
we plot the powers with corresponding baseline incidence.   
 
Figure 5.3.10 shows a power analysis plot for various Weibull distributions yielding 
constant HRs at different levels of baseline incidences for the study period ending at T1. 
There is little or no effect of different levels of baseline incidences in terms of power 
under Method A. That certainly is not the case with Method B, which extends the FU for 
events but not for non-events. For higher level of baseline incidence, the difference in 
power is not quite high for a sample size of 1000, but is substantial for smaller 
incidences. In this case, Method A demonstrates values for power that are consistently 
higher; at some point high as much as by 23 percentage points. 
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Figure 5.3.10 Power Analysis Results for Various Baseline Weibull Distributions with 
Study Period through T1, N=1000. 
 
 
 
Figure 5.3.11 shows a power analysis plot for various Weibull distributions yielding 
constant HRs at different levels of baseline incidences for the study period extended 
through T2. Again the Method A power is not affected by the baseline incidence, while 
Method B power decreases with lower baseline incidence. 
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Figure 5.3.11 Power Analysis Results for Various Baseline Weibull Distributions with 
Study Period through T2, N=1000. 
 
 
 
 
When we extend the FU through T3 (figure 5.3.12), Method A almost always yields a 
consistent power irrespective of the level of incident events at baseline. Method B shows 
a strong effect of baseline incidences on its power. Here, Method A exhibits greater 
power – as much as by about 32 percentage points for a smaller baseline incidence. 
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Figure 5.3.12  Power Analysis Results for Various Baseline Weibull Distributions with 
Study Period through T3, N=1000. 
 
 
 
 
We reproduced the above power curves with the same scenario but with a smaller sample 
of 250 subjects per group at study periods through T1, T2 and T3 respectively. These are 
shown in tables 5.3.13 through 5.3.15. With a smaller sample, we would anticipate 
somewhat less power for both Methods A and B which is evident from the three plots. 
However, at each baseline incidence, with the FU through each of T1, T2 and T3 
respectively, Method A consistently outperforms Method B. As is the case with a large 
sample, this is more evident when the baseline incidence is small.  
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Figure 5.3.13 Power Analysis Results for Various Baseline Weibull Distributions with 
Study Period through T1, N=500. 
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Figure 5.3.14 Power Analysis Results for Various Baseline Weibull Distributions with 
Study Period through T2, N=500.  
 
 
 
 
 
 
 
 
 
 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
Method A Method B
P
o
w
e
r 
[Reprents Decreasing Baseline Incidence, all at HR = 2]  
151 
 
 
Figure 5.3.15 Power Analysis Results for Various Baseline Weibull Distributions with 
Study Period through T3, N=500.  
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6. Discussion 
 
Motivated by the Framingham Heart Study (FHS) with stroke, myocardial infraction and 
congestive heart failure as endpoints of interest, in this research we described, compared, 
and provided interpretations of four censoring methods for non-events and evaluated their 
impact on estimates of disease incidence and on tests of associations between risk factors 
and disease incidence.  The risk factors we considered include diabetes mellitus, stage I 
hypertension, smoking status, atrial fibrillation and C-reactive protein. We further 
investigated the effect of early censoring of non-events (as compared to events) under 
various scenarios with respect to incidence estimation, robustness, and power using a 
simulation study of  Weibull survival models over a range of sample sizes and 
distribution parameters. In this simulation study, we retained the proportional hazards 
structure of the model and accommodated two different censoring methods, interpretation 
of which was the key element of comparison. 
 
6.1 Summary of Censoring Methods and Applications to the FHS 
 
In chapter three, using the FHS as an example of a longitudinal cohort study, we  
undertook an overview of data generation and censoring methods.  Our primary 
focus was on the analytic issues and interpretations based on differences in follow -
up time between participants with and without the event of interest as a result of 
different censoring mechanisms. We proposed and described four censoring 
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methods, which we then used to produce analysis data sets.  
 
We also presented a brief overview of classical methods used to estimate disease 
incidence based on K-M method and the Cox proportional hazards regression 
model to assess association between risk factors and disease incidence. In addition, 
we summarized methods used to evaluate model performance, such as the 
discrimination C-statistic, the calibration Chi-square statistic, and the newer NRI 
and IDI. All of these methods were applied to three different data sets generated 
with stroke, MI and CHF as endpoints of interests.  
 
The application of the four censoring methods to the three FHS data sets was 
presented in Chapter 4. We compared and contrasted the impact of these methods 
of censoring on the estimation of disease incidence and the association between 
specific RF and disease incidence. We also investigated the performance measures 
of these four censoring methods.  
 
We started with stroke followed by MI and CHF as events of interest and each of 
diabetes mellitus, hypertension, current smoking status, atrial fibrillation and C – 
reactive protein as risk factors of interest. 
 
With stroke as the event of interest, Method I, where events and  non-events were 
followed through the same examination cycle (first through exam 7(1998-2001) and 
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then through exam 8 (2005-2008)), and Method III, which extends the follow up for 
both events and non-events through the same period after examination cycle (for 
instance through 2002, 2004, 2006 or after exam 8 through 2009) produced similar 
stroke incidence, as expected, since both stroke and non-stroke cohorts were 
followed through at approximately the same period of time from baseline with these 
methods. Method II, which extended the FU between examinations for events but 
not for non-events, yielded considerably higher estimates of stroke incidence in 
each of the FU periods. Method IV, which  extends the FU for events and non -
events, similar to Method III, but with FU for non-events based on overall CVD 
event status instead of specific to stroke, resulted in higher estimates of stoke 
incidence than those from Methods I and III. Similar results were obtained with MI 
and CHF respectively as disease endpoints. 
 
Method III estimates of HR are similar to those Method I estimates at exam 8, while 
Method II generally produces estimates of HR that are consistently much closer to the 
null (HR=1).  
 
6.2 Summary of Simulation Results 
 
 
We found that Method B, in which non-events were censored at     consistently 
overestimated the cumulative incidence - irrespective of whether the FU was extended for 
events (and, in Method A, for non-events) through               . The estimate was more 
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precise when the incidence was higher, but when the incidence was low, the difference 
between the methods was fairly large. This difference in estimates of incidence between 
Method B as compared to Method A is perhaps due to the fact that there was no non-
event data in the study period after    as we extend the FU for events through each of 
               respectively, but in each of these study periods, non-events were censored 
at    resulting in the mean FU for events well exceeding that of non-events. We saw a 
similar pattern when the exponential distribution was used as a limiting case of Weibull 
distribution. 
 
Estimated HRs under the null hypothesis were close to 1 at each of the FU periods under 
both methods. This was anticipated with Method A, but it was interesting for Method B, 
given the fact that the incidences were over estimated. We also found that both methods 
were robust, with approximately 5% of tests rejected under the null hypothesis of no 
difference in survival (that is, HR=1). 
 
When the two groups were from different populations, Method A, which extends FU for 
both events and non-events, yielded estimates of HR close to the “true” HR. These 
estimates were very consistent, irrespective of how far we extended the FU. By contrast, 
Method B, which extends the FU for events but not for non-events, always produced 
estimates closer to the null, underestimating when the true HR was greater than 1, and 
overestimating when the true HR was less than 1. 
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When the “true” HR was extreme (for example, ≤ 0.25 or ≥ 3.0), Methods A and B 
seemed equally powerful in all of the iterations (close to 100% power, with sample of 
2000 subjects).  As the HR approached the null, the power decreased. However, the 
power in Method B was consistently lower than the power in Method A. Additionally, 
with increasing FU time, the power of Method A increased, which was expected, as with 
the extended study period, the number of events increased and the FU was extended for 
both events and non-events. By contrast, the power in Method B did not always increase 
with the extended study period. This trend continued not only when halving the sample 
size, but also when reducing it to one quarter of the original sample. We obtained very 
similar results when we set the shape parameter of Weibull at 1 to get the exponential 
distribution. 
 
6.3  Conclusion 
 
In conclusion, our FHS data analyses and simulation studies showed early censoring of 
non-events resulted in over estimation of disease incidence, particularly when the 
baseline incidence was low. Early censoring of non-events did not affect the robustness 
of the test [HR=1]. However, with all endpoints of interest  in FHS as well as over the 
range of simulation scenarios, under early censoring of non-events, estimated HRs were 
closer to the null, and power to detect associations with risk factors was markedly 
reduced. 
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This dissertation provides information for researchers who intend to analyze time-to-
event data and wish to study disease incidence and estimate the association between risk 
factor(s) and disease incidence. We believe the critical point of this project is to offer a 
cautionary note that when the follow-up is extended for events and restricted for non-
events, although the approach seems to be robust, it results in an overestimation of the 
incidence, and has reduced power to detect associations between risk factors and 
outcomes. While our research is based on limited scenarios and with only three end 
points of interests from the FHS domain, we hope that this will provide a framework for 
others dealing with similar set of data. 
 
In terms of future research, we suggest the evaluation of the performance of censoring 
methods relaxing the proportional hazard representation of the Weibull distribution. We 
also propose modeling survival time using the Gompertz, the gamma, the log-normal and 
the log-logistic distributions. Also, we would like to see how these models perform when 
the study sample is even smaller than the sizes we evaluated. For example, with rare 
events or in case of clinical trials survival data the sample size will be relatively smaller 
than what we have assessed in this research. In addition, it is not quite clear why the 
magnitude of the calibration Chi-Square varies so much and this is an area that needs 
some research. We also wonder why, and under which other scenarios, Method IV 
performs as well as Methods I and III, and propose this as a topic of future study.   
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APPENDIX A 
Table A.1 Integrated Discrimination Improvement results for various risk factors on Stroke data   
  [Full Follow-up] 
 
Exam 7 
(1998-2001) 
 
Exam 8 
(2005-2008) 
 
Method I 
Events|Non-Events 27|3448 96|3379 
Follow-up, years 7 years 14 years 
Age, Sex, DM 
0.017 
[0.007,0.068] 
0.009 
[0.005,0.017] 
Age, Sex, S1HTN 
0.0002 
[-0.004,0.004] 
0.009 
[0.006,0.015] 
Age, Sex, Smoking 
0.001 
[0.0002,0.005] 
0.002 
[0.001,0.006] 
Age, Sex, AF 
-0.0001 
[-0.0004,0.0001] 
0.0006 
[0.0001,0.001] 
Age, Sex, CRP 
-0.0002 
[-0.0008,0.000] 
0.0009[-
0.0007,0.003] 
 2002 2004 2006 2009 
 
Method II 
Events|Non-Events 
 
49|3426 75|3400 104|3371 137|3338 
Follow-up, years 8 years 10 years 12 years 15 years 
Age, Sex, DM 
0.005 
[0.0004,0.016] 
0.007 
[0.004,0.010] 
0.002 
[0.001,0.004] 
0.006 
[0.002,0.012] 
Age, Sex, S1HTN 
0.003 
[-0.001,0.008] 
0.008 
[0.006,0.010] 
0.041 
[0.028,0.073] 
0.026 
[0.021,0.045] 
Age, Sex, Smoking 
0.011 
[0.006,0.025] 
0.009 
[0.007,0.012] 
0.007 
[0.004,0.012] 
0.001 
[-0.0001,0.004] 
Age, Sex, AF 
0.001 
[0.0003,0.003] 
0.004 
[0.003,0.005] 
0.003 
[0.001,0.005] 
0.004 
[0.002,0.008] 
Age, Sex, CRP 
0.010 
[0.006,0.026] 
0.009 
[0.007,0.012] 
-0.012 
[-0.022,-0.008] 
-0.022 
[-0.034,-0.020] 
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Table A.1 Integrated Discrimination Improvement results for various risk factors on Stroke data      
[Full Follow-up] contd. 
 
 2002 2004 2006 2009 
 
Method III 
Events|Non-Events 
 
49|3426 75|3400 104|3371 137|3338 
Follow-up, years 8 years 10 years 12 years 15 years 
Age, Sex, DM 
0.016 
[0.006,0.060] 
0.008 
[0.005,0.013] 
0.020 
[0.013,0.052] 
0.015 
[0.008,0.030] 
Age, Sex, S1HTN 
0.004 
[-0.0001,0.018] 
0.006 
[0.004,0.009] 
0.018 
[0.013,0.045] 
0.016 
[0.009,0.030] 
Age, Sex, Smoking 
0.012 
[0.005,0.043] 
0.005 
[0.003,0.008] 
0.007 
[0.004,0.018] 
0.007 
[0.004,0.013] 
Age, Sex, AF 
0.002 
[0.001,0.009] 
0.0004 
[0.000.001] 
0.001 
[0.0004,0.003] 
0.005 
[0.002,0.011] 
Age, Sex, CRP 
0.019 
[0.009,0.070] 
0.004 
[0.002,0.007] 
0.003 
[0.002,0.008] 
-0.005 
[-0.011,-0.003] 
 
Method IV 
Events|Non-Events 
 
49|2952 75|2932 104|2911 137|3019 
Follow-up, years 8 years 10 years 12 years 15 years 
Age, Sex, DM 
0.018 
[0.007,0.060] 
0.012 
[0.006,0.020] 
0.039 
[0.031,0.103] 
0.028 
[0.014,0.055] 
Age, Sex, S1HTN 
0.011 
[0.005,0.035] 
0.011 
[0.008,0.016] 
0.067 
[0.057,0.169] 
0.018 
[0.010,0.035] 
Age, Sex, Smoking 
0.009 
[0.003,0.033] 
0.011 
[0.006,0.018] 
0.020 
[0.016,0.053] 
0.013 
[0.007,0.026] 
Age, Sex, AF 
0.007 
[0.002,0.026] 
0.003 
[0.0001,0.008] 
0.009 
[0.006,0.025] 
0.016 
[0.007,0.034] 
Age, Sex, CRP 
0.003 
[-0.003,0.013] 
0.006 
[0.003,0.010] 
0.001 
[-0.002,0.004] 
-0.007 
[-0.016,-0.003] 
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Table A.2 Integrated Discrimination Improvement results for various risk factors on Stroke data   
  [10 years Follow-up] 
 
 
Exam 7 
(1998-2001) 
 
Exam 8 
(2005-2008) 
 
Method I 
Events|Non-Events 27|3448 96|3379 
Follow-up, years 7 years 10 years 
Age, Sex, DM 
0.017 
[0.007,0.068] 
0.005 
[0.003,0.009] 
Age, Sex, S1HTN 
0.0002 
[-0.004,0.004] 
0.005 
[0.004,0.007] 
Age, Sex, Smoking 
0.001 
[0.0002,0.005] 
0.003 
[0.002,0.005] 
Age, Sex, AF 
-0.0001 
[-0.0004,0.0001] 
0.0002 
[-0.0001,0.001] 
Age, Sex, CRP 
-0.0002 
[-0.0008,0] 
-0.002 
[-0.003,-0.001] 
 2002 2004 2006 2009 
 
Method II 
Events|Non-Events 
 
49|3426 75|3400 104|3371 137|3338 
Follow-up, years 8 years 10 years 10 years 10 years 
Age, Sex, DM 
0.005 
[0.0004,0.016] 
0.007 
[0.004,0.010] 
0.007 
[0.004,0.012] 
0.005 
[0.003,0.008] 
Age, Sex, S1HTN 
0.003 
[-0.001,0.008] 
0.008 
[0.006,0.010] 
0.008 
[0.006,0.012] 
0.008 
[0.006,0.011] 
Age, Sex, Smoking 
0.011 
[0.006,0.025] 
0.009 
[0.007,0.012] 
0.002 
[0.001,0.004] 
0.001 
[0.000,0.001] 
Age, Sex, AF 
0.001 
[0.0003,0.003] 
0.004 
[0.003,0.005] 
0.0002 
[-0.0002,0.001] 
0.001 
[0.000,0.003] 
Age, Sex, CRP 
0.010 
[0.006,0.026] 
0.009 
[0.007,0.012] 
0.0004 
[-0.0003,0.001] 
-0.004 
[-0.005,-0.003] 
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Table A.2  Integrated Discrimination Improvement results for various risk factors on Stroke data   
  [10 years Follow-up] contd. 
 
 2002 2004 2006 2009 
 
Method III 
Events|Non-Events 
 
49|3426 75|3400 104|3371 137|3338 
Follow-up, years 8 years 10 years 10 years 10 years 
Age, Sex, DM 
0.016 
[0.006,0.060] 
0.008 
[0.005,0.013] 
0.008 
[0.004,0.014] 
0.006 
[0.003,0.010] 
Age, Sex, S1HTN 
0.004 
[-0.0001,0.018] 
0.006 
[0.004,0.009] 
0.012 
[0.009,0.019] 
0.007 
[0.005,0.009] 
Age, Sex, Smoking 
0.012 
[0.005,0.043] 
0.005 
[0.003,0.008] 
0.003 
[0.001,0.006] 
0.002 
[0.001,0.003] 
Age, Sex, AF 
0.002 
[0.001,0.009] 
0.0004 
[0.000.001] 
0.0004 
[-0.0001,0.001] 
0.002 
[0.000,0.003] 
Age, Sex, CRP 
0.019 
[0.009,0.070] 
0.004 
[0.002,0.007] 
0.0004 
[-0.0004,0.001] 
-0.003 
[-0.005,-0.002] 
 
Method IV 
Events|Non-Events 
 
49|2952 75|2932 104|2911 137|3019 
Follow-up, years 8 years 10 years 10 years 10 years 
Age, Sex, DM 
0.018 
[0.007,0.060] 
0.012 
[0.006,0.020] 
0.029 
[0.018,0.045] 
0.011 
[0.005,0.017] 
Age, Sex, S1HTN 
0.011 
[0.005,0.035] 
0.011 
[0.008,0.016] 
0.015 
[0.010,0.022] 
0.010 
[0.007,0.013] 
Age, Sex, Smoking 
0.009 
[0.003,0.033] 
0.011 
[0.006,0.018] 
0.006 
[0.003,0.011] 
0.004 
[0.002,0.007] 
Age, Sex, AF 
0.007 
[0.002,0.026] 
0.003 
[0.0001,0.008] 
0.008 
[0.004,0.014] 
0.009 
[0.003,0.016] 
Age, Sex, CRP 
0.003 
[-0.003,0.013] 
0.006 
[0.003,0.010] 
0.002 
[-0.000,0.004] 
-0.004 
[-0.007,-0.002] 
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Table A.3 Integrated Discrimination Improvement results for various risk factors on MI data    
  [Full Follow-up] 
  
 
Exam 7 
(1998-2001) 
 
Exam 8 
(2005-2008) 
 
Method I 
Events|Non-Events   
Follow-up, years 7 years 13 years 
Age, Sex, DM 
0.009 
[0.005,0.016] 
0.017 
[0.012,0.023] 
Age, Sex, S1HTN 
0.001 
[0.0004,0.002] 
0.009 
[0.007,0.011] 
Age, Sex, Smoking 
0.009 
[0.005,0.014] 
0.030 
[0.022,0.040] 
Age, Sex, AF 
0.004 
[0.001,0.008] 
0.001 
[0.0002,0.002] 
Age, Sex, CRP 
0.003 
[0.001,0.005] 
0.012 
[0.009,0.016] 
 2002 2004 2006 2009 
 
Method II 
Events|Non-Events 
 
    
Follow-up, years 8 years 10 years 12 years 15 years 
Age, Sex, DM 
0.015 
[0.009,0.025] 
0.003 
[0.000,0.007] 
0.016 
[0.013,0.025] 
0.019 
[0.012,0.032] 
Age, Sex, S1HTN 
0.010 
[0.007,0.015] 
0.044 
[0.031,0.075] 
0.024 
[0.022,0.038] 
0.015 
[0.011,0.025] 
Age, Sex, Smoking 
0.008 
[0.004,0.013] 
0.074 
[0.051,0.128] 
0.044 
[0.040,0.070] 
0.025 
[0.017,0.041] 
Age, Sex, AF 
0.011 
[0.006,0.018] 
0.002 
[0.001,0.004] 
0.0001 
[0.000,0.0001] 
0.001 
[0.0001,0.0013] 
Age, Sex, CRP 
0.002 
[0.001,0.005] 
0.025 
[0.016,0.044] 
0.024 
[0.022,0.040] 
0.013 
[0.008,0.023] 
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Table A.3 Integrated Discrimination Improvement results for various risk factors on MI data    
  [Full Follow-up] contd. 
 
 2002 2004 2006 2009 
 
Method III 
Events|Non-Events 
 
    
Follow-up, years 8 years 10 years 12 years 15 years 
Age, Sex, DM 
0.019 
[0.013,0.028] 
0.029 
[0.023,0.153] 
0.035 
[0.021,0.092] 
0.016 
[0.012,0.022] 
Age, Sex, S1HTN 
0.009 
[0.007,0.013] 
0.060 
[0.052,0.293] 
0.027 
[0.016,0.068] 
0.010 
[0.008,0.012] 
Age, Sex, Smoking 
0.019 
[0.013,0.027] 
-0.008 
[-0.055,0.002] 
0.038 
[0.023,0.096] 
0.025 
[0.019,0.033] 
Age, Sex, AF 
0.010 
[0.006,0.017] 
0.002 
[0.0002,0.013] 
0.002 
[0.001,0.008] 
0.001 
[0.0002,0.002] 
Age, Sex, CRP 
0.009 
[0.006,0.013] 
-0.005 
[-0.028,0.001] 
0.018 
[0.010,0.048] 
0.014 
[0.010,0.019] 
 
Method IV 
Events|Non-Events 
 
    
Follow-up, years 8 years 10 years 12 years 15 years 
Age, Sex, DM 
0.027 
[0.017,0.040] 
0.043 
[0.028,0.183] 
0.045 
[0.029,0.119] 
0.024 
[0.017,0.032] 
Age, Sex, S1HTN 
0.012 
[0.008,0.017] 
0.030 
[0.020,0.128] 
0.035 
[0.022,0.087] 
0.014 
[0.011,0.018] 
Age, Sex, Smoking 
0.023 
[0.015,0.035] 
0.024 
[0.011,0.103] 
0.046 
[0.029,0.116] 
0.032 
[0.023,0.043] 
Age, Sex, AF 
0.010 
[0.004,0.018] 
0.003 
[-0.0002,0.016] 
0.008 
[0.004,0.024] 
0.004 
[0.001,0.006] 
Age, Sex, CRP 
0.009 
[0.005,0.014] 
0.007 
[0.001,0.037] 
0.009 
[0.004,0.028] 
0.017 
[0.012,0.023] 
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Table A.4 Integrated Discrimination Improvement results for various risk factors on MI data    
  [10 years Follow-up] 
 
 
Exam 7 
(1998-2001) 
 
Exam 8 
(2005-2008) 
 
Method I 
Events|Non-Events   
Follow-up, years 10 years 10 years 
Age, Sex, DM 
0.009 
[0.005,0.016] 
0.017 
[0.012,0.023] 
Age, Sex, S1HTN 
0.001 
[0.0004,0.002] 
0.009 
[0.007,0.011] 
Age, Sex, Smoking 
0.009 
[0.005,0.014] 
0.030 
[0.022,0.040] 
Age, Sex, AF 
0.004 
[0.001,0.008] 
0.001 
[0.0002,0.002] 
Age, Sex, CRP 
0.003 
[0.001,0.005] 
0.012 
[0.009,0.016] 
 2002 2004 2006 2009 
 
Method II 
Events|Non-Events 
 
    
Follow-up, years 10 years 10 years 10 years 10 years 
Age, Sex, DM 
0.015 
[0.009,0.025] 
0.003 
[0.000,0.007] 
0.011 
[0.009,0.014] 
0.014 
[0.010,0.018] 
Age, Sex, S1HTN 
0.010 
[0.007,0.015] 
0.044 
[0.031,0.075] 
0.012 
[0.010,0.014] 
0.007 
[0.006,0.009] 
Age, Sex, Smoking 
0.008 
[0.004,0.013] 
0.074 
[0.051,0.128] 
0.031 
[0.026,0.037] 
0.019 
[0.014,0.025] 
Age, Sex, AF 
0.011 
[0.006,0.018] 
0.002 
[0.001,0.004] 
0.0001 
[0.000,0.0001] 
0.0002 
[0.000,0.001] 
Age, Sex, CRP 
0.002 
[0.001,0.005] 
0.025 
[0.016,0.044] 
0.014 
[0.012,0.018] 
0.008 
[0.006,0.011] 
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Table A.4  Integrated Discrimination Improvement results for various risk factors on MI data    
  [10 years Follow-up] contd. 
 
 2002 2004 2006 2009 
 
Method III 
Events|Non-Events 
 
    
Follow-up, years 10 years 10 years 10 years 10 years 
Age, Sex, DM 
0.019 
[0.013,0.028] 
0.029 
[0.023,0.153] 
0.015 
[0.010,0.021] 
0.012 
[0.009,0.016] 
Age, Sex, S1HTN 
0.009 
[0.007,0.013] 
0.060 
[0.052,0.293] 
0.008 
[0.006,0.011] 
0.007 
[0.005,0.008] 
Age, Sex, Smoking 
0.019 
[0.013,0.027] 
-0.008 
[-0.055,0.002] 
0.025 
[0.018,0.035] 
0.018 
[0.013,0.024] 
Age, Sex, AF 
0.010 
[0.006,0.017] 
0.002 
[0.0002,0.013] 
0.001 
[0.0001,0.002] 
0.001 
[0.0001,0.001] 
Age, Sex, CRP 
0.009 
[0.006,0.013] 
-0.005 
[-0.028,0.001] 
0.011 
[0.008,0.016] 
0.010 
[0.007,0.013] 
 
Method IV 
Events|Non-Events 
 
    
Follow-up, years 10 years 10 years 10 years 10 years 
Age, Sex, DM 
0.027 
[0.017,0.040] 
0.043 
[0.028,0.183] 
0.028 
[0.019,0.038] 
0.018 
[0.012,0.025] 
Age, Sex, S1HTN 
0.012 
[0.008,0.017] 
0.030 
[0.020,0.128] 
0.012 
[0.009,0.016] 
0.009 
[0.007,0.012] 
Age, Sex, Smoking 
0.023 
[0.015,0.035] 
0.024 
[0.011,0.103] 
0.035 
[0.025,0.048] 
0.024 
[0.016,0.032] 
Age, Sex, AF 
0.010 
[0.004,0.018] 
0.003 
[-0.0002,0.016] 
0.006 
[0.003,0.010] 
0.003 
[0.001,0.005] 
Age, Sex, CRP 
0.009 
[0.005,0.014] 
0.007 
[0.001,0.037] 
0.015 
[0.010,0.022] 
0.011 
[0.007,0.016] 
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Table A.5 Integrated Discrimination Improvement results for various risk factors on CHF data   
  [Full Follow-up] 
 
 
Exam 7 
(1998-2001) 
 
Exam 8 
(2005-2008) 
 
Method I 
Events|Non-Events   
Follow-up, years 7 years 14 years 
Age, Sex, DM 
0.055 
[0.023,0.324] 
0.044 
[0.028,0.063] 
Age, Sex, S1HTN 
0.003 
[0.001,0.023] 
0.007 
[0.002,0.013] 
Age, Sex, Smoking 
0.009 
[0.003,0.054] 
0.005 
[0.002,0.008] 
Age, Sex, AF 
0.062 
[0.024,0.392] 
0.046 
[0.023,0.075] 
Age, Sex, CRP 
-0.001 
[-0.012,0.006] 
0.013 
[0.004,0.022] 
 2002 2004 2006 2009 
 
Method II 
Events|Non-Events 
 
    
Follow-up, years 8 years 10 years 12 years 15 years 
Age, Sex, DM 
0.028 
[0.019,0.043] 
0.023 
[0.016,0.030] 
0.024 
[0.018,0.031] 
0.019 
[0.011,0.033] 
Age, Sex, S1HTN 
0.002 
[0.001,0.004] 
0.020 
[0.017,0.024] 
0.015 
[0.012,0.018] 
0.003 
[-0.002,0.009] 
Age, Sex, Smoking 
0.004 
[0.002,0.006] 
0.021 
[0.018,0.026] 
0.007 
[0.005,0.009] 
0.001 
[-0.001,0.003] 
Age, Sex, AF 
0.011 
[0.005,0.023] 
-0.004 
[-0.008,0.0004] 
0.001 
[-0.003,0.006] 
0.010 
[0.003,0.021] 
Age, Sex, CRP 
0.003 
[0.001,0.006] 
0.003 
[0.002,0.005] 
0.005 
[0.004,0.008] 
0.003 
[-0.004,0.010] 
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Table A.5  Integrated Discrimination Improvement results for various risk factors on CHF data   
  [Full Follow-up] contd. 
 
 2002 2004 2006 2009 
 
Method III 
Events|Non-Events 
 
    
Follow-up, years 8 years 10 years 12 years 15 years 
Age, Sex, DM 
0.038 
[0.025,0.057] 
0.049 
[0.029,0.077] 
0.043 
[0.026,0.070] 
0.039 
[0.023,0.059] 
Age, Sex, S1HTN 
0.003 
[0.0002,0.006] 
0.014 
[0.006,0.025] 
0.010 
[0.003,0.019] 
0.011 
[0.004,0.019] 
Age, Sex, Smoking 
0.003 
[0.002,0.006] 
0.014 
[0.008,0.025] 
0.008 
[0.004,0.014] 
0.004 
[0.001,0.007] 
Age, Sex, AF 
0.053 
[0.030,0.086] 
0.039 
[0.018,0.071] 
0.021 
[0.006,0.044] 
0.051 
[0.029,0.080] 
Age, Sex, CRP 
0.007 
[0.003,0.014] 
0.010 
[0.003,0.020] 
0.016 
[0.008,0.028] 
0.023 
[0.011,0.036] 
 
Method IV 
Events|Non-Events 
 
    
Follow-up, years 8 years 10 years 12 years 15 years 
Age, Sex, DM 
0.068 
[0.042,0.105] 
0.069 
[0.044,0.110] 
0.066 
[0.044,0.103] 
0.053 
[0.032,0.082] 
Age, Sex, S1HTN 
0.006 
[0.002,0.011] 
0.018 
[0.009,0.030] 
0.014 
[0.005,0.025] 
0.011 
[0.002,0.021] 
Age, Sex, Smoking 
0.005 
[0.001,0.011] 
0.018 
[0.009,0.031] 
0.013 
[0.007,0.022] 
0.007 
[0.002,0.013] 
Age, Sex, AF 
0.080 
[0.042,0.136] 
0.029 
[0.004,0.062] 
0.027 
[0.009,0.051] 
0.051 
[0.025,0.083] 
Age, Sex, CRP 
0.009 
[0.001,0.018] 
0.013 
[0.004,0.024] 
0.024 
[0.014,0.040] 
0.020 
[0.007,0.034] 
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Table A.6 Integrated Discrimination Improvement results for various risk factors on CHF data   
  [10 years Follow-up] 
 
 
Exam 7 
(1998-2001) 
 
Exam 8 
(2005-2008) 
 
Method I 
Events|Non-Events   
Follow-up, years 10 years 10 years 
Age, Sex, DM 
0.055 
[0.023,0.324] 
0.040 
[0.025,0.057] 
Age, Sex, S1HTN 
0.003 
[0.001,0.023] 
0.007 
[0.001,0.012] 
Age, Sex, Smoking 
0.009 
[0.003,0.054] 
0.005 
[0.002,0.008] 
Age, Sex, AF 
0.062 
[0.024,0.392] 
0.044 
[0.023,0.069] 
Age, Sex, CRP 
-0.001 
[-0.012,0.006] 
0.009 
[0.001,0.018] 
 2002 2004 2006 2009 
 
Method II 
Events|Non-Events 
 
    
Follow-up, years 10 years 10 years 10 years 10 years 
Age, Sex, DM 
0.028 
[0.019,0.043] 
0.023 
[0.016,0.030] 
0.014 
[0.009,0.020] 
0.030 
[0.018,0.044] 
Age, Sex, S1HTN 
0.002 
[0.001,0.004] 
0.020 
[0.017,0.024] 
0.008 
[0.006,0.010] 
0.006 
[0.001,0.011] 
Age, Sex, Smoking 
0.004 
[0.002,0.006] 
0.021 
[0.018,0.026] 
0.005 
[0.003,0.006] 
0.002 
[0.001,0.004] 
Age, Sex, AF 
0.011 
[0.005,0.023] 
-0.004 
[-0.008,0.0004] 
0.003 
[-0.001,0.008] 
0.037 
[0.019,0.058] 
Age, Sex, CRP 
0.003 
[0.001,0.006] 
0.003 
[0.002,0.005] 
0.003 
[0.001,0.005] 
0.010 
[0.002,0.018] 
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Table A.6  Integrated Discrimination Improvement results for various risk factors on CHF data   
  [10 years Follow-up] contd. 
 
 2002 2004 2006 2009 
 
Method III 
Events|Non-Events 
 
    
Follow-up, years 10 years 10 years 10 years 10 years 
Age, Sex, DM 
0.038 
[0.025,0.057] 
0.049 
[0.029,0.077] 
0.029 
[0.016,0.045] 
0.027 
[0.014,0.040] 
Age, Sex, S1HTN 
0.003 
[0.0002,0.006] 
0.014 
[0.006,0.025] 
0.006 
[0.0002,0.012] 
0.007 
[0.001,0.012] 
Age, Sex, Smoking 
0.003 
[0.002,0.006] 
0.014 
[0.008,0.025] 
0.003 
[0.001,0.007] 
0.002 
[0.001,0.004] 
Age, Sex, AF 
0.053 
[0.030,0.086] 
0.039 
[0.018,0.071] 
0.026 
[0.010,0.045] 
0.043 
[0.022,0.068] 
Age, Sex, CRP 
0.007 
[0.003,0.014] 
0.010 
[0.003,0.020] 
0.008 
[0.002,0.015] 
0.008 
[0.0001,0.017] 
 
Method IV 
Events|Non-Events 
 
    
Follow-up, years 10 years 10 years 10 years 10 years 
Age, Sex, DM 
0.068 
[0.042,0.105] 
0.069 
[0.044,0.110] 
0.062 
[0.040,0.088] 
0.045 
[0.026,0.066] 
Age, Sex, S1HTN 
0.006 
[0.002,0.011] 
0.018 
[0.009,0.030] 
0.009 
[0.001,0.018] 
0.008 
[0.001,0.015] 
Age, Sex, Smoking 
0.005 
[0.001,0.011] 
0.018 
[0.009,0.031] 
0.006 
[0.001,0.011] 
0.004 
[0.001,0.008] 
Age, Sex, AF 
0.080 
[0.042,0.136] 
0.029 
[0.004,0.062] 
0.035 
[0.014,0.061] 
0.054 
[0.025,0.086] 
Age, Sex, CRP 
0.009 
[0.001,0.018] 
0.013 
[0.004,0.024] 
0.014 
[0.005,0.024] 
0.008 
[-0.003,0.019] 
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APPENDIX B 
Table B.1 Estimates of Cumulative Incidence Indexed by Weibull Distribution Parameters  
 
Distribution 
Study 
Period 
N=500  N=1000 N=2000 
Method A Method B  Method A  Method B Method A  Method B 
 
Weibull (1.00, 0.12) 
T1 61.59±2.90 99.22±0.15 61.67±2.07 99.61±0.05 61.69±1.47 99.80±0.02 
T2 69.71±2.98 99.44±0.10 69.81±2.12 99.72±0.03 69.85±1.50 99.86±0.01 
T3 83.22±3.12 99.57±0.07 83.33±2.17 99.78±0.02 83.42±1.55 99.89±0.00 
 
Weibull (1.00, 0.06) 
T1 38.02±2.51 99.04±0.21 38.07±1.75 99.51±0.07 38.09±1.22 99.75±0.03 
T2 44.99±2.64 99.36±0.12 45.06±1.87 99.68±0.04 45.08±1.31 99.84±0.02 
T3 59.24±2.85 99.59±0.06 59.31±2.04 99.79±0.02 59.32±1.45 99.89±0.01 
 
Weibull (1.00, 0.03) 
T1 21.24±1.94 98.50±0.40 21.30±1.38 99.24±0.14 21.31±0.97 99.61±0.05 
T2 25.82±2.12 99.06±0.21 25.87±1.51 99.52±0.07 25.88±1.06 99.76±0.03 
T3 36.14±2.46 99.46±0.09 36.18±1.72 99.72±0.04 36.20±1.20 99.86±0.01 
 
Weibull (1.00, 0.0214) 
T1 15.61±1.70 98.03±0.60 15.68±1.20 99.00±0.21 15.71±0.85 99.50±0.07 
T2 19.16±1.86 98.80±0.30 19.22±1.33 99.38±0.11 19.23±0.90 99.69±0.04 
T3 27.36±2.18 98.33±0.13 27.41±1.55 99.66±0.05 27.42±1.08 99.83±0.02 
 
Weibull (1.00, 0.015) 
T1 11.17±1.46 97.31±1.00 11.25±1.03 98.66±0.33 11.28±0.74 99.32±0.12 
T2 13.80±1.59 98.39±0.48 13.87±1.14 98.18±0.17 13.90±0.81 99.58±0.06 
T3 20.04±1.90 99.14±0.20 20.10±1.35 99.56±0.07 20.12±0.95 99.78±0.03 
 
Weibull (1.00, 0.01) 
T1 7.58±1.24 96.13±1.84 7.64±0.85 97.08±0.59 7.67±0.61 99.03±0.20 
T2 9.40±1.36 97.72±0.83 9.47±0.95 98.84±0.29 9.49±0.68 99.41±0.10 
T3 13.80±1.59 98.82±0.32 13.87±1.14 99.39±0.12 13.90±0.81 99.69±0.04 
 Results are mean ± std 
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Table B.2   Robustness Results for Weibull Distribution, N=2000.  
 
Distribution 
Study 
Period 
Method A  Method B 
HR [Q1, Q2] % Rejected HR [Q1, Q2] % Rejected 
 
Weibull (1.00, 0.12) 
T1 1.00 [0.95, 1.05] 4.9 1.00 [0.95, 1.05] 4.6 
T2 1.00 [0.95, 1.05] 4.9 1.00 [0.96, 1.05] 5.0 
T3 1.00 [0.95, 1.05] 5.0 1.00 [0.96, 1.04] 4.8 
 
Weibull (1.00, 0.06) 
T1 1.00 [0.95, 1.05] 4.8 1.00 [0.94, 1.05] 5.4 
T2 1.00 [0.95, 1.05] 5.0 1.00 [0.95, 1.05] 5.3 
T3 1.00 [0.95, 1.05] 4.9 1.00 [0.95, 1.05] 5.2 
 
Weibull (1.00, 0.03) 
T1 1.00 [0.93, 1.07] 5.2 1.00 [0.94, 1.08] 5.1 
T2 1.00 [0.94, 1.06] 5.0 1.00 [0.94, 1.07] 5.2 
T3 1.00 [0.95, 1.06] 4.8 1.00 [0.94, 1.06] 5.0 
 
Weibull (1.00, 0.0214) 
T1 1.00 [0.93, 1.09] 4.9 1.00 [0.92, 1.09] 5.0 
T2 1.00 [0.93, 1.08] 5.5 1.00 [0.93, 1.08] 4.9 
T3 1.00 [0.94, 1.06] 4.9 1.00 [0.94, 1.07] 5.0 
 
Weibull (1.00, 0.015) 
T1 1.00 [0.91, 1.10] 5.2 1.00 [0.91, 1.10] 5.3 
T2 1.00 [0.92, 1.09] 5.1 1.00 [0.92, 1.09] 5.0 
T3 1.00 [0.93, 1.08] 5.4 1.00 [0.93, 1.08] 5.4 
 
Weibull (1.00, 0.01) 
T1 1.00 [0.90, 1.12] 4.9 1.00 [0.89, 1.12] 4.6 
T2 1.00 [0.90, 1.11] 5.3 1.00 [0.91, 1.11] 4.5 
T3 1.00 [0.92, 1.09] 5.1 1.00 [0.92, 1.09] 5.4 
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Table B.3  Robustness Results for Weibull Distribution, N=1000.  
 
Distribution 
Study 
Period 
Method A  Method B 
HR [Q1, Q2] % Rejected HR [Q1, Q2] % Rejected 
 
Weibull (1.00, 0.12) 
T1 1.00 [0.94, 1.06] 4.6 1.00 [0.94, 1.07] 4.9 
T2 1.00 [0.94, 1.06] 4.7 1.00 [0.94, 1.07] 4.6 
T3 1.00 [0.94, 1.06] 4.8 1.00 [0.94, 1.06] 5.0 
 
Weibull (1.00, 0.06) 
T1 1.00 [0.92, 1.08] 4.9 1.00 [0.93, 1.07] 5.1 
T2 1.00 [0.93, 1.07] 5.0 1.00 [0.93, 1.08] 4.8 
T3 1.00 [0.93, 1.07] 4.7 1.00 [0.94, 1.07] 5.4 
 
Weibull (1.00, 0.03) 
T1 1.00 [0.91, 1.10] 4.9 1.00 [0.91, 1.11] 5.2 
T2 1.00 [0.91, 1.09] 5.2 1.00 [0.92, 1.10] 4.8 
T3 1.00 [0.92, 1.08] 4.7 1.00 [0.92, 1.08] 5.4 
 
Weibull (1.00, 0.0214) 
T1 1.00 [0.90, 1.13] 4.8 1.00 [0.89, 1.12] 4.8 
T2 1.00 [0.90, 1.11] 4.7 1.00 [0.90, 1.11] 4.9 
T3 1.00 [0.92, 1.09] 5.2 1.00 [0.92, 1.09] 5.5 
 
Weibull (1.00, 0.015) 
T1 1.00 [0.87, 1.14] 4.8 1.00 [0.88, 1.15] 5.3 
T2 1.00 [0.89, 1.13] 4.8 1.00 [0.88, 1.13] 5.8 
T3 1.00 [0.91, 1.11] 4.6 1.00 [0.90, 1.11] 5.0 
 
Weibull (1.00, 0.01) 
T1 1.01 [0.86, 1.18] 5.2 1.01 [0.85, 1.18] 5.2 
T2 1.00 [0.87, 1.15] 5.3 1.01 [0.87, 1.16] 5.1 
T3 1.00 [0.89, 1.13] 5.0 1.00 [0.88, 1.13] 5.5 
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Table B.4 Robustness Results for Weibull, N=500.  
 
Distribution 
Study 
Period 
Method A Method B 
HR [Q1, Q2] % Rejected HR [Q1, Q2] % Rejected 
 
Weibull (1.00, 0.12) 
T1 0.99 [0.91, 1.10] 4.8 1.00 [0.91, 1.10] 4.9 
T2 1.00 [0.91, 1.09] 4.9 1.00 [0.91, 1.10] 4.4 
T3 1.00 [0.91, 1.09] 4.6 1.00 [0.92, 1.09] 4.8 
 
Weibull (1.00, 0.06) 
T1 1.00 [0.90, 1.11] 4.7 0.99 [0.89, 1.11] 5.1 
T2 1.01 [0.90, 1.11] 4.7 0.99 [0.90, 1.10] 5.0 
T3 1.00 [0.91, 1.10] 4.9 1.00 [0.91, 1.10] 5.4 
 
Weibull (1.00, 0.03) 
T1 0.99 [0.87, 1.14] 5.1 1.01 [0.87, 1.16] 5.4 
T2 0.99 [0.88, 1.13] 5.0 1.00 [0.88, 1.14] 5.2 
T3 0.99 [0.89, 1.11] 4.8 1.00 [0.89, 1.12] 6.0 
 
Weibull (1.00, 0.0214) 
T1 1.00 [0.85, 1.18] 5.3 1.00 [0.85, 1.18] 4.9 
T2 1.00 [0.87, 1.16] 5.2 1.01 [0.86, 1.17] 5.3 
T3 1.00 [0.88, 1.13] 5.1 1.00 [0.88, 1.14] 5.3 
 
Weibull (1.00, 0.015) 
T1 1.00 [0.83, 1.22] 4.8 1.00 [0.83, 1.23] 4.9 
T2 1.00 [0.85, 1.19] 4.9 1.00 [0.84, 1.20] 5.2 
T3 1.00 [0.87, 1.15] 5.2 1.00 [0.87, 1.16] 5.7 
 
Weibull (1.00, 0.01) 
T1 1.00 [0.80, 1.27] 4.4 1.01 [0.79, 1.28] 5.0 
T2 1.00 [0.82, 1.24] 4.7 1.01 [0.81, 1.25] 5.0 
T3 1.00 [0.85, 1.19] 4.9 1.00 [0.84, 1.20] 5.5 
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Table B.5  Power Analysis Results for Baseline Weibull Distribution (1.0, 0.03), N=2000.  
Group 2 
Distribution 
HR 
Study 
Period 
Method A  Method B 
HR [Q1, Q2] Power (%) HR [Q1, Q2] Power (%) 
Weibull (1.0, 0.12) 
HR=0.25 
T1 0.25[0.18,0.35] 100 0.25[0.16,0.38] 100 
T2 0.25[0.18,0.35] 100 0.33[0.22,0.45] 100 
T3 0.25[0.19,0.34] 100 0.37[0.27,0.49] 100 
 
Weibull (1.0, 0.06) 
HR=0.50 
T1 0.50 [0.45, 0.55] 100 0.60 [0.55, 0.65] 100 
T2 0.50 [0.46, 0.54] 100 0.63[0.57, 0.67] 99.98 
T3 0.50 [0.46, 0.54] 100 0.66 [0.58, 0.73] 99.96 
 
Weibull (1.0, 0.0375) 
HR=0.80 
T1 0.80[0.75, 0.86] 61.28 0.85[0.80, 0.91] 36.88 
T2 0.80[0.75, 0.85] 68.52 0.87[0.82, 0.93] 33.68 
T3 0.80[0.76, 0.84] 79.88 0.89[0.84, 0.94] 33.38 
 
Weibull (1.0, 0.03) 
HR=1.0 
T1 1.00[0.94,1.07] 5.03 1.00[0.94,1.07] 5.46 
T2 1.00[0.95,1.06] 5.02 1.00[0.94,1.06] 5.28 
T3 1.00[0.95,1.05] 4.98 1.00[0.95,1.05] 5.16 
 
Weibull (1.0, 0.025) 
HR=1.2 
T1 1.20[1.16,1.29] 40.28 1.13[1.05,1.22] 22.10 
T2 1.20[1.12,1.28] 46.80 1.11[1.04,1.19] 19.36 
T3 1.20[1.14,1.27] 58.70 1.10[1.04,1.17] 19.74 
 
Weibull (1.0, 0.0214) 
HR=1.4 
T1 1.40[1.30,1.51] 86.50 1.26[1.17,1.37] 54.90 
T2 1.40[1.31,1.50] 92.20 1.22[1.14,1,31] 51.42 
T3 1.40[1.32,1.49] 97.28 1.18[1.12,1.26] 49.06 
 
Weibull (1.0, 0.015) 
HR=2.0 
T1 1.99[1.84,2.17] 100 1.63[1.50,1.76] 97.90 
T2 2.00[1.85,2.16] 100 1.52[1.41,1.64] 96.88 
T3 2.00[1.88,2.13] 100 1.40[1.32,1.49] 94.84 
 
Weibull (1.0, 0.01) 
HR=3.0 
T1 2.99[2.73,3.29] 100 2.20[2.02,2.43] 100 
T2 3.00[2.75,3.26] 100 1.97[1.82,2.15] 99.98 
T3 3.00[2.80,3.22] 100 1.71[1.60,1.84] 99.96 
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Table B.6  Power Analysis Results for Baseline Weibull Distribution (1.0, 0.03), N=1000.  
Group 2 
Distribution 
HR 
Study 
Period 
Method A  Method B 
HR [Q1, Q2] Power (%) HR [Q1, Q2] Power (%) 
Weibull (1.0, 0.12) 
HR=0.25 
T1 0.25[0.15,0.39] 100 0.33[0.20,0.50] 100 
T2 0.25[0.15,0.39] 100 0.36[0.21,0.54] 100 
T3 0.25[0.16,0.37] 100 0.36[0.23,0.55] 100 
 
Weibull (1.0, 0.06) 
HR=0.50 
T1 0.50[0.30,0.79] 99.98 0.60[0.34,1.02] 97.90 
T2 0.50[0.31, 0.77] 100 0.63[0.42,1.01] 97.14 
T3 0.50[0.33,0.74] 100 0.65[0.44,0.94] 97.60 
 
Weibull (1.0, 0.0375) 
HR=0.80 
T1 0.80[0.73, 0.88] 36.06 0.85[0.77, 0.93] 21.56 
T2 0.80[0.74, 0.87] 40.74 0.87[0.80, 0.95] 19.52 
T3 0.80[0.74, 0.86] 50.20 0.89[0.82, 0.95] 19.08 
 
Weibull (1.0, 0.03) 
HR=1.0 
T1 1.00[0.89,1.13] 4.82 1.00[0.88,1.14] 5.52 
T2 1.01[0.90,1.12] 4.62 1.00[0.89,1.12] 5.78 
T3 1.00[0.91,1.09] 4.86 1.00[0.91,1.11] 5.18 
 
Weibull (1.0, 0.025) 
HR=1.2 
T1 1.20[1.08,1.33] 22.66 1.13[1.02,1.26] 13.38 
T2 1.20[1.09,1.32] 25.70 1.13[1.02,1.23] 12.28 
T3 1.20[1.11,1.30] 33.36 1.13[1.01,1.19] 12.30 
 
Weibull (1.0, 0.0214) 
HR=1.4 
T1 1.40[1.26,1.56] 57.76 1.26[1.14,1.41] 31.44 
T2 1.40[1.28,1.54] 66.14 1.23[1.11,1.35] 29.52 
T3 1.40[1.29,1.52 78.44 1.19[1.09,1.29] 27.12 
 
Weibull (1.0, 0.015) 
HR=2.0 
T1 2.00[1.78,2.25] 98.74 1.63[1.46,1.83] 80.68 
T2 2.00[1.80,2.23] 99.46 1.52[1.38,1.70] 76.40 
T3 2.00[1.83,2.19] 99.96 1.41[1.29,1.54] 71.32 
 
Weibull (1.0, 0.01) 
HR=3.0 
T1 3.01[2.64,3.41] 100 2.22[1.95,2.55] 98.92 
T2 3.00[2.67,3.39] 100 1.98[1.76,2.23] 97.96 
T3 3.00[2.72,3.32] 100 1.73[1.56,1.91] 95.72 
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Table B.7 Power Analysis Results for Baseline Weibull Distribution (1.0, 0.03), N=500.  
Group 2 
Distribution 
HR 
Study 
Period 
Method A  Method B 
HR [Q1, Q2] Power (%) HR [Q1, Q2] Power (%) 
Weibull (1.0, 0.12) 
HR=0.25 
T1 0.25[0.10,0.45] 100 0.33[0.14,0.57] 100 
T2 0.25[0.13,0.46] 100 0.35[0.19,0.64] 100 
T3 0.25[0.13,0.44] 100 0.36[0.19,0.63] 100 
 
Weibull (1.0, 0.06) 
HR=0.50 
T1 0.50[0.23,0.97] 96.72 0.59[0.30,1.05] 80.72 
T2 0.50[0.26,0.92] 98.28 0.62[0.33,1.20] 77.20 
T3 0.50[0.28,0.86] 99.52 0.65[0.33,1.14] 78.82 
 
Weibull (1.0, 0.0375) 
HR=0.80 
T1 0.80[0.70,0.92] 20.48 0.85[0.74,0.97] 13.00 
T2 0.80[0.71,0.91] 22.56 0.87[0.76,0.99] 12.60 
T3 0.80[0.72,0.89] 28.30 0.88[0.79,0.99] 11.48 
 
Weibull (1.0, 0.03) 
HR=1.0 
T1 1.00[0.89,1.13] 4.82 1.00[0.88,1.14] 5.52 
T2 1.01[0.90,1.12] 4.62 1.00[0.89,1.12] 5.78 
T3 1.00[0.91,1.09] 4.86 1.00[0.91,1.11] 5.18 
 
Weibull (1.0, 0.025) 
HR=1.2 
T1 1.20[1.04,1.39] 13.48 1.13[0.98,1.32] 9.08 
T2 1.21[1.05,1.37] 15.06 1.12[0.98,1.28] 8.70 
T3 1.20[1.08,1.35] 19.06 1.10[0.98,1.24] 8.84 
 
Weibull (1.0, 0.0214) 
HR=1.4 
T1 1.41[1.21,1.64] 34.42 1.27[1.09,1.48] 18.28 
T2 1.41[1.22,1.61] 39.42 1.23[1.07,1,42] 17.40 
T3 1.41[1.25,1.58] 50.10 1.19[1.06,1.34] 16.40 
 
Weibull (1.0, 0.015) 
HR=2.0 
T1 2.01[1.71,2.38] 83.12 1.64,[1.39,1.95] 50.98 
T2 2.01[1.74,2.34] 89.52 1.54[1.32,1.79] 47.86 
T3 2.01[1.77,2.28] 96.46 1.42[1.24,1.62] 44.24 
 
Weibull (1.0, 0.01) 
HR=3.0 
T1 3.01[2.50,3.68] 99.02 2.25[1.88,2.74] 84.20 
T2 3.01[2.55,3.59] 99.70 2.02[1.70,2.39] 78.38 
T3 3.02[2.63,3.48] 100 1.74[1.50,2.02] 72.78 
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Figure C.1 
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Figure C.2 
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Figure C.3 
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Figure C.4 
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Figure C.5 
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Figure C.6 
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Figure C.7 
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Figure C.8 
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Figure C.9 
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